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GLOSSARY OF TERMS
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ABSTRACT

One of the big challenges facing evidence-based nutrition is the apparent discord
between the study of whole foods and of their constituent nutrients. Fish and long chain
omega-3 polyunsaturated fatty acids (LC n-3 PUFA) are a case in point where questions
lie as to the relative value of the food versus a key nutrient. Likewise, little research
considers the effectiveness of dietary advice, in addition to the efficacy on health
outcomes, of consuming whole foods versus nutrients, and numerous methodological
challenges exist for exposing both factors. Finally, there is a paucity of biomarkers that
reflect health rather than disease. An emerging biomarker of health is adiponectin,
which has been associated with both fish and LC n-3 PUFA consumption; however
there is little research comparing their effects on adiponectin levels. The central
hypothesis of this thesis is that consuming fish may be more beneficial to health than
supplements of LC n-3 PUFA, however, behavioural issues may impede the
effectiveness of advice targeting habitual fish consumption.
In this thesis, methodological issues relating to fish consumption were addressed
and adiponectin was considered as a biomarker of health. Data from a 12 month clinical
trial involving consumption of fish and LC n-3 PUFA supplements was analysed, and a
separate study comparing fish with LC n-3 PUFA supplements was conducted. It was
first necessary to ensure methods were available to accurately measure fish and LC n-3
PUFA consumption. Because of the popularity of canned fish products in Australia, a
database of the percentage fish in canned products was developed and validated. Dietary
data collected over the duration of a 12 month clinical trial was converted to an updated
Australian food composition database via a defined strategy to allow for measurement
of LC n-3 PUFA intake.
26

Dietary methodology was applied to investigate changes in fish and LC n-3
PUFA consumption over the duration of the 12 month clinical trial and to assess
compliance to intake recommendations (effectiveness of dietary advice). Fish
consumption was highest at the three month time point of the trial and compliance to
intake recommendations was higher for supplements than for fish. To further investigate
why these patterns of consumption were seen, a study in the social research domain was
conducted. Six semi-structured focus group interviews were then held to compare
perceptions of fish and LC n-3 PUFA consumption in participants of the trial and
control individuals from the host institution. A number of barriers to fish consumption
were identified, including price, preferences of family members and availability of fish.
In comparison, whilst a preference for natural alternatives to LC n-3 PUFA supplements
and enriched foods was expressed, these products were perceived as a more convenient
way of increasing LC n-3 PUFA consumption than fish. Participation in a clinical trial
incorporating dietary advice did not appear to substantially influence perceptions of fish
and LC n-3 PUFA.
The findings of this first set of studies were then used to design a six week
clinical trial to compare the impact of consuming fish and LC n-3 PUFA supplements
on total and high molecular weight (HMW) adiponectin levels in overweight humans.
Fish consumption was found to result in a favourable increase in HMW adiponectin
levels, whilst LC n-3 PUFA supplement consumption did not. This finding was made in
the absence of confounding dietary or genetic factors.
This thesis provided early evidence that consuming fish may be more beneficial
to health than LC n-3 PUFA supplements. It provided proof-of-concept that fish is
more efficacious than LC n-3 PUFA supplement consumption in improving adiponectin
levels. This research supports the value of focusing nutrition research and advice on
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whole foods in preference to single nutrients. However, investigation into the
comparative effectiveness of advice to consume fish and LC n-3 PUFA supplements
suggests that fish intake at the levels studied in this thesis may not be achievable
through dietary advice alone. Future research might well identify strategies for
increasing fish consumption to the level that positive effects can be achieved.
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CHAPTER 1 – INTRODUCTION
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This chapter reviews the scientific literature relevant to this thesis, focussing on
the effects of fish and long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA)
consumption in the context of metabolic health in humans, and considers the relevance
of this research to developing evidence-based dietary advice. It exposes the gaps in the
current literature and relates this to the empirical chapters of the thesis.

1.1 Evidence-based dietary advice in dietetics: efficacy versus effectiveness

Dietetic intervention has been shown to result in a reduced risk of developing
lifestyle diseases such as type 2 diabetes mellitus (1), and is dependent upon the dietary
advice provided to patients. Evidence-based dietary advice is central to ensuring
adequate practice and patient outcomes, and such advice must be updated regularly to
mirror current research findings (2).
When developing evidence-based dietary advice and education strategies, the
efficacy of the diet or dietary component, which is the impact it has on an outcome
under ideal conditions (3), must be considered. However, like all evidence-based
guidelines, dietetic education should also consider the concept of effectiveness (4, 5).
The concept of effectiveness considers the likely impact of an intervention in the ‘freeliving’ environment, and takes into account factors such as long-term adherence and
participant satisfaction with the intervention (4, 6). In the case of developing dietary
advice strategies, the effectiveness of the advice and recommendations themselves
should be considered. Whilst dietary interventions may be found to be efficacious in the
research setting, for example when participants are given food to eat, they may have
limited effectiveness in the ‘free-living’ environment, when only dietary advice is
given, restricting their application as potential education strategies in dietetic practice.
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Much nutrition research focuses on the efficacy of dietary interventions and nutrition
advice but fails to consider the effectiveness of this advice.

1.2 The concept of food synergy

In addition to limited research on the effectiveness of dietary recommendations,
evidence-based dietary advice is also currently hindered by inconsistencies in the
literature regarding the use of whole foods or single nutrients as the primary variable in
research. There is an increasing tendency for research investigating the influence of
dietary components on specific diseases or health states to focus exclusively on
individual nutrients such as vitamins, minerals or specific fatty acids (7). Whilst this
approach may assist in analysing the effects on the body from a biochemical or
mechanistic perspective, it may overlook the role of whole foods in preventing disease
and maintaining heath (7).
Reviews have argued for the importance of whole foods, rather than their
constituent nutrients, for the maintenance of health (7-9). The concept of food synergy
recognises that many bioactive elements constitute a whole food, and together may
explain the complex effects of diet on the body. The whole food may thus have a greater
effect than if each individual component was examined separately (9).
The concept of food synergy in regards to health benefits has been well
documented throughout the literature. For example, epidemiological evidence has
linked increased tomato consumption (and as a result increased intake of lycopene, a
carotenoid found in tomatoes) with a decreased risk of prostate cancer (10). However,
research in rat models found that consumption of tomato extract resulted in a significant
decrease in the risk of developing prostate cancer, whilst consumption of lycopene
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droplets did not (11). The authors of this study suggest that the favourable effects of
tomato consumption on prostate cancer may be the result of any number of
phytochemicals present in tomatoes, of which lycopene is only one, providing evidence
for investigation into the health effects of whole foods, rather than single nutrients.
Further evidence for this argument is provided by Seeram et al. (12), who
compared the in vitro antioxidant activities of pomegranate juice with its constituent
nutrients ellagic acid, punicalagin, and total pomegranate tannin. Whole pomegranate
juice was found to have a greater antioxidant capacity and ability to cause apoptosis in
cancerous cells than its individual components, a finding which remained even when the
nutrients were present in the same concentrations at which they would be found in the
juice. This finding is thought to be due to the large number of additional antioxidant
compounds found in the juice, which act synergistically to provide whole food based
health benefits that a single nutrient cannot contend with. This finding is also supported
by a study conducted by Eberhardt et al. (13), who compared the total antioxidant
activity of whole apples to those with the skin removed. Whole apples had a higher
total antioxidant activity and were found to reduce in vitro tumour cell proliferation to a
significantly greater extent than apples with the skin removed. The authors of this study
suggested that this may be due to the balance of antioxidants provided by the whole
fruit, which is not available when individual components are consumed separately.
More recently, an experimental study comparing the impact of consuming fresh
broccoli to a broccoli supplement also provided evidence for the importance of food
synergy (14). This study found that consumption of fresh broccoli for seven days
resulted in significantly greater excretion of metabolites of isothiocyanate, a
glucosinolate derived compound which is thought to inhibit cancer progression, than
broccoli supplements. The presence of myrosinase, an enzyme required for the
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conversion of glucosinolates to isothiocyanate, in fresh broccoli is thought to be
responsible for this finding, as this enzyme was not present in the supplement. This
emphasizes the concept that many components, acting synergistically, may be
responsible for the effects of a whole food, and that separating these components into
supplement form may not yield the same beneficial effects.
Whilst experimental findings such as these provide support for the importance of
whole foods rather than individual nutrients for the promotion of health, much of the
literature continues to focus on single nutrients. This can be clearly seen in the case of
LC n-3 PUFA and fish.

1.3 Fish and LC n-3 PUFA

1.3.1 Observational evidence for health benefits of fish consumption

Observational evidence has long linked fish consumption with improved health
outcomes in a wide range of areas, but particularly in regards to cardiovascular health.
Increased consumption of fish has been found to be related to reductions in the
incidence of congestive heart failure (15) and stroke (16), including lacunar infarction
(17) and ischemic stroke (18, 19), as well as the incidence of heart failure (20, 21) and
infarct size (22). Intake of fish has also been associated with reduced rates of mortality
from a number of causes, including from ischemic heart disease (23, 24), sudden cardiac
events (25, 26), myocardial infarction (27), heart failure (24), total coronary heart
disease (27-29) and total cardiovascular disease (24). Inclusion of regular fish meals
may also be related to the management of risk factors for cardiovascular disease,
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including a reduction in triglycerides (30, 31), systolic and diastolic blood pressure,
heart rate, and an increase in high density lipoprotein levels (31).
Whilst consumption of fish seems to be linked with favourable health outcomes
overall, some contradictory findings have been reported. A prospective cohort study of
n = 44 895 males aged 40 – 75 years found consumption of fish to be positively
associated with risk of coronary events, with an increased risk seen for individuals who
consumed fish more than six times per week compared to those who did not eat fish
(32). Whilst this finding was reported to be mainly due to the high incidence of fish
consumption in men with coronary artery bypass grafting, a non-significant relationship
was also found between myocardial infarction and fish consumption. This study may
suggest a potential detrimental effect of excessive fish intake, possibly as the result of
increased intake of the contaminants found in some species of fish, such as mercury or
persistent organic pollutants (33). Indeed, the findings of other observational studies
support this concept of a threshold effect, with the most beneficial associations with fish
consumption found when populations consumed one to three serves of fish per week,
with no further benefits for higher amounts (15, 18, 20, 25). Potential detrimental
effects of excessive fish consumption have also been suggested by Djoussé et al. (34),
who found an increased risk of type 2 diabetes mellitus in women who consumed high
amounts of fish and LC n-3 PUFA, with the highest risk found for women who
consumed more than two serves of fish or 0.20g of LC n-3 PUFA per day.
In addition, the findings of these observational studies may also be affected by
the quality of their study design. Whilst a study by Landmark et al. (22) reported a
negative association between fish consumption and infarct size, the dietary
measurement used investigated fish intake alone, and did not measure total diet, thus did
not account for a large number of potential confounding variables, for example
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saturated fat intake. Grouping and categorisation of fish in dietary assessments is also
an issue for observational studies, with some studies grouping all types and preparations
of fish together for their analyses (22, 31, 35), despite the finding that the type of fish
meal may influence potential cardiovascular benefits (23), which may result in incorrect
conclusions being drawn.
Despite these issues, such observational studies have highlighted fish as an
important dietary component, and resulted in a range of intervention trials to further
elucidate the health impacts of fish consumption. They have also resulted in
investigation into the health effects of LC n-3 PUFA which have been found to be
linked to similar health benefits to fish in some (17, 20, 24-26, 29, 31, 32), but not all
studies. LC n-3 PUFA have often been assumed to be the main or sole mediator of the
beneficial health outcomes seen with fish consumption (17, 19, 20, 23, 24, 28, 29),
overlooking the potential importance of fish as a whole food. This assumption is
reflected in recommendations for fish consumption made by health bodies and
governments in a range of countries, with the National Heart Foundation advising
Australians to consume two – three serves of 150 grams of fatty fish rich in LC n-3
PUFA per week (36). Recommendations made by other countries also emphasise the
preferential consumption of fatty fish (37-39).

1.3.2 Sources of LC n-3 PUFA

Fish and seafood are the main dietary sources of the nutrients LC n-3 PUFA,
which include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). LC n-3
PUFA are also present in small amounts in meat products and eggs (40), and a range of
LC n-3 PUFA enriched foods such as dairy foods, bread and eggs are now available
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(40). LC n-3 PUFA can also be obtained via LC n-3 PUFA supplements, which tend to
contain the marine LC n-3 PUFA EPA and DHA. These supplements are recommended
as a method of increasing LC n-3 PUFA intake by health authorities in Australia and
internationally (36, 37, 39). A summary of the LC n-3 PUFA content in a range of
common sources is shown in Table 1.1.

Table 1.1 LC n-3 PUFA content (mg per 100g edible portion) of common sources
Source name

LC n-3 PUFA content (mg/100g)

Salmon, Atlantic, fillet, raw

1968

Tuna, canned in brine, drained

561

Snapper, flesh, raw

266

Shark (flake), skinless fillet, raw
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Oyster, raw

549

Beef, mince, regular fat, raw

51

Lamb, loin chop, lean, raw

78

Egg, chicken, whole, raw

82

Milk, cow, fluid, reduced fat (~1.5%),

29^

added omega-3
Bread, from white flour, added

50^

omega-3 polyunsaturates
Fish oil (ie LC n-3 PUFA supplement),

19563

capsule formation, not further
specified
Data taken from AUSNUT2007 food composition database (40). All data reported in this table is based on analysed
levels of LC n-3 PUFA
^ LC n-3 PUFA content of non-enriched varieties is 0mg/100g edible portion
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LC n-3 PUFA can also be synthesised in the body from α-linolenic acid (ALA),
a shorter chain n-3 PUFA, via the pathway shown in Figure 1.1.

18:3 (ALA)
∆6-desaturase
18:4
Chain elongation
20:4
∆5-desaturase
20:5
Chain elongation
22:5 (EPA)
Chain elongation
24:5
∆6-desaturase
24:6
Chain shortening
22:6 (DHA)

Figure 1.1: Pathway of ALA conversion [adapted from Sinclair et al. (41)]

Whilst LC n-3 PUFA are able to be produced via the above pathway, the
efficiency of such conversion is questionable. It has been suggested that the amount of
EPA and DHA endogenously converted from ALA may be as low as 0.2% and 0.047%
respectively (42). The amount of LC n-3 PUFA synthesised from ALA may also be
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dependent on the relative amounts of omega-6 polyunsaturated fatty acid (n-6 PUFA)
and n-3 PUFA in the diet (43). Therefore, whilst it is possible to synthesise LC n-3
PUFA from dietary ALA, the low efficiency of this pathway and its vulnerability to
other dietary factors may mean that it is virtually impossible to obtain the necessary
amounts of LC n-3 PUFA in this way, suggesting that it must be consumed as part of
the diet, or via supplements. Current Suggested Dietary Targets for LC n-3 PUFA
consumption in Australia are 430mg and 610mg per day for women and men
respectively (NHMRC, 2006).

1.3.3 Metabolic effects of LC n-3 PUFA

In order to understand the health impacts of fish and LC n-3 PUFA
consumption, potential mechanisms of action must be considered as an important part of
the overall evidence base. A large body of evidence exists concerning the numerous
effects of LC n-3 PUFA on biological systems, with most of the scientific developments
made 10 or more years ago. A review by Stillwell and Wassall (44) highlighted the
impact of increased levels of DHA upon membrane properties. As a result of the
unsaturated nature of LC n-3 PUFA, they may lead to alterations in membrane
properties such as an increase in the fluidity and permeability of cell membranes (44),
which are required for the normal functioning of body tissue (45).
LC n-3 PUFA also exert physiological effects via their ability to regulate the
production of eicosanoids. Eicosanoids are hormone derivatives of the n-6 PUFA
arachidonic acid (AA) and the LC n-3 PUFA EPA, and include families such as the
prostaglandins, thromboxanes, and leukotrienes (46). AA and EPA compete for
production of eicosanoids, and the physiological effect of each eicosanoid is dependent
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on the fatty acid it is derived from, with AA derived eicosanoids tending to be
associated with pro-inflammatory actions (47). Conversely, treatment with EPA results
in decreased production of the prostaglandins, thromboxanes and leukotrienes
associated with inflammation, platelet aggregation and vasoconstriction, and increased
levels of the eicosanoids associated with vasodilation, with only weak increases in
inflammatory and aggregatory processes (46) as a result of its competition with AA.
The processes of lipid and carbohydrate metabolism and utilisation are also
known to be influenced by LC n-3 PUFA, through mediation of gene expression and
regulation (48). These changes in gene expression are regulated by a number of nuclear
receptors which include peroxisome proliferator-activated receptors (PPARs) and sterol
regulatory element binding proteins (SREBP), and are known to be influenced by the
presence of fatty acids such as LC n-3 PUFA (49).
PPARs are a family of nuclear receptor proteins, for which LC n-3 PUFA act as
ligands, activating PPARs and allowing them to regulate the expression of specific
genes (49). Experimental research has shown both PPAR-α and PPAR- γ to be activated
by LC n-3 PUFA DHA and EPA, which act as ligands to activate the receptors (50, 51).
The resulting activation of PPAR-α and PPAR- γ lead to an increase in fatty acid
oxidation and transport via upregulated of proteins such as carnitine
palmitoyltransferase, acyl-CoA- dehydrogenases, uncoupling protein-3 and peroxisomal
acyl-CoA oxidase (52, 53).
LC n-3 PUFA also exert effects on metabolism via their inhibition of SREBPs,
specifically SREBP-1c, a gene transcription factor associated with an increase in the
synthesis of lipogenic enzymes (49). Dietary sources of EPA and DHA have been
shown to reduce the mature content of SREBP-1 by up to 85%, resulting in a decreased
rate of transcription of fatty acid synthase, an enzyme complex required for the
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synthesis of fatty acids (53). The inhibition of SREBP by LC n-3 PUFA has also been
described as a mechanism for the down-regulation of several genes associated with fatty
acid synthesis and glucose metabolism, including acetyl-CoA carboxylase and fatty acid
synthase (54). These known effects of LC n-3 PUFA on biological systems suggest
plausible mechanisms for the health outcomes seen in humans; however, it is not clear if
LC n-3 PUFA is solely responsible for the health benefits of fish consumption, or if
food synergy may also play a role.

1.3.4 Comparison of the relative effects of fish and LC n-3 PUFA

As discussed above, the current body of evidence suggests that consumption of
fish and LC n-3 PUFA results in favourable health outcomes, however whether the food
and the nutrient provide the same effect is as yet unknown. A recent meta-analysis
concluded that consumption of LC n-3 PUFA decreased the incidence of sudden cardiac
death in patients suffering from a myocardial infarction (55). However, of the eight
randomised controlled trials investigated in this analysis, only one study involved the
use of fish (56), resulting in a conclusion that is biased towards LC n-3 PUFA
supplementation.
Furthermore, the results of this study suggest that it cannot be concluded that the
effects of fish and LC n-3 PUFA supplement consumption are the same. Burr et al. (56)
initially commenced the Diet and Reinfarction Trial of n = 3114 males with angina with
one arm instructed to consume fatty fish twice a week. However, following compliance
problems with fish consumption, this group was later divided into those consuming fatty
fish or LC n-3 PUFA supplements providing 0.5 grams of EPA per day. The study
found an increased risk of sudden and cardiac death in those randomised to receive fish
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or LC n-3 PUFA supplementation. This has resulted in the conclusion that high LC n-3
PUFA intake may not be recommended for patients suffering from angina (55),
however, it must be noted that only those randomised to receive LC n-3 PUFA
supplements had a statistically significant increased risk of death, whilst those
consuming fish did not reach significance. Furthermore, adverse effects were mainly
confined to the second half of the trial, after the commencement of the LC n-3 PUFA
supplements.
The outcomes of this study suggest that whilst in most populations consumption
of LC n-3 PUFA may be beneficial, the effect of LC n-3 PUFA supplement intake may
not necessarily mimic that of fish consumption. Indeed, fish may contain additional
elements which act to somewhat protect from the adverse health effects which may
occur following supplement consumption. Despite this suggestion, however, little
research has considered the possibility that fish as a whole food and LC n-3 PUFA as a
single nutrient may have different effects on health, or that fish may contain other
beneficial components, which may be required for LC n-3 PUFA to exert its
physiological effects. The literature that does exist however is suggestive of such a
possibility.
In a prospective cohort study of n = 20 551 males, Albert et al. (25) found that
of all types of fish investigated, high LC n-3 PUFA ‘dark meat fish’ (defined as
mackerel, salmon, sardines, bluefish, or swordfish) alone was not associated with a
reduced risk of sudden cardiac death. In addition, whilst consumption of LC n-3 PUFA
was associated with a decreased risk of sudden cardiac death, there was no evidence of a
linear dose-response relationship as was seen for fish intake. Similarly, a cross-sectional
study by Dallongeville et al. (31) found heart rate to be inversely associated with fish
consumption, but the relationship between erythrocyte LC n-3 PUFA levels and heart
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rate lost statistical significance after adjusting for confounding variables, suggesting the
association between LC n-3 PUFA intake and heart rate was not as strong as that of fish
consumption.
Supporting these findings are the results of Streppel et al. (26), who found fatty
fish alone to be associated with a reduction in the risk of sudden cardiac death, but there
was no dose-response relationship evident for LC n-3 PUFA intake. A similar finding
was made by Belin et al. (21), who found that whilst dark meat fish high in LC n-3
PUFA (defined as boiled and baked salmon, mackerel and bluefish) alone was
associated with a significantly reduced risk of heart failure, there was no association
between LC n-3 PUFA consumption and heart failure. Furthermore, lean fish low in LC
n-3 PUFA (described in the study as cod, saithe, and fish fingers) but not fatty or fried
fish, was found to be associated with a significantly lower risk of total stroke and
cerebral infarction in Swedish women (16). Similarly, van Bussel et al. (57) found total
fish intake to be inversely associated with changes in biomarkers of endothelial
dysfunction and low-grade inflammation. Whilst intake of EPA plus DHA explained
83% and 40% of the changes in biomarkers of endothelial dysfunction and low-grade
inflammation respectively, there was no significant difference between the impact of fat
and lean fish on these biomarkers after fish was grouped based on LC n-3 PUFA
content. These results, in accordance with the above observational studies suggest that
whilst LC n-3 PUFA may have an important role in mediating health benefits, it may
not be the only element in fish to do so.
This suggestion is supported by the results of the few intervention trials which
have compared fish and LC n-3 PUFA supplements. Cobiac et al. (58) highlighted the
potential differences between fish and LC n-3 PUFA supplements in an eight week trial
involving mildly hyperlipidaemic men. Participants of the trial received dietary advice
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in addition to either fish or LC n-3 PUFA supplements (both providing 4.5 – 4.6g of LC
n-3 PUFA per day), or a control diet. This study found that whilst fish and supplements
similarly lowered triglycerides and very low density lipoproteins (VLDL) significantly
and significantly increased high density lipoproteins (HDL), only the diet rich in fish
resulted in favourable changes in the hemostatic factors fibrinogen and thromboxane.
Similarly, Mori et al. (59) found that treatment of healthy men with diets differing in
fish and LC n-3 PUFA content resulted in dissimilar health effects for those who
consumed fish and LC n-3 PUFA supplements. Treatment with approximately 5.2g n-3
PUFA per day via supplements resulted in significant increases in low density
lipoproteins (LDL) levels compared to control diets, whereas a diet inclusive of 3.2 –
4.1g n-3 PUFA per day (60) from fish did not. Whilst this study is limited by the
differing levels of n-3 PUFA in the various diets, taken together these studies suggest
that health benefits provided by LC n-3 PUFA supplements may not be equivalent to
those of fish consumption.
The ability of fish consumption to influence markers of health independent of
LC n-3 PUFA content has also been shown by Thorsdottir et al. (61). Over the course of
an eight week trial, participants were placed on an isocaloric diet and randomised to
receive fish with a low LC n-3 PUFA content (cod), fish with a high LC n-3 PUFA
content (salmon), a LC n-3 PUFA supplement or a placebo capsule. Significant weight
reductions were reported for males consuming either type of fish, or LC n-3 PUFA
supplements, suggesting that fish itself, irrespective of LC n-3 PUFA content, is
important for mediating its health benefits. Similarly, Pot et al. (62) compared the
effects of regular consumption of salmon, cod or general healthy eating advice over six
months on a variety of outcomes including circulating levels of C-reactive protein
(CRP), a protein which is released in response to inflammation (63). The groups
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consuming fish experienced significant decreases in CRP (25 – 35% reduction), whilst
there were no significant changes in the CRP levels of the group receiving only healthy
eating advice. Given that improvements were seen regardless of the LC n-3 PUFA
content of the fish, the results of this study suggests that other components of fish in
addition to LC n-3 PUFA may play a role in the health benefits seen with fish
consumption.
There is limited evidence to suggest what these components may be. It is known
that fish contributes a variety of nutrients to the diet, with fish and seafood found to be
the major contributor to iodine, selenium, vitamin B12 and vitamin D in a population
with high fish consumption (64). Streppel et al. (26) highlighted the high vitamin D
content of fatty fish, compared to lean fish, as a potential cause of its association with
decreased mortality from sudden cardiac death. A recent study by Berr et al. (65) found
that with increasing fish consumption, plasma selenium levels increased along with
erythrocyte LC n-3 PUFA levels. Fish consumption also explained 16% of the variance
in plasma selenium, whereas it explained only 2.6% of the variance in erythrocyte LC n3 PUFA. Selenium, which has antioxidant capabilities and thus may act to counter the
peroxidising effect of LC n-3 PUFA (65), may play a role in the synergistic effect of
fish consumption, which would not be seen with LC n-3 PUFA supplement
consumption alone.
Proteins present in fish may also play a role in mediating its health effects. Fish
protein has been found to result in lower blood pressure (66), triglyceride secretion rates
(67), glucose and insulin response and increase insulin sensitivity (68) in animal
models. Combining LC n-3 PUFA and fish protein hydrolysates resulted in a greater
reduction in the expression of tumour necrosis factor-α (TNF-α) than treatment with LC
n-3 PUFA alone in an in vitro study utilising human monocyte-derived macrophages
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(69). Human intervention studies have also provided evidence for the health benefits of
fish protein. In a study conducted by Soucy and LeBlanc (70), changes in insulin and
glucagon levels were measured following consumption of either beef or cod. The
change in the insulin:glucagon ratio was significantly lower following consumption of
the fish meal. Similarly, Ouellet et al. (71) provided insulin resistant participants with a
diet containing either cod or lean beef, pork, veal, eggs, milk and milk products for four
weeks each using a cross-over design. Consumption of the cod protein diet resulted in
significantly higher insulin sensitivity than the diet that did not include fish.
Consumption of diets rich in fish protein has also been shown to increase satiety (72),
and reduce the energy consumed at subsequent meals compared to control diets (73).
An additional component of fish which may play a part in its health impacts is
taurine, a derivative of the amino acid methionine found commonly in fish and seafood
(74). Twenty four hour urinary taurine excretion, a marker of consumption, was found
to be negatively associated with ischaemic heart disease in a multi-centre crosssectional study (74).
Therefore, fish contains a range of viable components which could be
responsible for mediating its known health effects, in addition to LC n-3 PUFA.
However, given the evidence for the value of food synergy (11-14), it is plausible that it
is in fact the combination of these and other components of fish which act together to
mediate the positive health effects seen with fish consumption, which may not be seen
with consumption of any single nutrient in isolation, for example LC n-3 PUFA
supplements.
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1.4 Applicability of fish and LC n-3 PUFA research to dietetic practice and advice

From the literature discussed above, it is clear that whilst both fish and LC n-3
PUFA consumption play important roles in metabolic health, there is currently
insufficient evidence for clinicians to confidently advise the preferential consumption of
the food or the nutrient. Research is now required to further compare the health effects
of fish and LC n-3 PUFA consumption, in a way that will be applicable to dietetic
practice and to guiding evidence-based dietary advice. In order to do so, several factors
must be first addressed which have historically been overlooked in the literature, and
have thus prevented accurate comparison of fish and LC n-3 PUFA intake on health
outcomes. These include the accurate measurement of fish and LC n-3 PUFA intake,
and factors influencing the effectiveness of dietary advice to consume fish and LC n-3
PUFA.

1.4.1 Measurement of fish and LC n-3 PUFA intake

Firstly, in order to elucidate the effects of fish consumption on health outcomes
and compare them to those achieved with LC n-3 PUFA supplements, accurate methods
for the measurement of fish and LC n-3 PUFA intake are required. A limitation of the
current body of literature is the lack of adjustment for the presence of additional
ingredients in canned fish products or mixed dishes (such as fish pasta dishes)
potentially overestimating fish consumption. Of the numerous observational studies
investigating the effect of fish consumption on health outcomes (15-21, 23-31) all seem
to have assumed fish intake to be equal to that reported, as no known studies have
adjusted for the presence of additional ingredients.
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Measurement of fish intake is also problematic in intervention trials. Whilst
several studies have provided participants with fish (59, 61, 75, 76) thus circumventing
the problem of measuring fish intake, not all interventions have done so. Burr et al. (77)
advised participants to consume two serves of fish per week but did not the measure
amount of fish eaten, instead using plasma EPA levels as a proxy measure of fish
intake. However, the varying levels of EPA and other fatty acids in different species of
fish (78) make this a flawed way of approximating fish intake. Whilst a study conducted
by Guebre-Egziabher et al., (79) did measure fish intake via a food diary, the presence
of additional ingredients in fish products were not taken into account, potentially
resulting in inaccurate measurement.
Accurate methods of approximating dietary LC n-3 PUFA from marine and
other sources is also required. In the current body of literature, observational studies
typically estimate LC n-3 PUFA content of fish varieties using food composition
databases specific to their country (15, 17, 20, 24-27, 29, 32, 80-82). Intervention
studies have also reported using country-specific food databases to measure LC n-3
PUFA intake (79, 83), or have done so via analysis of the LC n-3 PUFA content in the
case that fish was provided to participants (58, 59, 61).
However, a gap in the literature exists for dietary studies specifically targeting
the Australian context which do not provide fish to participants. Geographical
differences in the fatty acid quantities in fish and meat products (84, 85) mean a local
food composition database is required where possible. An Australian fatty acid database
developed by Mann et al. (86) has been used to measure LC n-3 PUFA intake in a
dietary intervention (87) and in population-based studies (84, 88). However, this
database is limited by the number of foods it contains, resulting in inappropriate
substitutions when a matching food is not available (89). Whilst the database has been
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updated from its original form to include more foods, the range of foods available
remains insufficient for dietary data collected using open-ended dietary tools.

1.4.2 Measurement of compliance to fish and LC n-3 PUFA consumption
recommendations

In dietary trials examining the health outcomes associated with consumption of a
food or nutrient, measuring compliance to recommendations is essential to accurately
measure the effect of any dietary modification, or incorrect conclusions may be made
(90). Furthermore, measurement of compliance to fish intake recommendations in
clinical trials is particularly prudent given the known low habitual fish consumption in
Australia (91), as in many countries. Measuring compliance in dietary trials thus
provides a vehicle to evaluate the effectiveness of recommendations to increase fish and
LC n-3 PUFA intake, and hence the suitability of such recommendations for dietetic
practice.
Whilst compliance to recommendations is not reported in all clinical trials
investigating the health impact of fish consumption, several studies have measured this
and reported their findings. Mori et al. (59) investigated the effect of different doses of
fish and LC n-3 PUFA supplements on serum lipids in men with elevated serum
cholesterol over a 12 week period. Participants randomised to the fish diet were
instructed to consume one fish meal per day as part of a low sodium diet and were
provided with the recommended amount of fish. Compliance to the study diet inclusive
of fish intake was measured via 24 hour diet records and changes to plasma fatty acids,
and was found to be over 95%. Dietary compliance was also measured in a study
conducted by Lara et al. (76) which examined the effect of fish consumption on markers
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of cardiovascular disease. In a cross-over design, participants were provided with 125
grams of salmon per day for four weeks, followed by a four week period where
participants were advised not to consume fish. During the fish consumption period, food
diaries and food frequency questionnaires suggested compliance to fish intake
recommendations was almost 100%, a finding which was supported by changes in
plasma fatty acid levels.
Compliance to fish consumption recommendations were also found to be high
in a study on the effects of fish intake on weight loss (90). The aim of the parent study
(61) was to investigate the effects of fish consumption on weight loss over an eight
week period. As previously mentioned, participants were randomised to one of four
groups which included placebo, LC n-3 PUFA supplements or either 150 grams of fish
low in LC n-3 PUFA (cod) or fish high in LC n-3 PUFA (salmon) three times per week.
Participants instructed to consume fish were provided with all required fish by the study
investigators and fish intake was measured using a validated food frequency
questionnaire. Dietary compliance to fish intake recommendations was found to be
high, with only 4% of participants in the fish group unable to consume the required
amount of fish. Similarly, compliance to fish intake recommendations was reported to
be good in a study conducted by Kondo et al. (83). Participants were provided with fish
during an eight week dietary intervention aimed at investigating the impact of fish
consumption on serum adiponectin levels. Over the duration of the study, participants
were found to significantly increase their fish intake as measured by a 3 day food record
and a daily food diary.
Whilst these studies all reported high levels of compliance with fish intake
recommendation, they all provided study participants with fish meals at no cost. There
is evidence to suggest provision of food increases compliance to dietary interventions
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and resultant health outcomes (92-94), and it was concluded by a recent systematic
literature review that such food provisions can be a successful component of dietary
counselling (95), potentially making this a key component in the high compliance levels
seen in these studies. Furthermore, these clinical trials were relatively short term, with
the longest trial running for 12 weeks (59). Levels of compliance to other dietary
recommendations have been found to decrease over the duration of longer term dietary
trials (96, 97), and may be the result of participant fatigue over the course of the study.
The provision of fish and the short duration of these studies mean that they do
not reflect dietetic intervention in the clinical or community environment. The high
levels of compliance with fish intake recommendations reported in these studies thus
cannot be extrapolated to draw conclusions regarding the effectiveness of dietary advice
relating to fish consumption. There are currently no studies which examine compliance
to fish consumption recommendations in a time period longer than three months without
provision of fish. Research in this area is needed to determine if increasing fish
consumption through evidence-based nutrition advice is achievable and practical for
consumers. Measuring compliance in long term studies which do not provide fish is also
required to ensure participants meet dietary recommendations and to guarantee the
accurate comparison of fish and LC n-3 PUFA intake.

1.4.3 Influence of perceptions and attitudes on fish and LC n-3 PUFA consumption

In addition to investigating the practicality of fish and LC n-3 PUFA
consumption recommendations, investigating perceptions of fish and LC n-3 PUFA
consumption can also provide insight for developing effective evidence-based dietary
advice strategies. The perception of fish as a healthy food has been reported widely in
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the literature (98-102), however, it remains unclear if this perception influences
consumption. Pieniak et al. (102) found that the belief that fish is healthy did not have a
strong impact on the frequency of fish consumption, and it has been concluded by both
Olsen (103) and Bredahl and Grunert (104) that variations in patterns of fish
consumption between countries cannot be explained by consumer’s perceptions of the
health benefits, as these are widely agreed upon. Alternate perceptions and attitudes to
fish consumption must thus play a larger role in influencing consumption.
Social research incorporating qualitative methods have identified barriers to fish
consumption through a variety of methods including focus groups, interviews and
written questionnaires. Barriers impeding fish consumption documented in the literature
include price (98, 100, 105), presence of bones (100, 105, 106), smell (98, 105),
preferences of other family members (98, 105), access and availability (105) and
cooking ability (105).
Research has also highlighted determinants which can influence perceptions of
fish consumption. Age of individuals has been found to influence the amount (100) and
type (99) of fish consumed, as well as individual’s perceptions of the convenience of
fish products, with older participants found to perceive fish as more convenient and
easier to prepare than younger participants (103, 107). Habitual fish consumption and
experience with fish have also been found to influence perceptions of fish, with
individuals with higher fish intake and experience perceiving fewer barriers to fish
consumption than those with less experience (98, 100, 106, 108). Furthermore, a study
conducted by Pieniak et al. (101) across five European countries found that traditional
fish intake habits accounted for more differences in fish consumption between countries
than a medical history of cardiovascular disease.
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The presence and age of children in a household has also been found to
influence the type (99) and frequency (100, 107) of fish consumed, with the presence of
teenagers found to be associated with the lowest fish consumption (107). The influences
of an individual’s education level and income are less clear. Whilst some studies have
found that a higher education level is associated with increased consumption of total
fish (107) and fatty fish (99), Verbeke and Vackier (100) found that higher education
was associated with a higher intention to eat fish, but not a higher fish consumption per
se. Higher income was similarly found to be associated with an intention to consume
fish which did not translate to behaviour (100), and has also been found to have no
association with fish consumption (107).
Only one study was found investigating consumer perceptions of fish in the
Australian context. McManus et al. (105) conducted seven focus groups with the
mothers of young children and identified barriers to fish consumption which included
price, availability, freshness and lack of confidence in cooking fish. Given the known
role that traditional diets play in influencing perceptions of fish (101), it is important
that further research be conducted in the Australian context, and that it is expanded to
the adult population.
Whilst a number of studies have investigated perceptions of fish, very few have
addressed perceptions of other sources of LC n-3 PUFA, such as LC n-3 PUFA
supplements or LC n-3 PUFA enriched foods. Patch et al. (109) conducted six focus
groups in overweight adults aimed at identifying salient beliefs regarding LC n-3 PUFA
enriched foods. Functional foods enriched with LC n-3 PUFA were viewed as being a
suitable alternative to fish, and were seen as overcoming some of the barriers associated
with fish consumption, such as access to fresh fish. However, the quantity of LC n-3
PUFA contained in enriched foods was viewed as being unclear and was a concern for
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some participants, leading them to favour supplements as a source of LC n-3 PUFA.
Due to the limited literature available regarding perceptions of LC n-3 PUFA
supplements, more research is needed in this area to determine how perceptions differ to
those regarding fish consumption.
An additional gap in the literature exists concerning the influence of dietary
advice on perceptions of fish and LC n-3 PUFA intake, with no known studies
investigating the effect of dietary intervention incorporating dietetic education and
advice. It is currently unknown whether an intervention utilising dietary advice would
influence perceptions of fish and LC n-3 PUFA consumption and if such an intervention
could be used to overcome some of the known barriers to fish consumption.
Investigating the impact of dietary advice on perceptions of fish and LC n-3 PUFA
consumption would provide further insight into the effectiveness of such dietary advice,
and its potential application within dietary interventions and research.

1.5 The impact of fish and LC n-3 PUFA consumption on a novel biomarker of
metabolic health

As previously outlined, the current body of literature can be seen as inadequate
to compare the effects of fish and LC n-3 PUFA supplements due to methodological
and behavioural issues which have not been addressed. Attending to these issues means
that the comparative efficacy of fish and LC n-3 PUFA consumption on a specific
health outcome can be measured.
A biomarker of health could be utilised as a viable outcome of a dietary
intervention to compare the effect of fish and LC n-3 PUFA consumption. The Institute
of Medicine defines biomarkers as “characteristics that are objectively measured and
evaluated as indicators of normal biological processes, pathological processes, or
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pharmacologic responses to an intervention” (110) (pg. 1). However, as acknowledged
in a recent review, biomarkers tend to be indicators of the presence or progression of a
disease, whilst the central aim of nutrition is to enhance and maintain health (111).
There is thus a need for novel biomarkers of health which can be used as outcome
measures in dietary studies. Furthermore, as health covers a range of different domains,
it is prudent that such biomarkers relate to improvements in health issues of major
prevalence and severity, such as obesity and the metabolic syndrome.

1.5.1 Obesity and the metabolic syndrome

Obesity is a health issue of increasing prominence in Australia. The 2007-2008
National Health Survey found 25% of respondents aged 18 years and over were obese,
whilst a further 37% were overweight (112). The prevalence of obesity has increased
since 1995, when 18.3% of respondents aged 19 years and over were recorded as being
obese by the National Nutrition Survey (NNS) (113).
The health repercussions of obesity are many and varied. Obesity is associated
with increased risks of developing type 2 diabetes mellitus, cardiovascular disease,
osteoarthritis, and a number of cancers, including colorectal, breast, uterine, and kidney
(114). The degree to which obesity affects these health conditions is clearly seen in a
report published by Diabetes Australia (114), which stated that 10.8% of all type 2
diabetes mellitus cases could be attributed to obesity. Similar findings were outlined for
other associated health conditions, with obesity found to be the cause of 14% of
hypertension, 12% of coronary heart disease, 12% of stroke, 14% of osteoarthritis, 13%
of colorectal and kidney cancers, and 16% of breast and uterine cancers (114).
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It is now well recognised that obesity is characterised by a low level of chronic
inflammation (115). A potential mechanism for this inflammation is the presence of a
state of hypoxia, caused by the inability of the increased weight of fat mass to obtain its
required levels of oxygen (116). This hypoxic state may result in increased levels of
markers of inflammation such as TNF-α, which is related to the development of insulin
resistance (116). Obesity associated inflammation has also been linked to the
development of atherosclerosis and thrombosis (117).
This concept of chronic inflammation also underpins the development of the
metabolic syndrome, which is defined as a cluster of risk factors including abdominal
obesity, raised blood pressure, insulin resistance and dyslipidaemia (118). Research now
needs to focus on metabolic factors which may play a role in attenuating inflammation
and the metabolic syndrome and promoting metabolic health, and to identify dietary
components which may assist with this process. Fish or LC n-3 PUFA may be potential
dietary candidates, as is outlined below.

1.5.2 The effect of fish and LC n-3 PUFA consumption on adiponectin, a novel
biomarker of metabolic health.

As previously discussed, the concept of chronic inflammation underpins the
public health issues of obesity and the metabolic syndrome. In order to elucidate the
effect of fish and LC n-3 PUFA consumption on health, a biomarker of health which
indicates improvements in inflammation as well as the broader problems of obesity and
the metabolic syndrome is needed. A viable candidate is the adipocyte hormone
adiponectin. Adiponectin is widely known to play a role in mediating inflammation
(119), as well as having insulin sensitising (120) and anti-obesity (121) effects. A
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summary of the actions of adiponectin on the body is shown in Figure 1.2. These effects
are mediated by the ability of adiponectin to activate the enzyme 5' adenosine
monophosphate-activated protein kinase (AMPK) in skeletal muscle and liver, resulting
in increased fatty acid oxidation and glucose uptake (122). Adiponectin has also been
shown to increase expression of acyl-CoA oxidase and uncoupling protein 2 and 3 in
rats, resulting in increased fatty acid oxidation and energy utilisation (123). Adiponectin
also suppresses inflammation by reducing monocyte adhesion (124) and preventing the
process by which macrophages form foam cells (125). Adiponectin concentrations are
known to be lower in individuals suffering from obesity (126) or type 2 diabetes
mellitus (127), and decreases in circulating levels of the hormone can be seen prior to
the onset of hyperinsulinaemia (128). Conversely, treatment with adiponectin in animal
models improves insulin sensitivity and lowers blood glucose levels (129), increases
weight loss (121), and attenuates metabolic changes associated with the development of
atherosclerosis (123), illustrating the wide variety of health processes mediated by this
hormone.
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Adipose tissue

Adiponectin
Monocytes and
macrophages
↓ monocyte
adhesion (124)
↓ conversion of
macrophages to
foam cells (125)

Liver
 Activates AMPK
(122)
↑ glucose utilisation
↓ glucose production
↑ insulin sensitivity
↑ fatty acid oxidation

Skeletal muscle
 Activates AMPK
(122)
↑ glucose utilisation
↑ insulin sensitivity
↑ fatty acid oxidation

Heart and vascular
tissue
Prevents
atherosclerosis (123)
↓ vascular
inflammation

Figure 1.2. Summary of the actions of adiponectin in the body (adapted from Chandran
et al., (130) and Swarbrick and Havel (122).

Reflecting the tendency of the literature to relate biomarkers to disease
outcomes, low circulating levels of adiponectin have been described as a biomarker of
the metabolic syndrome (131-133). However, the diversity of adiponectin’s actions in
the body, the improved health outcomes seen following treatment with the hormone
(121, 123, 129) and the reduced prevalence of metabolic disorders in individuals with
higher levels of adiponectin (126, 127, 134, 135) suggests this hormone should be
considered primarily as a biomarker of health rather than disease. This conclusion is
supported by Cambuli et al. (136), who found adiponectin to be good biomarker of
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positive metabolic outcomes in overweight and obese children following a one year
dietary intervention. Therefore, utilising adiponectin as a biomarker of metabolic health
could be an approach to compare the efficacy of differing dietary strategies, such as fish
and LC n-3 PUFA consumption.
Evidence from animal studies suggests that feeding a diet high in LC n-3 PUFA
results in increased circulating adiponectin concentrations. Following two weeks of a
control high fat diet, Flachs et al. (137) fed obese diabetic mice either a high fat diet
with 15% of lipids as LC n-3 PUFA or the control diet for five weeks. Mice were
further assigned to receive free access to food or to experience a 30% caloric restriction.
Plasma adiponectin levels and adipocyte expressed of the adiponectin encoding gene
ADIPOQ increased significantly in the mice fed LC n-3 PUFA, regardless of energy
restriction. Similarly, Todoric et al. (138) fed diabetic and non-diabetic mice either a
low fat diet, or a high fat diet supplemented with either lard oil, safflower oil or LC n-3
PUFA for six weeks. Adiponectin gene expression was significantly lower in the
diabetic mice consuming a high fat diet compared to a low fat diet, with the exception
of those consuming the LC n-3 PUFA diet. Including LC n-3 PUFA reversed the
downregulation of adiponectin seen with consumption of a high fat diet, with these
changes reflected in the serum adiponectin concentrations. Similarly, Itoh et al. (139)
found significant increases in serum adiponectin levels following treatment with EPA in
obese mice only, whilst the change did not reach significance for wild-type mice,
potentially suggesting that the effects of LC n-3 PUFA are greater in metabolically
compromised individuals.
In the animal model, there is evidence to suggest that LC n-3 PUFA can increase
adiponectin levels in a dose-dependent manner. Neschen et al. (140) found significant
increases in plasma adiponectin levels in mice fed diets containing LC n-3 PUFA at
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concentrations of 8%, 14.5% and 27% of the weight of the total diet, with a 2.7 fold
increase in plasma adiponectin found for the mice consuming the 27% LC n-3 PUFA
diet compared to control. Similarly, Duda et al. (141) found dose-dependent increases in
the plasma adiponectin levels of mice consuming 0.7%, 2.3% and 7% of total energy as
LC n-3 PUFA, with significant increases found for the diets containing 2.3% or more
energy as LC n-3 PUFA. This dosage corresponded to human consumption of
approximately 5.1g LC n-3 PUFA per day (141).
Given the high doses of LC n-3 PUFA used in animal studies, it could be
questioned whether these doses are plausible for human consumption. However,
evidence from the small number of human studies examining the effects of LC n-3
PUFA or fish consumption on adiponectin concentrations suggests that such changes in
adiponectin are achievable. Cross-sectional studies have found biomarkers of LC n-3
PUFA consumption to be associated with higher levels of adiponectin (142, 143). These
findings are largely mirrored in the results of dietary interventions. Lara et al. (76)
measured changes in adiponectin levels in n = 48 healthy Scottish adults following
consumption of a four week diet providing 125 grams of salmon (2.4g EPA + DHA) per
day during a crossover trial and reported a significant increase of 1.21ug/mL in mean
adiponectin levels. The lack of a washout period between the intervention and control
arms however detracts from the validity of the results of the trial, and may have been
the reason that the change in adiponectin between the control and intervention periods
did not reach statistical significance. A trial conducted by Guebre-Egziabher et al. (79)
in n = 17 healthy French adults found that instructions to replace high n-6 PUFA foods
with regular fish meals (providing an average of 1.25g EPA + DHA per day) resulted in
a significant increase of 1.13ug/mL in mean plasma adiponectin compared to baseline.
However, this study is limited by its lack of a control group. Similarly, Kondo et al.
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(83) measured changes in adiponectin levels of n = 17 healthy Japanese adults who
consumed approximately 3g of n-3 PUFA from fish for eight weeks. Significant
increases of 2.3ug/mL in mean serum adiponectin levels were seen for the female
participants, but the lack of a control group and small sample size again limit the quality
of these results.
The literature also suggests that supplementation with LC n-3 PUFA may result
in increased adiponectin concentrations. In a crossover design, Sneddon et al. (144)
gave lean and obese young men (aged 23 – 38 years) and lean and obese older men
(aged 50 – 64 years) from the United Kingdom a combination of conjugated linoleic
acid and LC n-3 PUFA (1.53g EPA + DHA per day), or control oil. Supplementation
with conjugated linoleic acid and LC n-3 PUFA resulted in a mean increase of
0.21ug/mL in plasma adiponectin levels in the young obese group only, which was
reflected in the changes in anthropometric measures. Krebs et al. (145) found significant
increases of 2.33ug/mL in mean adiponectin levels following supplementation with 4.2g
LC n-3 PUFA per day as part of a weight loss programme, inclusive of a low energy
meal replacement diet, in overweight women from the United Kingdom. Likewise, Itoh
et al. (139) found supplementing obese Japanese adults with 1.8g EPA per day for three
months resulted in significant increases of 2.77ug/mL in mean plasma adiponectin
levels, with the EPA treatment found to be the only independent determinant of
adiponectin levels. Similarly, a recent study found increases of 0.55ug/mL in mean
adiponectin levels of overweight Danish participants following treatment with LC n-3
PUFA supplements providing 1.12g EPA + DHA per day for six weeks (146). In
contrast, when measuring the impact of consumption of supplements providing 1.4% of
daily energy as LC n-3 PUFA on adiponectin levels in overweight and obese American
adults, Kratz et al. (147), did not report a significant change in adiponectin
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concentrations. However the results of this study may have been confounded by the
presence of two hyperinsulinaemic participants in the intervention group, which is
associated with lower levels of adiponectin (122).
The mechanism through which LC n-3 PUFA acts on adiponectin is thought to
be via PPARs, which play numerous roles in regulating carbohydrate and lipid
metabolism through genetic alterations (122, 140), including an increase in the synthesis
of adiponectin (148). Research in animal models has highlighted this relationship. One
mouse model study found an increase in adiponectin concentration following LC n-3
PUFA supplementation dependent on the presence of PPAR-γ, but was not affected by
PPAR-α concentrations (140). As previously mentioned, DHA and EPA act as ligands
for PPAR-γ, increasing PPAR-γ mRNA expression in vitro (51).
Whilst a plausible mechanism exists for the effect of LC n-3 PUFA on
adiponectin, given the differing impact of fish and LC n-3 PUFA supplement
consumption on health outcomes reviewed previously, it is prudent to question whether
this effect is best achieved through consumption of fish or LC n-3 PUFA supplements,
and if other components of fish may also play a role. Only one study has compared the
effects of fish and LC n-3 PUFA supplements on total adiponectin in humans. In a
previously mentioned study, Ramel et al. (149) provided participants with LC n-3
PUFA supplements, fish low in LC n-3 PUFA (cod), fish high in LC n-3 PUFA
(salmon), or a control diet of chicken with placebo capsules over eight weeks and found
a reduction in total adiponectin in all groups, with no significant difference between
groups. However, a limitation of this study is that that whilst the salmon diet provided
2.1 grams of LC n-3 PUFA per day, the LC n-3 PUFA supplement provided only 1.3
grams per day (149). The fact that the LC n-3 PUFA provided by the salmon and
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supplement diets was not matched means that making comparisons between the effects
of the whole food and supplement is problematic.
An additional limitation of this study and of the current body of evidence overall
is the type of adiponectin measured. Adiponectin circulates in multimers of varying
metabolic weights, including high molecular weight (HMW) adiponectin (150). HMW
is thought to be the more physiologically active form of adiponectin, with HMW
adiponectin levels found to be a better predictor of insulin resistance and the metabolic
syndrome than total adiponectin (151). Furthermore, changes in HMW adiponectin
cannot be assumed to be the same of those of total adiponectin, with HMW adiponectin
concentrations found to increase post-weight loss even when no changes in total
adiponectin were seen (152). In the literature, only one known study has investigated
the effect of fish or LC n-3 PUFA supplements on HMW adiponectin, and found no
effect of supplements (147). There is a need for research which compares the effect of
fish and LC n-3 PUFA supplement consumption on both HMW and total adiponectin in
order to understand the comparative effects of the whole food and nutrient on this
biomarker.

1.6 Summary of evidence and gap in the literature

Evidence exists for the beneficial effect of consumption of both fish and LC n-3
PUFA on a wide range of health outcomes. However, from the current body of literature
it cannot be said that the effects of the food and nutrient are the same; indeed evidence
exists to suggest fish may exert additional health benefits, possibly as a result of food
synergy.
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A limitation of the current body of evidence is that few studies are designed in a
way for their results to be interpreted for the development of evidence-based dietary
advice. Methodological issues, including measurement of fish and LC n-3 PUFA, and
factors influencing the effectiveness of fish and LC n-3 PUFA consumption
recommendations have historically been overlooked and must all be addressed before
the efficacy of fish and LC n-3 PUFA supplements can be compared.
Biomarkers serve as viable study outcomes to assess the efficacy of dietary
strategies; however, there is a paucity of biomarkers which reflect health rather than
disease. The adipocyte hormone adiponectin can be considered to be an emerging a
biomarker of metabolic health, and evidence from animal and human studies suggests
that both fish and LC n-3 PUFA supplements may result in increases in circulating
levels of the hormone. Research is now needed to compare the influence of fish and LC
n-3 PUFA supplements on adiponectin levels, and which also addresses the
aforementioned methodological and behavioural issues, allowing for the interpretation
of findings within the context of evidence-based dietary advice.
This review has identified the following gaps in the literature, which will be
addressed in this thesis:
-

The current methods used for the measurement of fish and LC n-3 PUFA intake
are inadequate, particularly for use the Australian context in the case of LC n-3
PUFA intake

-

There is a lack of long-term studies which measure compliance to fish
consumption recommendations and thus a paucity of research on the
effectiveness of dietary advice to increase fish and LC n-3 PUFA consumption
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-

There is little research on consumer perceptions of LC n-3 PUFA supplements.
No known studies have investigated the influence of dietary education and
advice on perceptions of fish and LC n-3 PUFA intake.

-

There is a lack of research comparing the effects of fish and LC n-3 PUFA on
novel biomarkers of health such as total and HMW adiponectin levels in
humans.

1.7 Aims and hypothesis

In accordance with the evidence and the gaps in the literature identified above,
the central aim of this thesis was to compare the impact of fish and LC n-3 PUFA
consumption on health, from both an efficacy and effectiveness standpoint.
The individual aims of each study were:
-

Study 1: to develop and validate a database of the percentage fish contained in a
range of common canned seafood products

-

Study 2: to develop a defined strategy to convert dietary data from a 12 month
clinical trial to an updated Australian food composition database

-

Study 3: to assess the effectiveness of dietary advice to increase fish and LC n-3
PUFA consumption on fish and LC n-3 PUFA (from both dietary and
supplement sources) intake over the duration of a 12 month dietary trial

-

Study 4: to investigate perceptions of fish and LC n-3 PUFA supplements
following dietary advice and education and compare them to those expressed by
individuals who had not received dietary education

-

Study 5: to compare the effect of fish and LC n-3 PUFA supplement
consumption on total and HMW adiponectin levels in humans.
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The central hypothesis of this thesis is that consuming fish may be more beneficial
to health than supplements of LC n-3 PUFA, however, behavioural issues may impede
the effectiveness of advice targeting habitual fish consumption. An overview of the
studies included in this thesis, and their relationship to the central hypothesis is shown
in Figure 1.3.
The individual hypotheses of each study were:
-

Study 1: A canned fish database will be a valid method of estimating the
percentage fish in canned products and will be an improved methodology for
measuring fish intake.

-

Study 2: Converting clinical trial data to an updated food database will provide
a way of measuring LC n-3 PUFA intake in dietary data, and will be comparable
to the original data.

-

Study 3: The effectiveness of dietary advice to increase fish consumption will
be highest at the three month time period of a 12 month clinical trial, and will
decline in latter stages of the trial. The effectiveness of advice to consume LC n3 PUFA supplements will be greater than that of fish over the duration of the
study.

-

Study 4: Consumers will report both motivating factors and barriers to fish and
LC n-3 PUFA supplement consumption. Fewer barriers will be expressed by
participants of a 12 month clinical trial incorporating dietary advice than control
participants from the host institution.

-

Study 5: Fish consumption will result in greater increases in total and HMW
adiponectin levels in overweight humans than supplements providing the same
amount of LC n-3 PUFA.
65

Methods development studies

Effectiveness studies
Study 3:
Effectiveness of fish and LC n3 PUFA consumption during a
12 month clinical trial

Study 1:
Development of canned
fish database

Study 2:
Conversion of clinical trial
dietary data to an updated
food composition database

Study 4:
Perceptions of fish and LC n-3
PUFA consumption

Central hypothesis


Consumption of fish is more beneficial to
health than LC n-3 PUFA
 Behavioural factors impede the
effectiveness of advice targeting fish
consumption

Efficacy study

Study 5:
Comparison of the impact of
fish and LC n-3 PUFA
consumption on a biomarker of
metabolic health
Figure 1.3: Overview of thesis studies in relation to the central hypothesis

1.8 Thesis structure

Chapter 2 outlines the methodology utilised in this thesis. It outlines methods
utilised in each study, including their strengths and weaknesses, and justifies the use of
each method in this thesis.
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Chapter 3 and 4 outline the development of the canned fish database and the
conversion of dietary data to an updated food database, respectively. These
measurement tools are then discussed in the context of the wider body of evidence.
Chapter 5 and 6 introduce and provide the results of analyses investigating the
effectiveness of fish and LC n-3 PUFA consumption recommendations. These analyses
investigate compliance to fish and LC n-3 PUFA intake recommendations (chapter 5)
and consumer perceptions of fish and LC n-3 PUFA consumption (chapter 6).
Chapter 7 is a culmination of the findings of the previous chapters, and
incorporates these findings into a proof-of-concept study. This study compares the
short-term effects of fish and LC n-3 PUFA supplement consumption on total and
HMW adiponectin levels in overweight humans, and results are presented and
discussed.
Chapter 8 summarises the findings of all experimental studies and uses these to
address the central aim of this thesis. It also generates recommendations for future
research.

1.9 Significance of research

The provision of accurate evidence-based nutrition guidelines which reflect
current research is central to the practice of dietetics. However, inconsistencies exist in
the literature regarding the use of whole foods or nutrients. Fish and LC n-3 PUFA are a
case in point of this issue, with much research focusing exclusively on LC n-3 PUFA
whilst overlooking the value of fish as a whole food.
Furthermore, as with all evidence-based guidelines, dietary advice should take
into account both the efficacy and the effectiveness of interventions which underpin
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recommendations. This research is the first to compare fish and LC n-3 PUFA
consumption within the theoretical framework of both efficacy and effectiveness. This
necessitated the development of improved methods of measuring fish and LC n-3 PUFA
consumption, which can be used in the clinical setting, and are specialised for the
Australian context. This thesis provides new insights into the effectiveness of dietary
advice to consume fish and LC n-3 PUFA, which are required for the development of
evidence-based dietetic practice. It highlights substantial issues in maintaining moderate
levels of fish intake in the long term, utilising data collected during a 12 month clinical
trial. Social research utilising qualitative methods conducted with participants of the
same trial identified numerous barriers to fish consumption, and comparison with
control participants revealed than dietary advice received during the trial had little
impact upon these perceptions.
As a result of the prevalence of obesity, the metabolic syndrome and their
associated health risks, it is prudent to identify lifestyle factors which can increase
levels of adiponectin, which is both a biomarker of health and a vehicle to improve
health outcomes in the body. This is the first known study to compare the effects of fish
and LC n-3 PUFA supplements on both total and HMW adiponectin, the more
physiologically active form of adiponectin which is rarely reported in the literature. This
thesis is the first research to provide proof-of-concept of the favourable effects of
consumption of fish over LC n-3 PUFA supplement on this hormone, which is likely to
be due to food synergy.
This research provides valuable insights into the efficacy and effectiveness of
fish and LC n-3 PUFA consumption and their application to evidence-based dietary
advice and practice. The findings of this thesis can also inform strategies to increase fish
and LC n-3 PUFA consumption. Finally, this research contributes new knowledge on
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the efficacy and effectiveness of fish and LC n-3 PUFA consumption in the Australian
context, which is particularly relevant given Australia’s growing prevalence of obesity
(112) and low habitual fish intake (91).
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CHAPTER 2 – METHODOLOGY
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As was highlighted in Chapter 1, the comparative efficacy and effectiveness of
fish and LC n-3 PUFA consumption in the context of metabolic health are not fully
understood. Research is needed to compare the adherence to fish and LC n-3 PUFA
consumption recommendations and the perceptions of the food and the nutrient, as well
as the impact of fish and LC n-3 PUFA consumption on adiponectin, a biomarker of
metabolic health. In order to address the central hypothesis of this thesis and the
theoretical concepts of effectiveness and efficacy to be fully elucidated, methodological
issues in the current body of literature must also be considered.
The above research questions will be addressed throughout this thesis using a
number of approaches, in accordance with the complexity of the central hypothesis.
These approaches include clinical trial study designs, dietary assessment methods and
social research. These methods will be discussed in detail below, with considerations
given to the strengths and weaknesses of each method, and their use in the current
thesis. An overview of the framework of this thesis and the methodology applied in
each study is shown in Figure 2.1
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Thesis component

Measurement of fish
and LC n-3 PUFA
intake

Effectiveness of fish
and LC n-3 PUFA
consumption
recommendations

Perceptions of fish
and LC n-3 PUFA

Efficacy of fish and
LC n-3 PUFA
consumption

Study number
Study 1

Study 2

Study 3

Study 4

Study 5

Study design
 Methods
development
(food
composition
databases)

 Secondary analysis
of randomised
controlled trial
(inclusive of diet
history and
biomarker data)

 Social research
(focus group
interviews)

 Proof-of-concept
intervention trial
(utilising diet
history, food
records, and
biomarkers of
intake and health)

Figure 2.1 Overview of thesis studies and study design

2.1 Study designs

2.1.1 Clinical trials

The central aim of this thesis was to compare the impact of fish and LC n-3
PUFA consumption on health. In order to do so, clinical trial study designs were utilised
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throughout the thesis. Clinical trials investigate the effect of an intervention, for
example increased fish or LC n-3 PUFA intake, on a given outcome in a controlled
setting (153). Historically, clinical trials have often been used for therapeutic drug
development, and were aimed at finding the appropriate drug dosages (Phase I studies),
assessing potential side-effects (Phase II), comparing new treatments with standard
therapy (Phase III) and monitoring additional side-effects (Phase IV) (154). Dietary
clinical trials typically take the form of a Phase III study, also known as a comparative
treatment efficacy trial (154). These studies examine the effect of a given treatment on a
defined endpoint, in comparison to a control group receiving a placebo or other standard
treatment (154). Therefore, in the dietary context, clinical trials allow researchers to
investigate the role of foods or nutrients on specified health outcomes, whilst
controlling for other factors which could confound results, such as other dietary and
lifestyle factors. Such clinical trials are essential for the development of evidence-based
dietary advice (2)
When evaluating the scientific evidence for the improvement of dietetic advice
and practice, it is vital to consider the quality of the research conducted. Guidelines
provided by the National Health and Medical Research Council (NHMRC) cite
evidence obtained from a systematic review of randomised controlled trials (RCTs) as
the highest level of scientific evidence, with the second highest level being at least one
properly designed RCT (155).
RCTs are able to provide high-quality evidence as a result of their study design.
Randomisation of study participants prior to the commencement of the trial minimises
potential differences between study groups which could confound results (153, 156).
Inclusion of a control group confirms any effects seen are the result of the intervention,
by eliminating potential confounders such as seasonality and familiarisation to study
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regime (153). As dietary research is particularly susceptible to confounding (157), it is
thus desirable to test the effects of foods or nutrients on health with a properly designed
RCT.
However, as with many other forms of research, large-scale RCTs are expensive
to implement, and require a large time and personnel commitment (156, 158). In many
RCTs however, a wide breadth of data is collected, much of which may not be utilised
in the primary analysis. A solution to these problems is secondary analysis, which is a
form of data analysis performed on previously collected dietary data (158). Secondary
analysis allows for the application of the data to research areas and questions not
considered by the original analysis, and can ensure the utilisation of all data collected
(158). Whilst care must be taken when conducting secondary data analysis to ensure the
research question is appropriate for the original data, it is a technique that is used
increasingly by researchers (158). In fact, in recent years alone, several secondary
analyses of large scale dietary trials have been published (159-162). For example, Zhou
et al. (162) conducted a secondary analysis of a double-blind placebo-controlled clinical
trial which originally aimed to examine the effect of calcium and vitamin D on
osteoporosis. After applying an exclusion criteria appropriate to the aims of the
secondary analysis, Zhou et al. (162) examined the effect of calcium and vitamin D on
body composition and found that calcium supplementation resulted in a reduced
increase in fat mass and a reduced loss of lean mass. This finding, which was not
examined during the primary analysis, highlights the relevance of secondary analysis in
adding to the body of evidence for the effects of dietary components on health.
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2.1.1.1 Secondary analysis of a 12 month randomised controlled trial

As discussed above, the cost and time commitment involved in conducting
RCTs has resulted in secondary analysis of RCT data becoming a viable option in
nutrition research. In this thesis, data collected during a 12 month dietary clinical trial
was utilised for methods development (Chapter 4) and to examine changes in fish and
LC n-3 PUFA consumption over the duration of the trial (Chapter 5).
The Smart trial was a 12 month RCT conducted between 2008-2010 by
researchers at the University of Wollongong, a major coastal city 70 kilometres south of
Sydney, Australia (163) (Australian New Zealand Clinical Trials Registry Number:
12608000425392, www.anzctr.org.au). The aim of this trial was to examine the effect
of increased LC n-3 PUFA intake on weight management, via supplement consumption
and dietary strategies such as increased fish and LC n-3 PUFA enriched food intake.
Participants were randomly assigned to one of three diet groups: general dietary advice
with one daily placebo capsule (1g olive oil) (‘Control’ group), general dietary advice
plus additional advice to consume fish with one daily placebo capsule (1g olive oil)
(‘Fish’ group), and general dietary advice plus additional advice to consume fish with
one daily LC n-3 PUFA supplement (420mg EPA and 210mg DHA) (‘Fish+S’ group).
All participants received counselling on a healthy food plan with a two megajoule (MJ)
deficit per day (including avoidance of high fat foods and use of low fat staple foods)
provided by Accredited Practising Dietitians. All participants received individualised,
face-to-face education sessions with a dietitian, consisting of dietary education (one
hour) and follow-up (30 minutes) sessions at baseline, one, two, three, six, nine and 12
months. Participants in both the ‘Fish’ and ‘Fish+S’ groups were specifically instructed
to consume 180 grams of fish per week, with an emphasis on consumption of fatty fish
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high in LC omega-3 PUFA. This prescription was supported by print materials on fish
based recipes and meal ideas. Participants in the control group were not given specific
advice regarding fish intake, but were instructed to consume a specific amount of foods
rich in protein, of which fish was an option. The design of the Smart trial is shown in
Figure 2.2.

All trial participants: 2 MJ deficit per day plus one of three trial diets

‘Control’
Daily placebo
capsule (1g olive
oil/day)

‘Fish’
Advised to
consume 180g
fish/week plus daily
placebo capsule (1g
olive oil/day)

‘Fish + S’
Advised to
consume 180g
fish/week plus daily
LC n-3 PUFA
capsule (630mg
EPA + DHA/day)

Figure 2.2: Study design of the Smart trial

Participants were recruited from the local community by media advertising.
Inclusion criteria were aged 18-60 years, body mass index (BMI) >25 and <37kg/m²,
waist circumference >94cm for men, >80cm for women, generally well. Exclusion
criteria were major illnesses, diabetes mellitus, LDL ≥6mmol/L, food allergies or habits
inhibiting compliance, illiteracy, inadequate conversational English, taking LC n-3
PUFA supplements, inability to undertake study requirements, pregnancy/lactation, not
weight stable (within three kg) for the past six months, or on a weight-reducing diet.
Ethical approval for the research and the secondary analyses reported in this thesis was
provided by the University of Wollongong Human Research Ethics Committee. Signed
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consent was given by all participants. Further information on the Smart trial can be
found in Appendix A. A copy of the letters granting ethical approval and relevant ethics
amendments are provided in Appendix B.

2.1.1.2 Proof-of-concept trials

Due to the aforementioned cost involved in undertaking full scale RCTs, short
term clinical trials with smaller sample sizes can be implemented in order to develop
proof-of-concept of the effect of a food or treatment on a health outcome, as in the case
of Hanzu et al. (164) and Hausmann et al. (165). This is particularly useful for
exploring the potential effects of foods or treatments for which minimal previous
research has been carried out. In this thesis, a short term dietary clinical trial was
conducted in order to assess proof-of-concept of the differing effects of fish and LC n-3
PUFA supplements on adiponectin in humans (Chapter 7). Use of this study design was
justified due to the paucity of research comparing the impact of the whole food and
nutrient on this health outcome.

2.1.1.3 Outcome measures of clinical trials: a biomarker of metabolic health

As was previously outlined, biomarkers of health provide viable outcomes in
clinical trials. However, when ascertaining the suitability of a biomarker as a clinical
trial outcome, issues relating to collection and analysis should be considered. The
literature suggests that ideally, biomarkers should be able to be measured in a biological
sample that can be readily collected and stored, for example plasma or serum blood
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samples (166). Furthermore, the methods used to assess biomarker levels should be
specific, standardised and sensitive (166).
As was outlined in Chapter 1, the adipocyte hormone adiponectin is a biomarker
of metabolic health, as a result of its known anti-inflammatory, insulin sensitising and
anti-obesity effects (119-121). From a methods perspective, adiponectin can also be
considered to be an appropriate biomarker of metabolic health firstly due to its practical
methods of collection and analysis. Fasting plasma or serum samples of adiponectin can
be collected via standard venipuncture techniques, and as it circulates in the body at
relatively high concentrations, only a small amount of sample is required (167).
Adiponectin levels have also been shown to experience minimal diurnal variation in
comparison to other hormones such as cortisol (168), decreasing the risk of differences
in collection time influencing concentrations. Once collected, adiponectin samples can
be analysed using commercial enzyme linked immunoassay (ELISA) or
radioimmunoassay kits, which are readily available (167).
Adiponectin concentrations are known to be higher in females than males (126,
135) and tend to be higher in older individuals (169). Whilst this could result in
difficulties in comparing adiponectin levels in a heterogeneous sample, Kusminski and
Scherer (133) highlight that measurements should focus on the change in an
individual’s adiponectin level over time. This would thus provide a more accurate
measurement of changes in metabolic health than a single measurement taken at any
one individual time point (133).
As discussed in Chapter 1, HMW adiponectin is widely thought to be the most
physiologically relevant form of adiponectin (151). It is thus important that HMW
adiponectin levels be measured as well as total adiponectin. Detection of protinase K, a
protease which can selectively digest low and middle molecular weight adiponectin,
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means that HMW adiponectin can be separated from total adiponectin and measured
(170). There is currently only one commercially available ELISA kit which can quantify
the concentrations of the different forms of adiponectin, including HMW adiponectin, in
a single sample. This assay has been shown to be sensitive and reproducible (171), and
was thus used in this thesis.
Circulating adiponectin levels are known to be strongly influenced by genetic
factors, with a recent review estimating that genetic factors accounted for between 30 –
70% of the variability in circulating levels (172). Given the degree of influence genetic
factors have on adiponectin levels, it is prudent that these factors be assessed when
measuring changes in adiponectin following a dietary intervention in order to remove a
potential confounding variable.
Single nucleotide polymorphisms (SNPs) are nucleotide alterations in the DNA
sequence of a gene which occur in more than 1% of the population and can result in
substantial variations in the functioning of a gene (173). Adiponectin is encoded by the
gene ADIPOQ, and SNPs in this gene have been shown to be associated with differing
levels of circulating adiponectin. For example, individuals carrying the C allele of the
ADIPOQ SNP rs266729 have been found to have lower levels of circulating
adiponectin than those homozygous for the G allele (174).
SNPs in genes associated with obesity may also be associated with alterations in
circulating levels of adiponectin. As highlighted in a recent review, SNPs in the fat
mass and obesity-associated gene (FTO) have been associated with an increased risk of
obesity in a variety of different populations (175). Due to the known links between
obesity, inflammation and decreased adiponectin levels (176), it is likely that SNPs in
FTO may also be linked to altered levels of adiponectin. In fact, Caucasian women who
were homozygous for the A allele of the FTO SNP rs9939609 have been found have
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lower circulating levels of adiponectin than those homozygous for the T allele (177).
The influence SNPs in ADIPOQ and FTO can have on circulating levels of adiponectin
and health outcomes highlights the need to assess them in dietary trials, in order to
eliminate potential confounding variables and fully elucidate the effect of the food or
nutrient on health. Therefore, in the proof-of-concept study comparing the effect of fish
and LC n-3 PUFA supplements on adiponectin levels outlined in this thesis, SNPs in
ADIPOQ and FTO were measured in order to remove this factor as a potential
confounding variable.

2.1.2 Dietary methodology

2.1.2.1 Dietary assessment methods

Dietary clinical trials rely upon collection of accurate dietary intake data. A
range of dietary assessment methods exist, each with their own inherent strengths and
limitations (178). The dietary tools utilised in this thesis include the diet history
interview and the food record, thus they will be discussed in greater detail.
Diet history (DH) interviews collect dietary data retrospectively via an openended narrative interview (179). They are typically conducted by a trained interviewer
who asks the participant about their usual food habits at each meal and snack, often with
prompts for commonly forgotten items, and usually have a duration of approximately
one hour. In the DH utilised for the work of this thesis, interviewers, namely Accredited
Practising Dietitians, obtained information on consumption of meals and snacks on a
weekly basis covering a time period of approximately three months prior to the
interview (179). After recalling the foods, participants were asked about the frequency
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and amount of food consumed, assisted by food models or images of different food
portions to improve the accuracy of portion size recall. Following the DH interview, a
frequency check list of commonly consumed foods was read to the participant, which
was designed to identify any foods the participant had forgotten to name (179). The DH
utilised in this thesis has been found to have good validity relative to another dietary
methodology over a 12 month period in an overweight population with type 2 diabetes
mellitus (179).
An advantage of DH interviews is that they result in minimal participant burden.
As they ask about foods consumed on a weekly, fortnightly, or monthly basis, they are
able to detect foods that may not be consumed on a daily basis, which are often
overlooked by other dietary assessment methods (178), such as fish or alcoholic
beverages. For this reason DH interviews also able to provide useful information about
dietary patterns and habitual intake (179). However, DH interviews are reliant on
participant’s memory, and are thus susceptible to recall bias. Furthermore, as DHs are
administered by interviewers, the quality of collected data can be dependent on the
experience and skill of the interviewer (180).
Conversely, food records (FRs) collect actual dietary intake data prospectively
(181). Participants record all foods and beverages consumed each day for a set number
of days. Whilst food records of different durations have been used in the literature,
shorter collection periods of three to four days have been shown to result in the most
accurate data, due to the high participant burden associated with lengthier recording
periods (182, 183). For the work of this thesis, dietary intake data was recorded and
collected over a three day period, a duration which has been found to account for most
of the variation in food intake over a two week period (184). Therefore, a recording
period of three days provides a good indication of long-term food consumption, whilst
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placing less burden on study participants than a longer period of recording time. In the
studies outlined in this thesis, participants were advised to record their individual
dietary intake on two weekdays and one weekend day, and were provided with a set of
measuring spoons and cups to assist them in recording their food intake.
An advantage of using FRs is that due to their prospective nature, they are not
reliant on participant’s memory and place minimal burden on study investigators (185).
However, FRs can be time-consuming to complete for study participants, and are
susceptible to bias whereby the act of recording dietary intake may cause participants to
change their food intake (181).
Both DH interviews (186) and FR (79) have been used in the literature to
measure fish intake. However, as previously mentioned, the occasional nature of fish
consumption in Australia (84) means DH interviews are best suited to detect fish intake,
as well as other infrequently consumed foods (178). Preliminary analysis conducted for
this thesis to compare the accuracy of fish intake data collected via DH and FR confirms
this, with only the DH measurement of baseline fish consumption in a 12 month RCT
found to be significantly correlated (p<0.001, r = 0.338) with a biomarker of LC n-3
PUFA intake (unpublished data). For this reason, only dietary data collected using the
DH was reported in Chapter 5 of this thesis. Conversely, as more frequent fish intake
was achieved in the experimental study described in Chapter 7, dietary data collected by
both DH and FR was reported.

2.1.2.2 Food composition databases

Food composition databases allow food intake data collected via dietary
assessment methodologies to be translated into nutrient data (187). Nutrient data
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calculated using food composition databases is useful for not only assessing the health
impacts of consuming a specific nutrient in dietary clinical trials, but also for
determining the nutritional adequacy of a population and evaluating the effects of
nutrition advice and education programmes (187). A wide range of food composition
databases have been developed around the globe, but, as was highlighted in Chapter 1,
food composition data which is specific to each country is most desirable (188).
Whilst food composition databases are a crucial part of analysing dietary intake
data, there are several limitations to their use. These limitations often relate to the
sources of the nutrient data. Whilst many foods may be directly analysed in a laboratory
to obtain their nutrient values, other values may be obtained by imputation of analysed
data from a similar food or by borrowing nutrient data from other food composition
databases, often from other countries (188). In the case of LC n-3 PUFA, borrowed data
in particular should be treated with caution, due to the variation that may exist in the
fatty acid content of fish and meat products between countries (84, 85). Variation in
water temperature results in geographical differences in the fatty acid content of fish at a
given time of year, with increased fat storage occurring in colder temperatures (85,
189). In addition, meat from grain-fed livestock has been found to have a lower LC n-3
PUFA content than ruminants fed grass (190), which is the feeding practice typically
used in Australia (84).
A number of Australian food composition databases exist, including the national
food composition database, the NUTrient Data TABle for Use in Australia (NUTTAB)
(191-193) and the survey specific database, the Australian Food and Nutrient Database
(AUSNUT) (40, 194). These databases are periodically updated in line with changes in
food consumption and nutrient content. In this thesis, dietary data was analysed using
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two versions of AUSNUT and thus these databases will be discussed in greater detail in
the following sections.

2.1.2.2.1 Australian Food and Nutrient Database 1999

AUSNUT1999 is a food composition survey database developed by Australia
New Zealand Food Authority, now known as Food Standards Australia and New
Zealand (FSANZ) (194). AUSNUT1999 contains nutrient data on n = 4,500 foods,
including nutrient data on recipe items (195)
AUSNUT1999 was based on data collected in the 1995 NNS of Australia, a
dietary survey which was carried out from February 1995 to March 1996. Dietary data
was collected from approximately n = 13,000 participants aged two years and older in
all states and territories of Australia. Dietary data was collected via a 24 hr recall
conducted by a trained nutritionist and a self-completed food frequency questionnaire
for participants aged 12 years or older. Information was also sought on participant’s
eating habits and patterns (113).
A strength of AUSNUT1999 is that dietary data was collected from participants
from a range of age groups, giving a representative indication of food habits for all age
ranges. Furthermore, as a survey database, the use of AUSNUT1999 has several
advantages compared to the reference database available at the same time, the national
food composition database, NUTTAB95 (191). As a survey database, AUSNUT1999
contained all data included in NUTTAB95, with the additional inclusion of a range of
branded food items and other food products reported by NNS participants, as well as the
full range of nutrient data for each item (196), making it more appropriate for use in the
clinical trial context.
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Conversely, a limitation of AUSNUT1999 is that as the NNS was conducted in
1995, it is likely that the nutrient data for many products is outdated, and the food items
may not be representative of the range of food products available to consumers today.
Furthermore, whilst it contains data for 28 nutrients, it lacks data on a number of
physiologically relevant nutrients such as iodine and individual fatty acids, including
LC n-3 PUFA. As AUSNUT1999 was the most up-to-date survey specific food
composition database available at the time of study commencement, dietary data
collected during the Smart trial was originally analysed using AUSNUT1999.
Therefore, in this thesis an alternate Australian food composition database inclusive of
LC n-3 PUFA data was required to measure dietary intake of this fatty acid.

2.1.2.2.2 Australian Food and Nutrient Database 2007

AUSNUT1999 remained the only survey database available within Australia for
a period of nine years. In October 2008, AUSNUT2007 was released (196).
AUSNUT2007 is a newer survey food composition database developed by FSANZ,
containing nutrient data on n = 4,225 food and beverage items, as well as dietary
supplement data (40). AUSNUT2007 was developed for the nutrient analysis of the
2007 National Children’s Nutrition and Physical Activity Survey (‘Kids Eat Kids
Play’). This survey was carried out in n = 4, 487 children aged two to 16 years old from
February to August 2007. Dietary data was collected using a computer-based 24-hr
recall conducted by trained interviewers, with data on eating habits also collected (197).
In comparison to AUSNUT1999, AUSNUT2007 contains updated nutrient data
for most food items, making it more relevant to current nutrient analyses. An additional
strength is the greater number of nutrients included in the database. AUSNUT2007 has
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data for 37 nutrients, including several ‘new’ nutrients of interest to researchers such as
iodine and individual fatty acids, including LC n-3 PUFA. Furthermore, AUSNUT2007
also contains nutrient data on a wide range of dietary supplements consumed by survey
participants (40).
However, a limitation of AUSNUT2007 is that as the survey was limited to
children, the nutrient data is thus limited to foods children consume. AUSNUT2007
therefore, does not contain nutrient data on all products consumed by the wider
population, and has minimal information on food items not typically consumed by
children, for example alcohol. This limitation was taken into consideration when using
AUSNUT2007 during this thesis.
In this thesis, dietary data collected during the Smart trial was converted from
AUSNUT1999 to AUSNUT2007 to allow for the measurement of LC n-3 PUFA
consumption via a defined strategy outlined in Chapter 4.

2.1.2.3 Biomarkers of fatty acid intake

Due to the inherent limitations association with the use of the dietary assessment
methods discussed in previous sections, biomarkers are often used as an objective
measure of dietary intake. In the case of fatty acids including LC n-3 PUFA, there are a
range of biological specimens used as biomarkers of dietary intake, including plasma,
erythrocytes, cholesterol esters, triglycerides, phospholipids, platelets and adipose tissue
(198). These specimens all have varying strengths and limitations to their use, however,
this section will discuss only the fatty acid biomarkers utilised in this thesis – plasma
and erythrocyte levels of LC n-3 PUFA.
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2.1.2.3.1 Plasma fatty acids as biomarkers of intake

Total plasma and plasma phospholipid levels of EPA and DHA are frequently
used as LC n-3 PUFA biomarkers due to their high levels of accessibility (166) and
simple isolation and analysis methods compared to some other blood fractions (199). A
recent review concluded that both total plasma and plasma phospholipids were good
biomarkers of DHA status in a number of groups including adults (200).
Changes in plasma levels of LC n-3 PUFA are typically thought to reflect recent
changes in diet (201). Cao et al. (202) found rapid and significant increases in the
plasma phospholipid LC n-3 PUFA concentrations of healthy volunteers supplemented
with LC n-3 PUFA for eight weeks. EPA concentrations returned to baseline levels two
weeks after the supplementation was ceased, highlighting this biomarker’s rapid
response to changes in LC n-3 PUFA intake.
Similar results have been found for total plasma levels of LC n-3 PUFA.
Metherel et al. (201) measured changes in levels of LC n-3 PUFA following LC n-3
PUFA supplementation in a number of blood fractions including total plasma. Increases
in levels LC n-3 PUFA, as a percentage of total fatty acids, occurred most rapidly in the
plasma samples and, when supplementation was ceased, plasma levels of LC n-3 PUFA
were significantly lower than those measured by any other blood fraction. These results
suggest that of the commonly measured blood fractions, both total plasma and plasma
phospholipids have the fastest response to changes in dietary intake. As plasma fatty
acids are sensitive to recent changes in dietary intake, this biomarker was used in the
short term proof-of-concept study outlined in Chapter 7 of this thesis. However, plasma
measures may not be appropriate as measures of habitual dietary intake, for example in
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the 12 month RCT utilised in this thesis, thus an alternate biomarker of fatty acid intake
was needed.

2.1.2.3.2 Erythrocyte fatty acids as biomarkers of intake

As with plasma fatty acids, erythrocyte membrane fatty acid levels are
commonly used in the literature as a biomarker of dietary intake, and have also been
shown to be a good biomarker of DHA status in a recent review (200). Erythrocyte
levels of LC n-3 PUFA have also been found to significantly correlate with levels of the
same fatty acids in human cardiac tissue (203).
In comparison to the short-term changes seen in plasma (201, 202), the literature
suggests erythrocyte fatty acids are more representative of long term dietary intake.
Katan et al. (204) investigated the effect of supplementation of different doses of LC n3 PUFA supplements over a one year period, followed by a six month wash-out period,
on LC n-3 PUFA levels in different lipid fractions. Whilst EPA levels were seen to
increase in erythrocytes three days after supplementation began, the rate of
incorporation was found to be slower than other lipid fractions, with half maximal
concentrations of EPA reached in 28 days in comparison to 4.8 days for serum EPA
levels. Furthermore, erythrocyte levels were also found to respond more slowly to
supplement cessation, with EPA levels only found to approach baseline levels by the
end of the study, six months after the supplementation had ceased. Similar results were
found by Cao et al. (202) and Metherel et al. (201), who both found erythrocyte LC n-3
PUFA levels responded more slowly to changes in supplementation than did plasma
phospholipids and whole plasma respectively, suggesting erythrocyte fatty acid levels
may not be as susceptible to recent dietary changes. A study by Skeaff et al. (205) did
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contradict these findings by noting similar changes in both erythrocytes and plasma
phospholipids in response to alterations in the fatty acid composition of the diet.
However, the short duration of this study and lack of a wash-out period mean the long
term responses of the blood fractions seen in the previous studies could not be assessed.
The erythrocyte lifespan of approximately 120 days may play a role in mediating this
time course, with study durations of longer than four months recommended in order to
observe all changes in LC n-3 PUFA levels (206, 207).
The slower response to recent dietary changes seen in erythrocytes means that
this blood fraction may be more appropriate for use as a measure of habitual LC n-3
PUFA intake. An observational study of n=306 women compared LC n-3 PUFA intake
as measured by a food-frequency questionnaire with erythrocyte and total plasma fatty
acid levels (208). Erythrocyte levels of both EPA and DHA were found to have a
stronger association with habitual LC n-3 PUFA intake than levels measured in plasma,
supporting the concept that erythrocytes are a preferable measure of long-term fatty acid
consumption.
In addition to being a biomarker of intake, erythrocyte fatty acids are also used
utilised as a potential risk factor for cardiovascular disease, the omega-3 index (209,
210). The omega-3 index is calculated as the EPA plus DHA content of erythrocyte
membranes as a percentage of the total fatty acids present (209). The omega-3 index has
been shown to be a biomarker of LC n-3 PUFA intake (209) and has been suggested to
be a risk factor for coronary heart disease, with a higher omega-3 index postulated to be
associated with the greatest cardioprotection (209). Whilst the omega-3 index has been
validated against other biomarkers of fatty acid intake, including plasma phospholipids,
whole blood samples (209) and cardiac biopsies (203), it requires further independent
validated in wider populations of varying metabolic statuses and backgrounds. Despite
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this limitation, due to its association with health outcomes and dietary intake (209) and
its tendency to reflect habitual diet, the omega-3 index has been utilised as a biomarker
of fatty acid intake in the 12 month RCT utilised in this thesis.

2.1.3 Social research methods

The clinical trial study design and dietary methods used in this thesis address
one component of the central hypothesis - the comparison of the impact of fish and LC
n-3 PUFA supplement consumption on health. However, in order to assess the
effectiveness of fish and LC n-3 PUFA consumption recommendations, behavioural
factors which can influence consumption must also be investigated. As was previously
highlighted in Chapter 1, investigating perceptions of fish and LC n-3 PUFA intake,
including motivators and barriers to consumption, is an important part of developing
evidence-based dietary advice. Dietary advice research can provide vital information on
the suitability of consumption recommendations, can help to evaluate the effects of
dietary advice, and can assist in the targeting of future advice and education strategies
(211).
A type of social research, a focus group is a form of group interview, during
which an emphasis is placed upon participant interaction (212). This use of participant
interaction and group discussion can facilitate participant communication and thus can
assist in exploring participant’s attitudes and perceptions (213). Focus group interviews
also allow not only for the exploration of knowledge and perceptions, but also the
reasons behind such perceptions (214), making them a valuable tool in the context of
evidence-based dietary advice.
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There are a number of elements which must be considered when designing focus
groups. The typical size of each focus group varies greatly, with sizes of four to eight
(214) and eight to 12 (215) participants recommended in the literature. It has been
suggested by Wong et al. (216) however, that a smaller number of four to six
participants, as used in this thesis, may be more suitable if the researcher wants to
ensure participation from each subject. Whilst the number of focus groups conducted
may depend on the resources of the researcher, it is desirable that a state of data
saturation be reached, meaning that later groups repeat themes, with no new information
collected (217). Confirmation of saturation was thus sought in the focus groups outlined
in this thesis.
An important consideration of conducting focus groups is the moderator. The
moderator leads the focus group and facilitates the group interaction and discussion
(218). They can also use probing questions in order to explore a concept or the
reasoning behind it further (219), which is a key feature of focus group interviews
(220). In scenarios where results of separate focus groups need to be compared, such as
in this thesis, the moderator can also design questions to ensure a higher level of
standardisation (220). Standardisation can be achieved via the technique of ‘funnelling’,
whereby a set of fixed questions are initially used to improve comparability between
groups, with later probing questions and discussion dependent on the specific needs of
each group (220). In addition to the moderator, the focus groups outlined in this thesis
included an observer, who acted to transcribe the discussion in addition to recording
non-verbal cues such as facial expressions or body language which would not be
detected by an audio-recording (216).
Whilst a number of techniques exist for the analysis of focus group data, the
current thesis utilised ‘framework’ analysis, as described by Ritchie and Spencer (221),
91

and which has been used widely in health-based social research (222-228). This type of
analysis involves five key stages: familiarisation; identifying a thematic framework;
indexing; charting; and mapping and interpretation. Familiarisation involves the
researcher acquainting themselves with the data collected during the groups, such as the
transcripts, audio recordings and observer’s notes, whilst during the second stage the
researcher uses these resources to begin identifying the themes of the groups. Following
this stage, the researcher then indexes the data, identifying exemplar quotes and noting
their use within and between groups, and applying the thematic framework to all of the
data. Quotes are sorted into themes as part of the charting stage. Data reduction is a key
component of both the third and fourth stage of ‘framework’ analysis and can be carried
out in several ways, such as by hand or, more recently, by using specially designed
computer programs to manage large quantities of data (217). NVivo (QSR International
Pty Ltd, Melbourne, Australia) is one example of such a computer program, which can
be used to aid researchers in managing focus group interview transcripts, organise
quotes and code and identify themes appearing in the data (229). NVivo has been
widely used in the literature to analyse focus groups, with a number of studies
conducted in recent years alone (230-234), and was used in this thesis to reduce and
analyse the focus group data.
The final stage of ‘framework’ analysis is mapping and interpretation. This
involves interpreting the meaning of the quotes and themes, as well as understanding
the links between each theme (235). It is recommended by Krueger (236), that when
interpreting the data a number of elements must be considered, including the meaning
of the words used, the context of the groups, the frequency and intensity of comments
made, the internal consistency of participant’s comments, the specificity of responses
and any big ideas that emerge throughout the discussion, rather than in individual
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quotes. Whilst variations on these elements have been developed in the literature (235),
the use of any set interpretation framework ensures internal consistency in interpretation
and reporting of focus group data.
Whilst there are many advantages to focus group research, there are some
limitations of this method which should be taken into account. Due to the group setting
there is some risk of dominant participants biasing opinions, with views also potentially
being biased by the presence of the moderator (216). However, an experienced
moderator can overcome these issues by ensuring all participants are included and
limiting the likelihood of one participant dominating the discussion, and by ensuring
participants know there is no right or wrong answer (216). An additional limitation is
that as focus group interviews tend to involve a small number of participants who are
typically not randomly selected and responses may not always be generalizable to the
wider population (219). Data collected during this thesis was thus interpreted with this
in mind.

The methodological framework utilised in this thesis has been established in this
chapter. In order to address all aspects of the central hypothesis that whilst consuming
fish is more beneficial to health than LC n-3 PUFA supplements, behavioural barriers
impede the effectiveness of habitual fish consumption recommendations, a number of
different methods were required. Therefore this framework considered several aspects
of study design, including secondary analysis of a RCT and a proof-of-concept study,
dietary methods and social research. A detailed overview of each method has been
provided in this chapter, which has also justified the use of each method in the wider
context of this thesis. Whilst this chapter has given an overview of the methodological
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framework utilised in this thesis and justified its use, the ensuing chapters will also
provide details of the methods specific to each study where relevant.
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CHAPTER 3 – DEVELOPMENT AND VALIDATION OF A DATABASE FOR
THE ESTIMATION OF THE FISH CONTENT IN CANNED PRODUCTS

The majority of this section is the substantive content of the published work: Neale EP, Probst
YC, Batterham MJ, Tapsell LC. Development and validation of an Australian database for estimating the
seafood content of canned products. Food and Nutrition Sciences. 2011; 2: 759 – 763
EN was responsible for the design of the study, organisation and leading the study, data
collection and analysis and preparation of the manuscript. LT, YP and MB were responsible for critical
discussions of the study design and analysis and critical revisions of the manuscript.

The findings of this study were also presented in: Neale EP, Tapsell LC, Probst YC, Batterham
MJ. Development and validation of a database for approximating the percentage fish in canned fish
products. Nutrition Society Annual Scientific Meeting, Perth. 2010 (oral presentation at national
conference)
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Accurate comparison of the impact of fish and LC n-3 PUFA consumption on
health is dependent upon the tools used to measure dietary intake, however, as was
previously outlined in Chapter 1, current methods for measuring fish intake fail to take
additional ingredients in canned fish products into account. Therefore, this chapter
outlines the development and validation of a database designed to estimate the fish
content of canned products to ensure accurate measurement of fish consumption, and to
address a methodological problem which has been overlooked in the literature. The
database is the first of its kind and was specifically designed for use in the Australian
context. The database was utilised in the studies outlined in subsequent chapters of this
thesis to estimate fish intake, in order to compare the impact of fish and LC n-3 PUFA
consumption on health.

3.1 Introduction

In order for the health impact of fish and LC n-3 PUFA consumption to be
compared with the goal of designing evidence-based dietary advice, accurate methods
of measuring intake of the food and nutrient must be developed. In the case of fish, this
is particularly relevant for canned products, as there is evidence that these products are
increasing in popularity as a convenient source of fish in Australia. The most recent
NNS, conducted in 1995, found that packed fish and seafood, which included canned
products, were on average 12.8% of all fish consumed (91). In contrast, a survey
conducted in 2006 in Melbourne, Victoria found that canned fish accounted for more
than one third of seafood purchases, and that canned tuna was the most popular fish
species bought for in-home consumption, indicating an increase in the consumption of
canned fish products (237).
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Australian and international nutrient databases such as AUSNUT 2007 (40) and
the United States Department of Agriculture (USDA) National Nutrient Database for
Standard Reference (238) contain nutrient data on a variety of canned fish products,
based on the edible portion of each product. Whilst this allows for the calculation of
nutrient intake, no data is available on the percentage fish in these canned products in
these databases, which is essential for accurately measuring consumption of fish.
FSANZ specifies that canned fish products, like most foods, must contain
percentage labelling of all characterising ingredients and components (239). Canned
fish products must list the percentage fish in the product, calculated as the weight of the
fish as a percentage of the total weight of the product (239). Percentage labelling of
canned fish is of particular significance given the popularity of the products in
Australia, and the inclusion of packing mediums such as oil, brine, and added
flavourings and sauces which may contribute a substantial percentage of the weight of
the total product (Choice, January/February 2004, p15 – 19). Furthermore, given the
large number of clinical trials investigating the effects of fish consumption on human
health (61, 71, 75, 76, 240, 241), it is of high importance that such studies adjust for the
percentage of fish contained in canned products, as the assumption that the weight of
fish consumed is the same as the net weight of the can’s contents could result in
dramatic overestimations of fish consumption. As was discussed in Chapter 1, to date
no known studies measuring fish consumption have reported an adjustment for this
variation.
The aim of this study was to develop and validate a database of the percentage
fish contained in a range of common canned products, which could in turn be used to
estimate fish consumption from canned products in the subsequent studies outlined in
this thesis.
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3.2 Methods

3.2.1 Development and validation of canned fish database

To identify all available varieties of canned fish, an audit was carried out on the
six major supermarket chains in the Illawarra region of New South Wales, Australia.
Data collected included name, total weight and percentage fish contained in the product,
as stated on the label. Samples were excluded from further analysis if they were not in
stock on the day the audit was taken or if the fish content was less than one third of the
total weight. A database of canned fish products was then developed, with products
categorised according to species and packing medium (for example springwater, oil,
brine, or added flavourings). Products were considered to be flavoured if they contained
any flavouring in addition to the water, oil or brine, for example tuna in springwater
with lemon.
As canned tuna products were found to be the dominant canned product
available, validation of the database was carried out in canned tuna products only. The
number of samples required to yield a sample mean within 10% of the population mean
was calculated according to the method described by Proctor and Meullenet (242). A
stratified sampling technique was used by dividing samples into their packing medium,
which included springwater, oil, brine, and flavoured tuna products and stratifying
according to brand (188). The required number of samples for each packing medium
and brand was then randomly selected using Statistical Package for Social Sciences
(SPSS) (Version 15, SPSS Chicago IL, 2006).
The amount of tuna in the selected canned products was measured using the
methods described in the Codex Alimentarius (243). Briefly, for samples canned in
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springwater, oil or brine, the contents of the can were poured through a pre-weighed
wire sieve, weighed on a CAS SW-1 scale. The fish was allowed to drain at an angle of
17 - 20º for two minutes. The sieve containing the drained fish was then weighed and
the total weight of the drained fish determined by subtracting the original weight of the
sieve.
For flavoured tuna samples, a similar procedure was used; however contents
were washed with warm water (approximately 30° Celsius) prior to weighing to remove
any sauces. Ingredients such as onion, chilli and beans were also removed with pincers
prior to weighing. Additional steps were then undertaken to improve the accuracy of the
measurement, following the findings of a pilot study using n=7 tuna products in
different packing mediums. After the removal of the fish, the can was filled with warm
water to remove any remaining fish. This water was then poured through the sieve as
well. Following this step, the fish was also pressed with paper towel to remove any
excess liquid, with care taken to ensure no fish adhered to the towel.

3.2.2 Statistical analysis

All statistical analyses were carried out using SPSS (Version 15, SPSS Chicago
IL, 2006). Statistical significance was set at p = 0.05. Mean and standard deviation (SD)
of data from the audited samples were calculated for the total grams of fish and
percentage fish as expressed on the label, in order to develop the database. After
weighing the tuna samples, grams of fish were converted to a percentage of the total
weight to allow for comparison between the different serving sizes used between
brands. The mean and SD of the percentage fish expressed on the product label and as
weighed were calculated. The normality of the label and weighed data were determined
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using the Shapiro-Wilks test. Independent sample t-tests and Mann-Whitney tests were
used to compare the label and weighed data for each category of canned tuna product,
for parametric and non-parametric data respectively.

3.3 Results

The supermarket audit found n = 223 canned fish products. Four samples were
excluded as they were not in stock on the day of the audit and n = 5 samples were
excluded as their fish content was less than a third of the total weight of the product,
resulting in n = 214 samples remaining for further analysis. Samples were recorded for:
canned tuna products (n = 144), canned salmon (n = 31), canned sardines (n = 23),
canned oysters (n = 5), canned mackerel (n = 3), canned herring (n = 2), canned mussels
(n = 2), canned anchovies (n = 1), canned kipper (n = 1), canned prawns (n = 1), and
canned crab (n = 1) (Appendix C). The mean and SD for these products is shown in
Table 3.1, as a summary of the database. The percent fish varied between the type of
fish in the canned products and the canning medium. Salmon canned in brine had the
highest reported percentage fish, whilst flavoured tuna products had the lowest.
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Table 3.1 Mean + SD grams and percentage fish in canned products, as expressed on
the label
Fish category

Grams fish (g)

Percent fish (%)

Tuna (n = 144)

71.7 + 48.1

60.4 + 11.3

- Springwater (n = 15)

106.5 + 84.5

70.2 + 5.3

- Oil (n = 20)

86.4 + 27.0

70.4 + 5.3

- Brine (n = 11)

147.8 + 95.1

69.6 + 5.2

- Flavoured (n = 98)

54.8 + 11.8

55.8 + 10.4

Salmon (n = 31)

99.8 + 69.5

72 + 14.7

- Springwater (n = 4)

96.9 + 37.8

64.5 + 5.3

- Brine (n = 13)

139.8 + 91.3

82.0 + 15.9

- Flavoured (n = 14)

63.5 + 10.5

64.6 + 9.1

Sardines (n = 23)

81.0 + 10.6

70.9 + 9.3

- Springwater (n = 3)

86.4 + 10.3

76.0 + 11.1

- Oil (n = 9)

85.1 + 7.5

75.0 + 9.5

- Flavoured (n = 11)

76.1 + 11.5

66.0 + 6.3

Oysters (n = 5)

64.2 + 3.8

73.0 + 2.7

- Oil (n = 3)

65.8 + 3.6

73.0 + 2.9

- Flavoured ( n = 2)

61.6 + 3.0

73.0 + 3.5

187. 1 + 91.3

67.3 + 4.0

- Oil (n = 1)

191.3 + -

65.0 + -

- Brine (n = 1)

93.8 + -

72 + -

- Flavoured (n = 1)

276.3 + -

65 + -

Herring (n = 2)

122.0 + 11.3

62.5 + 3.5

Mussels (n = 2)

66.9 + 4.4

72.5 + 3.5

Anchovies (n = 1)

26.1 + -

58.0 + -

Kipper (n = 1)

150.0 + -

75.0 + -

Prawns (n = 1)

120.0 + -

60.0 + -

Crab (n = 1)

120.7 + -

71.0 + -

Mackerel (n = 3)
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For validation of the database, samples were collected for: tuna canned in
springwater (n = 12), tuna canned in oil (n = 12), tuna canned in brine (n = 10), and
canned flavoured tuna (n = 25). The number of samples selected was sufficient to
provide a sample mean within 10% of the population mean (188). The mean and SD of
the percentage tuna reported on the label and found after weighing is shown in Table
3.2. There was no significant difference between the label and weighed data in all tuna
categories or in total tuna products. Weighed percentage tuna was found to be slightly
lower than reported percentage tuna for springwater, oil and brine, but was higher for
flavoured tuna products.

Table 3.2 Mean + SD and p-value of reported and weighed percentage fish in canned
fish products
Tuna Category

P – value

Reported percent fish

Weighed percentage

(%)

fish (%)

64.0 + 11.0

62.8 + 9.2

0.784a

- Springwater (n = 12)

71.1 + 5.1

67.2 + 6.0

0.111a

- Oil (n = 12)

71.2 + 5.4

69.9 + 7.3

0.271b

- Brine (n = 10)

69.3 + 5.3

66.8 + 6.4

0.349b

- Flavoured (n = 25)

51.9 + 9.9

54.6 + 7.7

0.535b

Total (n = 59)

a Mann-

Whitney test

b Independent

samples t-test

3.4 Discussion

The results of this study confirmed that the percentage labelling of fish in a
sample of canned products did not differ significantly from the actual percentage. This
study is the first known attempt to develop a database of the percentage fish present in
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canned products. Previous observational studies which have approximated fish
consumption through the use of dietary records and questionnaires often do not adjust
for the presence of additional ingredients in fish products, instead calculating fish
consumption as being equal to reported fish intake (15, 17, 18, 28-31).
The importance of accounting for the presence of additional ingredients in
canned products when calculating fish intake can be clearly seen in the findings of this
study. The results of the supermarket audit revealed some canned fish categories to
contain on average, as low as 55.8%, or 53 grams of fish per 95 gram serve,
highlighting the substantial contribution of added ingredients to the weight of the
product. Given the popularity of canned fish products in Australia (237), these findings
suggest that many Australian consumers may be overestimating their current fish
consumption, further highlighting the importance of percentage labelling of food
products. It is also clear that by not adjusting for percentage fish in canned products,
clinical trials are risking a large overestimation of the amount of fish consumed, which
could potential lead to inaccurate conclusions being drawn about fish intake patterns
and health outcomes.
Given the standards governing the labelling of percentage ingredients in food
products (239), it was expected that products would provide accurate representations of
the percentage fish they contain, as was found in this study. It should be noted,
however, that all categories of tuna other than flavoured varieties were measured as
containing less tuna than reported on the label. Conversely, flavoured tuna products
were found on average to contain more tuna than documented. This variation may have
been due to the contents of the flavoured tuna products, which often contained additions
such as pepper, oil and sauces. While care was taken to remove as much of these
ingredients as possible, it is inevitable that some could not be removed, and were
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weighed with the fish. However, whilst potentially more accurate methods of analysis,
such as measurement of the creatine content of the products (244), were considered,
these methods are inaccurate for use in fish products (Tume [CSIRO] 2009, pers.
comm. 11 November)
The selection of samples for validation of the database may also be considered a
limitation of this research, as only tuna samples were selected. This choice was made
based on the large variety of tuna samples noted in the audit, and was due to the known
popularity of canned tuna products in Australia (237). Performing the validation using
tuna products also satisfied the criteria required to provide a sample mean within 10%
of the population mean, which included all canned fish documented in the audit (188).
An additional limitation of the validation process is that the amount of tuna in each
sample was measured once, potentially limiting the reliability of these analyses.
However, the analyses were carried out according to a repeatable and published
methodology (243), with a pilot study conducted prior to this analysis to standardise the
process.
Finally, the audit of available fish products was limited to supermarkets in the
Illawarra area, meaning the results of this study cannot be extrapolated to different
geographical regions. For this database to be relevant to wider areas, future research
may be required to expand the auditing process to a broader geographical area.

3.5 Conclusion

This study resulted in the first known development and validation of a database
to approximate the percentage fish contained in canned products. The database has
improved the accuracy of the measurement of fish intake in both the dietary trial and
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clinical setting and has thus resulted in an improved ability to compare effects of fish
and LC n-3 PUFA consumption on health outcomes. This database was utilised in
subsequent chapters of this thesis and was required for the accurate measurement of fish
consumption, and as a result, was crucial in evaluating the comparative impact of fish
and LC n-3 PUFA consumption on health.
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CHAPTER 4 – A DEFINED STRATEGY TO CONVERT DIETARY DATA
FROM AUSNUT1999 TO AUSNUT2007 TO MEASURE FATTY ACID INTAKE

The majority of this section is the substantive content of the work accepted in the journal:
Journal of Food Science and Engineering: Neale EP, Probst YC, Thorne R, Zhang Q, O’Shea J,
Batterham MJ, Tapsell LC. A defined strategy to convert Australian dietary intake data from
AUSNUT1999 to AUSNUT2007 to measure fatty acid intake (accepted 19/12/11)
EN was responsible for the critical discussions of the design of the study, data collection and
analysis and preparation of the manuscript. YP was responsible for critical discussions of the study
design, analysis and critical revisions of the manuscript. LT and MB were responsible for critical
revisions of the manuscript, RT, QZ and JO contributed to data collection and reviewed the manuscript.

The findings of this study were also presented in: Neale EP, Probst YC, Thorne R, Zhang Q,
O’Shea J, Tapsell LC. Conversion of Australian food composition data from AUSNUT1999 to 2007 for
the measurement of the long chain omega-3 content of fish and seafood. National Nutrient Database
Conference, Bethesda, USA. 2011 (poster presentation at international conference)
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As in the case of fish consumption, measurement of dietary LC n-3 PUFA
consumption is also problematic, as outlined in Chapter 1. Accurate measurement of LC
n-3 PUFA consumption is required in order to compare the impact of a whole food, fish,
and its constituent nutrient, LC n-3 PUFA, on health. Whilst this thesis compares the
efficacy of consuming fish with supplements (as a vehicle for increasing LC n-3 PUFA
consumption) (Chapter 7), consumption of LC n-3 PUFA from total dietary sources
must also be assessed. This chapter outlines the conversion of clinical trial dietary data
from AUSNUT1999 (a food composition database lacking fatty acid data) to
AUSNUT2007 (an updated database inclusive of fatty acid data), to allow for the
measurement of LC n-3 PUFA intake in this thesis. The conversion of clinical trial data
from AUSNUT1999 to AUSNUT2007 provided a practical solution to a problem
encountered by many researchers and ensured fatty acid measurements are appropriate
for use in the Australian context.

4. 1 Introduction

Whilst the previous chapter addressed the issues in the literature for the
measurement of fish intake, the measurement of LC n-3 PUFA intake in the dietary trial
and clinical context is also problematic. The food composition database AUSNUT1999
has been utilised in a number of Australian dietary studies conducted in recent years
(245-250). However, as highlighted in Chapter 2, AUSNUT1999 does not include data
on individual fatty acids, including LC n-3 PUFA (194), and the applications of the
accompanying fatty acid database (86) are limited in the clinical trial context.
Whilst alternate methods exist for the calculation of LC n-3 PUFA intake, these
are unsuitable for use in the Australian dietary trial context. The USDA National
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Nutrient Database for Standard Reference (238) includes LC n-3 PUFA data, however
geographical differences in the fatty acid levels of meats mean that this database is not
suitable for analysing Australian data (84). European databases inclusive of LC n-3
PUFA data similarly pose such challenges as a result of regional differences affecting
fish diet and water temperatures, which in turn influence LC n-3 PUFA levels in fish
(189). Furthermore, the national food composition database, NUTTAB95 (191), does
not contain data on individual fatty acids. Whilst more recent releases of the NUTTAB
databases provide data on individual fatty acids, they contain only generic food data,
with no food composition data on branded food items, resulting in difficulties in coding
of data (196).
As AUSNUT2007 includes data on the LC n-3 PUFA content of foods (40) it
provides an alternate and more accurate method of calculating fatty acid intake.
Measurement of the LC n-3 PUFA content of dietary intake data originally analysed
using AUSNUT1999 can be achieved through the conversion of data to AUSNUT2007
(196). To ensure accuracy and reliability, a repeatable conversion process based on a
systematic approach was required.
In this study, data from the Smart trial (Chapter 2) was used to present a case
study highlighting the importance of this database conversion. The aim of this study
was to develop a defined strategy to convert dietary data from a 12 month clinical trial
originally referencing the AUSNUT1999 to AUSNUT2007. A secondary aim was to
assess the comparability of the conversion process by comparing macronutrient intake
as measured by the original and converted databases. Whilst the purpose of the database
conversion was to measure LC n-3 PUFA intake, consumption of LC n-3 PUFA over
the course of the clinical trial will be presented in Chapter 5.
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4.2 Methods

4.2.1 Context

This study utilised dietary data obtained from the Smart trial, which has been
detailed in Chapter 2.

4.2.2 Database Conversion

Dietary intake information was collected by Accredited Practising Dietitians
(including EN) at baseline, three months and 12 months via a validated DH interview
(179). Dietary data was initially entered into Foodworks (Version 5, Xyris Software,
Highgate Hill, QLD, 2007), using the ‘AUSNUT1999 All Foods’ and ‘AUSbrands
1999’ databases (194). The ‘AUSbrands 1999’ database accompanies AUSNUT1999
and is inclusive of options for brand name food items, which have been matched to
nutrient data from a corresponding generic food item. At the time of trial
commencement, AUSNUT1999 was the most up-to-date survey specific food
composition database available for use.
Conversion of nutrient data from AUSNUT1999 to AUSNUT2007 was
undertaken systematically using a number of approaches (Figure 4.1). Initially, all direct
food item matches were made using a matching file supplied by FSANZ. Food items
which were listed as ‘Not Further Specified’ (NFS) in the 1999 database were then
matched to those listed as ‘Not Specified’ (NS) in the 2007 version.
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Foods matched directly using FSANZ matching
file
Stage 1: All foods

Stage 2: Remaining
unmatched foods

AUSNUT1999 ‘Not
Further Specified’
(NFS) foods matched
manually to
AUSNUT2007 ‘Not
Specified’ (NS) foods

Brand foods
matched using
FSANZ matching
file

Individual
AUSNUT1999 foods
matched to
AUSNUT2007
alternatives based on
conceptual and
nutritional similarities

Recipes using
AUSNUT1999
foods converted to
AUSNUT2007
foods

Professional
judgement used
when exact match
not available
Stage 3: Remaining
unmatched foods

For remaining unmatched
foods, ‘composite foods’
created using a combination
of AUSNUT2007 foods
based on conceptual and
nutritional similarities

Figure 4.1 The process of conversion of AUSNUT1999 dietary data to AUSNUT2007.
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Branded food items were matched using an additional matching file
provided by FSANZ. Where exact brand names were present in the file,
AUSNUT1999 foods were matched to their AUSNUT2007 counterparts. For
food items where the specific brand name could not be found, or where some
confusion existed, but was unlikely to alter the outcome (for example Bakers
Delight Country Grain Block bread rather than Bakers Delight Country Grain
Loaf bread), professional judgement was used to locate the closest substitution
from the AUSNUT2007 matching file. These matches were then confirmed with
the study team which consisted of five Accredited Practising Dietitians. Finally,
for food items where no similar brands were available in the brand matching file
(for example branded cheese and chocolate items), generic food items which were
deemed to be closest from a conceptual and nutritional perspective were used via
the AUSNUT2007 matching file and confirmed with the team.
Individual food items were then matched to suitable AUSNUT2007
alternatives based on conceptual and nutritional similarities (for example ‘Beef
Mince Stew In Tom-Base Sauce From Basic Ingredients’ was matched to ‘Beef,
bolognaise pasta sauce, mince, tomato & olive oil, homemade’). Conceptual
similarities were prioritised to ensure the same form of food was chosen. This
meant that if, for example, a beef stir-fry dish was present, care would be taken to
ensure this food was matched to a conceptually similar food also using beef. This
would be in preference to a chicken dish for example, even if that food had a
closer nutrient profile to the original beef stir-fry dish. Where an appropriate
match for a food from the AUSNUT1999 database could not be found, a
‘composite food’ was created. Each composite food was made up of a number of
constituent AUSNUT2007 food items, which were chosen to reflect the range of
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potential foods or cooking methods that could be included in a single
AUSNUT1999 food item (for example, a composite food designed to match the
AUSNUT1999 food item ‘Beef, Steak, NS Cut, Grilled/Bbq, Lean&Fat’ would
include a range of different beef cuts, including sirloin and rump as those most
commonly consumed). Choice of the cuts of meat products used was guided by
advice from relevant industry bodies. As no recent consumption data was
available at the time of the present study, all foods included were weighted
evenly.
Finally, recipes created using the AUSNUT1999 database were converted
to consist of AUSNUT2007 foods. This was a standardised procedure which
involved matching individual ingredients following the same protocol used for
single foods and ensuring portion sizes were the same. The converted recipes
were then checked to ensure their nutrient profile was similar to the original.

4.2.3 Statistical Analysis

Data was analysed using SPSS (version 17.0, SPSS Chicago, IL, 2008).
Normality of the data was determined using the Shapiro-Wilks test. Mean and SD
of energy and macronutrients including: energy, protein, total fat, saturated fat,
monounsaturated fat, polyunsaturated fat, carbohydrate and fibre were calculated
for both the original and converted DH interview data at all time points to
examine the comparability of the converted database. The difference between the
original and converted DH interview data was then measured using paired
samples t-tests and Wilcoxon signed ranks tests.
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4.3 Results

Data on DH interviews was available for this analysis from n=118
participants at baseline, n=86 at three months, and n=64 at 12 months. Missing
data was the result of study dropouts, however as this was a secondary analysis of
a randomised controlled trial data analysis was performed on the subset of data
available. Foods were matched using a number of approaches at each time point
(Table 4.1).
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Table 4.1 Food items matched by the systematic approach at baseline, three and
12 months
Baseline Three

12 months

months
Total number of foods requiring conversion

8232

5258

3478 (735)

(individual food items)

(1614)

(1094)

Foods matched using matching file developed by

635

454

397

217

119

109

577

385

338

135

88

83

132

48

36

FSANZ (for example’ Salmon, baked or grilled, fat not
added in cooking’ [1999] matched to ‘Salmon, Atlantic,
fillet, grilled’ [2007])
Brand foods matched using matching file (for
example ‘Arnotts butternut cookie’ [1999] matched to
‘Biscuit, sweet, Anzac or butternut style’ [2007])
Foods matched using professional judgement (for
example ‘Dim sim, meat-filled, deep fried’ [1999]
matched to ‘Dim sim, meat and vegetable filling, deep
fried’ [2007])
Foods requiring development of a new composite
foods (for example ‘Meat curry, NFS’ [1999] matched
to a new composite food consisting of ‘Beef, curry,
prepared with curry powder, onions & stock’ [2007],
‘Chicken, curry, butter, Indian restaurant style’ [2007],
‘Lamb, curry, korma, Indian restaurant style’ [2007])
AUSNUT1999 recipes requiring conversion (for
example, constituent ingredients of ‘Sushi roll, crab,
avocado’ [1999] matched to ‘Seaweed, nori, dried’
[2007], ‘Rice, white, boiled without added salt’ [2007],
‘Crab, various types, fresh only, boiled or steamed’
[2007], ‘Avocado, raw, not further specified’ [2007]
based on original portion sizes

At baseline, all macronutrients measured after conversion to AUSNUT2007
dietary data were significantly different to the original AUSNUT1999 DH
interview data (Table 4.2). At three months, fat subtypes in the converted DH
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interview data were not significantly different from the original DH interview
data, whilst the other macronutrients measured were significantly different
between the original and converted DH interview data. By twelve months, protein
and fibre were the only macronutrients that were significantly different between
the original and converted DH interview data.
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Table 4.2 Mean + SD daily energy and macronutrient intake estimated by the original and converted diet histories at baseline, three
and 12 months
Baseline
Original

Converted

Energy

9973.05 +

9757.73 +

(kJ/day)

3.45

3.30

Protein

106.95 +

110.51 +

(g/day)

37.70

39.27

Total fat

93.89 +

88.76 +

(g/day)

42.01

39.03

Saturated

35.05 +

33.00 +

fat (g/day)

19.16

17.44

PUFA

14.88 + 8.00

14.45 + 8.29

MUFA

35.85 +

34.85 +

(g/day)

15.97

14.98

CHO

243.53 +

241.61 +

(g/day)

82.73

81.97

Fibre

27.60 +

29.74 +

(g/day)

10.25

11.32

p-value

three months
Original

Converted

6533.98 +

6479.10 +

1.43

1.42

86.06 +

89.18 +

22.05

22.63

45.77 +

44.26 +

15.64

15.40

14.07 +

13.68 +

4.88

4.89

0.042^

9.83 + 5.66

0.001^

0.000^

0.000^

0.000^

0.000^

p-value

12 months

p-value

Original

Converted

6901.86 +

6889.00 +

1.66

1.70

87.11 +

90.56 +

22.06

23.80

50.65 +

49.34 +

18.36

18.15

0.113^

16.06 + 6.76

15.83 + 6.35

0.525^

9.92 + 5.46

0.463^

10.26 + 7.36

10.25 + 6.82

0.664^

17.11 +

16.85 +

0.118^

19.15 + 7.62

19.22 + 7.89

0.915^

6.96

6.92

174.32 +

171.88 +

0.001^

181.47 +

180.69 +

0.376*

40.54

40.28

45.18

47.23

25.19 +

27.98 +

25.21 + 5.94

28.68 + 7.69

5.65

6.49

0.018^

0.000^

0.000^

0.682*

0.000*

0.071^

(g/day)

*paired samples t –test

0.009^

0.000^

0.000*

0.000*

^Wilcoxon signed ranks test
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4.4 Discussion

This is the first known study to convert Australian dietary intake data from
AUSNUT1999 to AUSNUT2007 via a systematic approach. This process will
allow for the measurement of LC n-3 PUFA consumption, which was previously
not possible in earlier versions of Australian nutrient databases. Measurement of
LC n-3 PUFA intake is essential in order to compare the impacts of fish and LC n3 PUFA consumption on health outcomes.
The database conversion undertaken in this study provides an alternative
to previous strategies of measuring the LC n-3 PUFA content of the diet, such as
the fatty acid database developed by Mann et al. (86). Whilst this database could
also be used to calculate the LC n-3 PUFA content of dietary data originally
analysed using AUSNUT1999, the limited range of foods included means it is not
viable as a method for measuring LC n-3 PUFA intake from open-ended DH
interviews, which typically contain a wide variety of different foods (180). The
current database conversion overcomes this problem by matching all foods
systematically.
Given the wide-spread use of AUSNUT1999 in the literature (245-250),
this conversion process could be of use to many Australian researchers to measure
fatty acid intake in previously collected data. Furthermore, the methodologies
developed in this study could also be adapted to be applicable to other nutrients
now available in updated food composition databases, for example iodine.
The accuracy of the conversion process appeared to be highest at the 12
month time point of the clinical trial. Whilst several significant differences were
noted between the original and converted DH interview data at baseline, there
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were no significant differences in the values for energy, saturated fat,
polyunsaturated fat, monounsaturated fat and carbohydrate at twelve months
(Table 4.2). This is likely to be the result of increased dietitian experience during
the progression of the clinical trial. Analysis of DH interview data entered at
baseline suggests that generic food options were often used (for example ‘meat,
cooked, nfs’), introducing more room for error whilst matching these foods to
AUSNUT2007 alternatives. In comparison, at the twelve month time point, more
specific food items were used, thus making it more likely that a suitable
alternative was chosen via professional judgement for the database conversion.
The results of the database conversion also provide insight into the
implementation of the conversion process. Fat subtypes appeared to be the closest
matched macronutrients, with no significant differences noted between the
original and converted databases at three and twelve months (Table 4.2). This
reflects the purpose of the conversion process, as the current clinical trial focused
on fat consumption, meaning that emphasis was placed on ensuring that matches
made using professional judgement were closest in fat sub-categories. Conversely
macronutrients such as protein and fibre were significantly different at all time
points, suggesting that the current approach may not be optimal for researchers
attempting to measure these nutrients as a primary outcome.
Whilst the database conversion outlined in this study was based on a
systematic approach, many of the choices were based on subjective professional
judgement, which could be considered a limitation of this research. However, all
decisions were confirmed with the study team of Accredited Practising Dietitians
before being finalised, which decreases the risk of bias. An additional limitation is
that as AUSNUT2007 was developed for the analysis of a children’s nutrition
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survey, it has little information on food categories not regularly consumed by
children, for example alcohol. This means that finding an appropriate match for
such AUSNUT1999 foods can be problematic.

4.5 Conclusion

Conversion of dietary trial data from AUSNUT1999 to AUSNUT2007
databases via a systematic approach was found to result in comparable
macronutrient values, particularly at the 12 month time point. Implementation of
this database conversion will allow for the measurement of LC n-3 PUFA intake,
and in a wider range of food items than previously available databases. This
methodology could be adapted in other Australian studies to allow for the
measurement of LC n-3 PUFA intake or other nutrients in previously collected
data. As in Chapter 3, the methodology outlined in this chapter was used in
subsequent chapters to measure LC n-3 PUFA intake, in order to address the
central hypothesis of this thesis and thus compare the impact of fish and LC n-3
PUFA consumption on health.
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CHAPTER 5 – EFFECTIVENESS OF FISH AND LC N-3 PUFA
CONSUMPTION RECOMMENDATIONS OVER THE DURATION OF A
12 MONTH CLINICAL TRIAL

The majority of this section is the substantive content of the work accepted for
publication in the journal: Food and Nutrition Sciences: Neale EP, Cossey A, Probst YC,
Batterham MJ, Tapsell LC. Effectiveness of dietary advice to increase fish consumption over a 12
month period (accepted 17/02/12).
EN was responsible for the design of the study, organisation and leading the study, data
collection and analysis and preparation of the manuscript. LT, YP and MB were responsible for
critical discussions of the study design and analysis and critical revisions of the manuscript. AC
contributed to data collection and reviewed the manuscript.

The findings of this study were also presented in: Neale E, Cossey A, Tapsell L, Probst
Y, Batterham M. Compliance to fish intake recommendations are highest at the three month time
point of a twelve month randomised controlled trial. International Seafood and Health Conference,
Melbourne. 2010 (oral presentation at international conference)
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This chapter evaluates the theoretical concept of effectiveness in the case
of fish and LC n-3 PUFA consumption recommendations. This ensures that in
addition to comparing the efficacy of fish and LC n-3 PUFA intake on health, this
thesis also considers the practicality of meeting fish and LC n-3 PUFA
recommendation in the ‘free-living’ environment.
This chapter utilises secondary analysis of data collected during a 12
month clinical dietary trial which recommended increased consumption of fish
and LC n-3 PUFA from dietary and supplement sources, to assess the practical
effectiveness of dietary advice to consume fish and LC n-3 PUFA in the clinical
trial setting. In order to do so, the methods developed in Chapter 3 and 4 are
utilised in this study to ensure accurate measurement of fish and LC n-3 PUFA
consumption.

5.1 Introduction

In order to develop appropriate health policy, including dietary advice
strategies, the effectiveness of such advice needs to be considered, in addition to
its efficacy (4, 5). This is particularly prudent in the case of fish consumption, as
habitual fish intake is known to fall below recommended levels in both Australia
(91) and many countries internationally (251).
Clinical trials which recommend increased intakes of fish or LC n-3 PUFA
provide a vehicle to test the effectiveness of these recommendations. Measuring
participant compliance and changes in dietary behaviour following advice to
increase fish or LC n-3 PUFA intake can allow researchers to assess the
practicality of these recommendations in the ‘free-living’ environment. However,
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in the case of fish consumption, the few studies which measure dietary
compliance to intake recommendations are poorly suited to assess effectiveness
due to their short duration and tendency to provide participants with food (58, 59,
76, 83, 90). Furthermore, in the case of LC n-3 PUFA consumption, changes in
the source of the fatty acid are also relevant for measures of effectiveness. Whilst
LC n-3 PUFA is found predominantly in fish (40), current eating habits mean that
meat products are a major contributor to LC n-3 PUFA in the diet (84). Measuring
not only the amount, but the source of dietary LC n-3 PUFA is required to
ascertain if increasing LC n-3 PUFA via fish intake is viable and to exclude
variations in meat intake as the causes of changes to total LC n-3 PUFA
consumption. Furthermore, in the case that LC n-3 PUFA supplements are
provided, it is valuable to assess the compliance to supplement consumption
recommendations as well as to total LC n-3 PUFA intake, in order to measure the
effectiveness of advising consumption of supplements as a vehicle for increasing
LC n-3 PUFA intake.
However, when measuring the effectiveness of dietary strategies, the
source of the data should also be considered. Whilst self-reported dietary data can
provide a breadth of data not available with biochemical measures of intake, selfreported measures of fish and LC n-3 PUFA are limited by reliance on memory
and susceptibility to underreporting, which is known to be more prevalent in
overweight populations (252). When assessing changes in eating behaviour, it is
thus prudent to compare self-reported data with a known biomarker of intake, for
example, the omega-3 index (209).
The aim of this study was to examine the effectiveness of dietary advice to
increase fish and LC n-3 PUFA consumption on fish and LC n-3 PUFA (from
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both dietary and supplement sources) intake over the duration of a 12 month
dietary trial. A secondary aim was to compare reported LC n-3 PUFA intake with
a biomarker of LC n-3 PUFA consumption.

5.2 Methods

5.2.1 Context

This study utilised data obtained from the Smart trial, which has been
detailed in Chapter 2.

5.2.2 Measurement of fish and LC n-3 PUFA consumption

Dietary information was collected by Accredited Practising Dietitians
(including EN) at baseline, three months and 12 months via a validated DH
interview (179). Dietary data was originally entered into Foodworks (Xyris
Software, Version 5, 2007), using the ‘AUSNUT1999 All Foods’ and
‘AUSbrands’ databases. Where possible, nutritional data for specific brands and
products was entered into the database.
Fish intake was calculated as grams of fish consumed per day, and the
percentage fish in each canned product was calculated based on the validated
database of canned fish products outlined in Chapter 3 (253). To estimate the
percentage fish contained in mixed dishes reported by study participants, for
example seafood mornay, five different recipes were found for each dish. The
recipes utilised were from a variety of sources including print recipe books, recipe
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websites, food industry websites and websites of large supermarkets. These
sources were chosen to reflect the range of recipes available to the consumer. The
amount of fish present in each recipe was then calculated as a percentage of the
total weight of the dish, and the mean percentage fish in the five recipes was
calculated for each dish. A summary of the recipe sources utilised in this thesis is
shown in Appendix C.
As consumption of fatty fish was emphasised in the study (Chapter 2), fish
consumed was then classified as either lean or fatty fish based on cut-off values
for total fat and LC n-3 PUFA respectively, set by Mina et al. (254) and Devore
et al. (255) (Figure 5.1). As AUSNUT2007, an updated nutrient database which
became available after the Smart trial commenced (40), contains fatty acid data,
this database was used to categorise fish as lean or fatty. If food items were not
available in AUSNUT2007, or confusion arose, NUTTAB2006 (192) was used to
confirm the categorisation, as the nutrient data contained in this database is
mainly from analysed food products (196).
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Stage 1:

Stage 2:

Fish containing high levels of total fat first identified
using the cut off value of 2% fat (252). If a brand
name was given, total fat from label data was used.

A second cut-off was then applied to fish identified as
fatty, to ensure fish were not categorised as fatty due
to canning liquid or the use of higher fat fish to
approximate generic fish items (eg fish, nfs). A cut-off
value of 1% LC n-3 PUFA was used (253).

If a fish item typically viewed as fatty did not meet
these criteria, it was checked if AUSNUT2007 data
was analysed or borrowed from another country. If
AUSNUT2007 data was analysed, the decision was
maintained. If data was borrowed, NUTTAB2006
Stage 3:
analysed data was used preferentially. NUTTAB2006
data was also used if a type of fish consumed by study
participants was not available in AUSNUT2007.

Fish types identified as ‘fatty’
Bream; gemfish; milkfish; morwong; mullet; orange roughy;
salmon (Atlantic); silver perch; tilapia; rainbow trout; fish,
not further specified; smoked salmon; green mussel; oyster;
fish roe; canned anchovies; canned salmon (all liquids);
canned sardines; canned tuna in brine (drained), mayonnaise,
vegetable oil, water (drained), flavoured (oil), fish finger
(raw), fish paste

Fish sub-types identified as ‘fatty’
Gemfish; salmon (Atlantic); silver perch; rainbow trout; fish
roe; canned salmon (all liquids)

Fish sub-types identified as ‘fatty’
Canned sardines; canned oysters – NUTTAB2006 (analysed)

-

Canned anchovies and smoked salmon remained
lean as AUSNUT2007 values were analysed

Therefore, fish categorised as fatty in this study:
Gemfish; salmon (Atlantic); silver perch; rainbow trout; fish
roe; canned salmon (all liquids); canned sardines; canned
oysters

Figure 5.1: Process of categorisation of fish items as either fatty or lean
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In order to measure LC n-3 PUFA consumption, dietary intake data was
converted from AUSNUT1999 to AUSNUT2007 using the methodologies
outlined in Chapter 4. Following conversion of all foods to the AUSNUT2007
database LC n-3 PUFA intake was calculated. To identify the food groups
contributing to LC n-3 PUFA intake, foods were categorised according to the food
groups outlined in the 1995 NNS (Appendix E) (256) and the median LC n-3
PUFA percentage provided by each food group was calculated. Care was taken to
ensure that all converted foods were categorised into the same food group as the
original AUSNUT1999 counterparts.

5.2.3 Compliance to fish and supplement consumption recommendations

Percentage compliance to fish and supplement recommendations was
calculated for all participants who remained in the trial at 12 months. In order to
calculate compliance to fish recommendations, an average of each participant’s
fish intake from all available DH interviews was taken, as described by Alhassan
et al. (257). This was then calculated as a percentage of the trial recommendation
to consume 180 grams of fish per week.
Compliance to LC n-3 PUFA and placebo supplement consumption
recommendations was obtained by asking participants to return all remaining
supplements at the conclusion of the trial. The number of supplements consumed
was thus extrapolated, and compliance was calculated as a percentage of the
number of days each participant was in the trial (obtained from trial consultation
records). For both supplement and fish intake compliance, consumption of greater
than 100% of the recommendations was equated to 100% compliance. Mean and
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standard deviation percentage compliance for both fish and supplements was then
calculated.
As a result of the large amount of variation in fish consumption reported in
the diet histories, trial participants were also classified as either meeting or not
meeting the Smart trial fish intake recommendations of 180 grams of fish per
week. The percentage of participants reaching the trial recommendations was then
calculated.

5.2.4 Measurement of erythrocyte fatty acids and omega-3 index

Fasting erythrocyte samples were taken at baseline, three, six, nine and 12
months by phlebotomists and analysed by a quality assured commercial laboratory
(ARL Pathology, Victoria, Australia) for fatty acid content. The samples were
mixed with methanol/chloroform and potassium chloride and centrifuged for 10
minutes. The samples were dried with nitrogen, and reconstituted with Meth-Prep
II methylation agent. The samples were then analysed using a 25m x 0.22mm
Schimadzu Gas-liquid Chromatograph with Flame Ionisation Detection (G-2010).
Fatty acids were identified using FAME qualitative standards (Supelco,
Australia). Individual fatty acids were listed as a percentage of the total fatty acids
present in the erythrocyte.
In line with the dietary data presented in this chapter, erythrocyte fatty
acid data from baseline, three and 12 months only were analysed in this chapter.
The omega-3 index was then determined by calculating the percentage of EPA
plus DHA present in the erythrocyte, as described by Harris & von Schacky (209),
in order to provide an objective measure of LC n-3 PUFA intake.
127

5.2.5 Statistical analysis

The analysis reported here was a secondary analysis from a trial powered
to test differences in weight loss. For this analysis, data was analysed using SPSS
(version 17.0, SPSS Chicago, IL, 2008). Normality of the data was determined
using the Shapiro-Wilks test. Median and interquartile range (IQR) of total, fatty
and lean fish consumed were calculated. As the ‘Fish+S’ and ‘Fish’ groups
received the same dietary advice to consume 180 grams of fish per week, they
were combined into one group for all further dietary analyses in the present study
(‘Fish advice’). The change in fish and LC n-3 PUFA consumption between
groups at each time point was measured using the Mann-Whitney test. The change
in fish and LC n-3 PUFA consumption within groups over the duration of the trial
was determined using the Friedman test. Where significant differences were
noted, post-hoc tests with Bonferroni adjustments were run to investigate the
source of the variation.
Following the calculation of the proportion of participants meeting trial
recommendations, Pearson chi-square analysis was used to determine if there was
a significant difference between the proportions of participants meeting fish intake
recommendations in the trial groups at each time point.
Mean and standard deviation of the omega-3 index at each time point was
calculated for parametric data, whilst median and interquartile range was used for
non-parametric data. As consumption of LC n-3 PUFA supplements would
influence the omega-3 index, data was separated into the three original study
groups, ‘Fish+S’ (180 grams of fish per week plus LC n-3 PUFA supplements),
‘Fish’ (180 grams of fish per week plus placebo supplement), and control (no fish
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advice and placebo supplement) for this analysis. The change in the omega-3
index within groups over the duration of the trial was determined using repeated
measures ANOVA for parametric data and Friedman test for non-parametric data.
The change in the omega-3 index between groups at each time point was
measured using one-way between-groups ANOVA for parametric data and
Kruskal-Wallis test for non-parametric data. Where significant differences were
noted, post-hoc tests with Bonferroni adjustments were run to investigate the
source of the variation.
To determine the relationship between the reported dietary LC n-3 intake
and the omega-3 index, Spearmans correlation was conducted at baseline, three
months and 12 months for each trial group.
It should be noted that in this analysis we were interested in the actual on
treatment compliance of the subjects participating in the study. Although the
dropout rate in the trial was substantial and the complete case analysis may affect
the generalisability of the results to a larger population (258), intention to treat
analysis and imputation approaches were not considered here as the interest was
on the actual behaviour of the study participants. This completers only approach
has previously been used in assessing dietary adherence as a secondary analysis
(257). The issue of study dropout was considered in the primary analysis where
several approaches were used to address the validity of the results for the primary
outcome of weight change (163).
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5.3 Results

Diet histories were collected for n = 118 participants at baseline, n = 86 at
three months, and n = 64 at 12 months. Missing data was the result of study
dropouts, however as this was a secondary analysis of a randomised controlled
trial with an objective of measuring change in fish consumption over time; data
analysis was performed on the subset of data available. Data is presented for only
those participants with dietary data available at all three time points. One
participant was excluded from further analysis due to implausible fish and LC n-3
PUFA intake. Figure 5.2 shows the number of participants present in each study
group at each time point.
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Baseline

Control
(n = 39)
One participant
excluded (n =38)

Fish
(n = 39)

Fish + S
(n = 40)

Three
months

Control
(n = 29)
One participant
excluded (n=28)

Fish
(n = 30)

Fish + S
(n = 28)

Control
(n = 18)
One participant
excluded (n=17)

Fish
(n = 25)

Fish
(n = 21)

12
months

‘Fish advice’
Baseline: n=79
3 months: n=68
12 months: n=46

Figure 5.2: Trial participants at baseline, three months and 12 months of the
Smart trial [Adapted from Tapsell et al. (under review)]

At baseline, the mean age of participants was 45.47 + 8.50 years. On
average participants were obese, with a BMI of 31.30 + 3.50 kg/m2, and
predominantly female (75.2%).
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5.3.1 Consumption of fish and LC n-3 PUFA

There were no significant changes in the median amount of total fish
consumed within groups over time or between groups at any time point in the
study (Table 5.1). However, when values for the median and IQR of categories of
fish consumption were considered, significant results emerged (Table 5.2).
Participants in the control group consumed significantly less fatty fish at the three
month time point than the ‘Fish advice’ group (p = 0.004).
Median dietary LC n-3 PUFA consumption over the duration of the study
is shown in Table 5.3. Participants instructed to consume fish consumed
significantly greater amounts of LC n-3 PUFA at 3 months than control
participants. Consumption of LC n-3 PUFA changed significantly (p = 0.019) in
the ‘fish advice’ group, with no changes seen in the control group. Wilcoxon
signed ranks test with Bonferroni adjustment indicated a significant change in LC
n-3 consumed from baseline to three months (p=0.006) in the ‘fish advice’ group
alone.
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Table 5.1: Median (IQR) total fish (grams/day) consumed at baseline, three and 12 months by trial group

Trial group

Baseline

Three months

12 months

Friedman test p-value

‘Fish advice’a

25.34 (10.24 –

33.55 (22.28 –

34.33 (17.53 –

0.072

(grams/day)

42.03)

52.11)

62.85)

Control

27.10 (11.80 -

28.57 (19.66 - 45.93)

28.06 (15.77 –

(grams/day)

81.93)

Mann-Whitney p-

0.311

0.790

59.38)
0.219

0.739

value
a

Includes combined results of ‘Fish’ and ‘Fish+S’ trial groups
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Table 5.2: Median (IQR) fatty and lean fish (grams/day) consumed at baseline, three and 12 months by trial group

Trial group

Fish category

Baseline

Three months

12 months

Friedman test
p-value

‘Fish advice’a

10.20 (0.00 – 24.07)

1.08 (0.00 – 13.76)

0.176

16.06 (6.64 –

22.81 (10.91 –

22.27 (9.95 – 45.37)

0.218

(grams/day)

39.55)

38.13)

Fatty

2.24 (0.00 –

2.17 (0.00 – 10.71)

0.00 (0.00 – 7.18)

0.853

(grams/day)

16.64)

Lean

22.86 (9.61 –

25.71 (10.10 –

22.19 (15.46 – 52.02)

0.662

(grams/day)

62.29)

41.16)

Mann-Whitney

Fatty

0.201

0.004

0.303

p-value

Lean

0.508

0.793

0.609

Control

a Includes

Fatty

0.50 (0.00 –

(grams/day)

13.42)

Lean

combined results of ‘Fish’ and ‘Fish+S’ trial groups
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Table 5.3: Median (IQR) LC n-3 PUFA (mg/day) consumed at baseline, three months and 12 months by trial group
Trial group

Baseline

Three months

12 months

Friedman test p-value

‘Fish advice’a

306.92 (189.72 –

437.55 (237.88 –

386.52 (142.77 –

0.019

502.84)

752.52)

707.42)

384.29 (228.70 –

351.83 (271.55 –

374.90 (186.18 –

820.20)

583.50)

490.69)

0.460

0.028

0.609

Control

Mann-Whitney

0.838

test p-value
a

Includes combined results of ‘Fish’ and ‘Fish+S’ trial groups
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Fish and seafood were the primary food group contributing to LC n-3 PUFA
intake, contributing 62 – 80% of the total dietary LC n-3 PUFA, followed by meat
products (Figure 5.2). LC n-3 PUFA was also provided in smaller amounts by eggs and
dairy foods.

100%

Median percentage contribution

90%
80%
70%
60%
Other

50%

Dairy
40%

Eggs

30%

Meat

20%

Fish

10%
0%
Fish advice

Control

Baseline

Fish advice

Control

Three months
Time point

Fish advice

Control

12 months

Figure 5.3 Median percentage contribution (%) of main food groups to total LC n-3
PUFA intake over the duration of the Smart trial

5.3.2 Compliance to study recommendations for fish and supplement consumption

The mean and SD compliance to fish intake recommendations was 79.95 +
21.43% for the ‘fish advice’ group. As a reference, the same calculation found 81.61 +
18.90% compliance in the control group. Mean and standard deviation compliance to all
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capsule recommendations (both LC n-3 PUFA and placebo supplements) was 93.67 +
9.84%.
The proportion of trial participants meeting the trial fish consumption
recommendations is shown in Table 5.4. A Pearson chi-square analysis indicated there
were no significant differences between the proportion of participants in the ‘Fish
advice’ or control groups meeting the total fish consumption recommendation at
baseline [χ2 (1) = 0.345, p = 0.557], three months [χ2 (1) = 2.714, p = 0.099], or 12
months [χ2 (1) = 0.027, p = 0.870].

Table 5.4: Proportion trial participants meeting recommendation to consume 180g fish
per week at baseline, three and 12 months

Trial group

Baseline

Three months

12 months

‘Fish advice’

23/46 (50%)

32/46 (69.6%)

26/46 (56.5%)

Control

9/17 (52.9%)

9/17 (52.9%)

10/17 (68.8%)

5.3.3 Omega-3 index

The omega-3 index differed significantly between trial groups at 12 months
(p=0.005) (Table 5.5). A Mann-Whitney test with Bonferroni adjustment indicated that
the ‘Fish + S’ group had a significantly higher omega-3 index than the ‘Fish’ group at
12 months (p=0.003). The omega-3 index changed significantly over the duration of the
trial in the ‘Fish + S’ group only (p=0.016), with post-hoc tests indicating that this was
due to a significant increase in the omega-3 index from baseline to three months
(p=0.008). Significant or near-significant positive associations were found between the
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omega-3 index and reported dietary LC n-3 PUFA intake at all time points for the ‘Fish’
and control groups (Table 5.6). A significant positive association was only found at
baseline in the ‘Fish + S’ group.

Table 5.5: Mean + SD [median (IQR)] omega-3 index (%) at baseline, three and12
months by trial group

Trial group

Baseline

Three

12 months

p-value

0.016^

months
Fish + S

Fish

Control

p-value

3.51 + 1.37

4.84 + 1.74

4.40 + 1.57

[3.20 (2.50 –

[4.50 (3.40 –

[4.20 (3.75 –

4.70)]

6.20)]

5.05)]

3.38 + 1.08

3.61 + 1.34

3.38 + 1.00

[3.30 (2.40 –

[3.50 (2.50 –

[3.1 (2.70 –

4.20)]

4.40)]

3.40)]

4.01 + 0.85

3.39 + 1.93

3.75 + 0.88

[3.95 (3.43 –

[2.90 (2.50 –

[3.50 (3.18 –

4.83)]

4.25)]

4.28)]

0.075#

0.070#

0.005†

0.360*

0.654^

^RMANOVA (Wilks’ Lambda) *Friedman test
#One-way between-groups ANOVA †Kruskal-Wallis test
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Table 5.6: Spearmans correlation between reported dietary LC n-3 PUFA intake and
omega-3 index at baseline, three and 12 months by trial group

Trial group

Baseline

Three months

12 months

Fish + S

rs = 0.470, p =

rs = 0.297, p =

rs = 0.221, p = 0.336

0.003

0.124

rs = 0.394, p =

rs = 0.413, p =

0.014

0.026

rs = 0.321, p =

rs = 0.614, p =

0.060

0.001

Fish

Control

rs = 0.392, p = 0.064

rs = 0.539, p = 0.047

5.4 Discussion

The results of this study suggest that specific advice to increase fish
consumption to 180 grams per week was most effective in the first three months of a
dietary trial. This pattern of fish consumption was the result of significantly higher fatty
fish consumption in the ‘Fish advice’ group at the three month time point.
In the present study, specific fish consumption advice appeared to be less
effective after three months, with decreased adherence to recommended fish
consumption targets and decreased intake of fatty fish and LC n-3 PUFA in the ‘fish
advice’ group after this time. This finding suggests that recommendations to increase
fish consumption may not be effective in the long term. Whilst the short-term nature of
previous studies in this area means they are unsuitable for assessing long-term
effectiveness of dietary changes (58, 59, 61, 76, 79, 83), decreased levels of adherence
over the duration of long-term dietary trials have been reported in other studies of a
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comparable duration (96, 97), and may be the result of participant fatigue over the
course of a twelve month trial. In addition, the structure of the present trial was such
that the first three months involved intensive sessions with a dietitian, which became
less intensive in the last nine months of the trial. Regular nutritional follow-up has been
shown to be associated with increased adherence to dietary trial regimes (259). The
reduction in adherence to the fish intake recommendations in the present study, which
coincided with fewer dietitian appointments, highlights the importance of continuing
dietetic intervention and support in improving the effectiveness of maintaining ongoing
dietary change.
Dietetic intervention incorporating specific fish consumption advice was also
seen to influence the type of fish and the amount of dietary LC n-3 PUFA consumed in
the trial. Significant differences in the consumption of fatty fish and LC n-3 PUFA were
seen between the control and ‘Fish advice’ groups at the three month time point (Table
5.2 and 5.3). As the intervention groups were advised to consume fatty fish rich in LC
n-3 PUFA preferentially, this suggests that specific dietetic advice favourably
influenced participant’s abilities to reach targets for the type in addition to the amount
of fish. Furthermore, whilst dietary LC n-3 PUFA can be obtained from sources other
than fish, the results of this study suggests fish was the major source of dietary LC n-3
PUFA at all time points (Figure 5.2). This suggests increasing fish intake is an effective
method of increasing dietary LC n-3 PUFA consumption in the long term and confirms
that the increases in LC n-3 PUFA were not due to changes in meat consumption.
However, consumption levels of total, fatty and lean fish and LC n-3 PUFA varied
greatly between individuals, irrespective of study group (Table 5.1, 5.2, 5.3). These
findings suggest that future efforts to alter fish consumption behaviour may benefit
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from individualised dietetic advice which takes into account baseline fish consumption
to assist in meeting dietary targets.
Measuring compliance to trial recommendations for fish and supplement
consumption allowed for comparison of the effectiveness of these recommendations. In
the current study mean percentage compliance was substantially higher for supplement
consumption compared to fish consumption. This suggests that maintaining regular
consumption of supplements may be more achievable than fish consumption, and thus
supplements may be a more effective means of consuming LC n-3 PUFA. In
comparison with the existing evidence base, compliance to fish consumption targets in
the current study were lower than those reported in similar studies in the literature,
which often report over 90% adherence to study recommendations (59, 76, 90). It
should be noted however that these studies provided participants with the recommended
amount of fish, whilst the present study gave structured dietary advice based on specific
food groups and portion sizes, which mimics that received in the clinical dietetic setting
and is thus more appropriately designed to measure the effectiveness of these
recommendations in the ‘free-living’ environment. Whilst long-term provision of
specific fish consumption advice did result in some increases in fish intake, many
participants did not reach the targets of the present study (Table 5.4). It must be noted
that the fish intake recommendations in the current study were substantially lower than
the national guidelines of 300 grams of fish per week (36), raising the question of the
achievability of these recommendations.
Furthermore, whilst the results of this study suggest that that a substantial
proportion of the study sample did not reach the targets for fish consumption, this may
have been in part due to methodological issues associated with measurement of fish
intake. For example, canned tuna products, which made up approximately one third of
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the fish consumed at each time point (data not shown), have been found to contain on
average 60.4% fish (Chapter 3) (253), thus individuals may overestimate their fish
consumption from these products. In the present study, fish consumption measurements
were adjusted to account for the percentage fish contained in such products. The
implementation of dietetic interventions which educate participants on the amount of
fish contained in canned products may overcome this problem, and may be a strategy to
facilitate changes in fish consumption behaviour in both clinical trials and the ‘freeliving’ environment.
The fish and LC n-3 PUFA consumption data presented in this study was based
on self-reported data taken via a DH interview, which is reliant on memory and is
susceptible to reporting bias (260), which could be a limitation of this research. In the
present study, however, changes in the omega-3 index, an objective measure of LC
omega-3 intake (209) correlated with measurements of dietary LC n-3 PUFA in the
‘Fish’ and control groups (Table 5.6), supporting fish consumption as reported by study
participants. As expected, significant positive correlations were only found at baseline
for the ‘Fish + S’ group, corresponding with the introduction of LC n-3 PUFA
supplements at three months, which became the primary source of LC n-3 PUFA for
this trial group.
This analysis is limited by the study context including the participation of
motivated volunteers for a dietary trial and the amount of drop-outs in the parent trial,
thus it is not possible to generalise these results to the wider population. However, as a
case study in providing dietary advice on fish consumption this study provides insights
on the comparative effectiveness of habitual fish and LC n-3 PUFA intake
recommendations.
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5.5 Conclusion

The findings of this study suggest that specific fish consumption advice was
advantageous in increasing fish and LC n-3 PUFA intake behaviour in the first three
months of a dietary trial. Decreases in the proportion of participants meeting fish
consumption targets over the remainder of the trial may have been influenced by a
reduction in the frequency of follow-up sessions after three months. Comparative
compliance to fish and supplement intake recommendations suggests that habitual
supplement consumption may be more achievable than fish consumption. Future
dietary studies may find that providing advice regarding portion sizes of canned
products in addition to specific fish intake advice improves participant’s abilities to
meet fish consumption targets. Future efforts to improve the effectiveness of dietary
advice to increase fish consumption may be aided by providing ongoing dietetic support
following fish intake advice and by basing such advice on individual’s initial fish
consumption habits.
Overall, the results of this study suggest that habitual consumption of fish is less
practical than that of LC n-3 PUFA supplements in a situation similar to the ‘freeliving’ environment. This supports the central hypothesis that the effectiveness of
dietary advice to increase fish consumption is problematic in the long term.
Identification of factors which play a role in impeding this effectiveness will be
addressed in the following chapter.
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CHAPTER 6 – PERCEPTIONS OF FISH AND LC N-3 PUFA CONSUMPTION:
COMPARISON BETWEEN CLINICAL TRIAL AND NON-TRIAL
PARTICIPANTS

The majority of this section is the substantive content of the work accepted for publication in the
journal: Nutrition and Dietetics: Neale EP, Nolan-Clark DJ, Probst YC, Batterham MJ, Tapsell LC.
Comparing attitudes to fish consumption between clinical trial participants and non-trial individuals
(accepted 26/08/11)
EN was responsible for the design of the study, organisation and leading the study, data
collection and analysis and preparation of the manuscript. DNC contributed to critical discussions of the
study design, data collection and analysis and revised the manuscript. LT was contributed to critical
discussion of the study design and analysis and critical revisions of the manuscript. YP contributed to
critical revisions of the manuscript. MB contributed to discussion related to statistical analysis.

The findings of this study were also presented in:
Neale E, Nolan D, Tapsell L, Probst Y, Batterham M. Motivators and barriers to fish and
seafood consumption within participants of a clinical weight loss trial and university staff members.
International Seafood and Health Conference, Melbourne. 2010 (oral presentation at international
conference)
Neale E, Nolan D, Tapsell L, Probst Y, Batterham M. Perceptions of long chain omega-3
fortified foods and supplements within participants of a clinical weight loss trial and University staff
member. International Symposium on Health Benefits of Food, Prague, Czech Republic. 2011 (poster
presentation at international conference)
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This chapter builds on the findings of the previous study by investigating
perceptions of fish and LC n-3 PUFA consumption in participants from the 12 month
clinical trial and control individuals from the host institution. This chapter uncovers the
perceptions which may underpin the concept of effectiveness for fish and LC n-3 PUFA
consumption advice. In addition, comparison of perceptions expressed by clinical trial
participants to those not exposed to nutrition education and advice allows for the
evaluation of dietary advice as a potential strategy to improve the effectiveness of fish
consumption overall. Therefore, the social research conducted in this chapter not only
elucidates the concepts underpinning differences in the effectiveness of fish and LC n-3
PUFA consumption advice, but also identifies potential strategies of improving the
effectiveness of habitual fish intake.

6.1 Introduction

Whilst habitual fish consumption has been associated with numerous health
benefits (15-29), survey data in the Australian context suggests habitual consumption is
low (91). Results presented in Chapter 5 indicated that maintaining habitual fish intake
over a 12 month period was highly problematic in the clinical trial context, whilst
compliance to supplement consumption recommendations was higher.
This suggests that factors such as perceptions of fish and LC n-3 PUFA
supplements may play a role in mediating these contrasting intake patterns. Whilst
research suggests that fish is widely viewed as being a healthy food (103, 104), many
barriers to frequent fish consumption have been identified in the international body of
literature (98, 100, 106). However, there is a paucity of literature examining perceptions
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of fish consumption in the wider Australian context, with the only known study
examining the perceptions of mothers of young children (105).
Furthermore, whilst results presented in the previous study suggest that there
may be fewer barriers to consuming LC n-3 PUFA supplements, no studies have
examined this. Functional foods enriched with LC n-3 PUFA have been reported to be
perceived as more accessible than fish products (109), however, no known research has
investigated whether this is also the case for LC n-3 PUFA supplements.
In addition to identifying barriers to fish and LC n-3 PUFA intake, the
effectiveness of intake recommendations could be improved by highlighting strategies
to overcome these barriers. Dietetic intervention incorporating dietary advice may be a
viable method of doing so. One way of testing this hypothesis is to compare opinions of
individuals who recently completed a clinical trial involving dietary intervention,
receiving supplements and specific and general advice regarding fish consumption, with
those expressed by participants who would not have participated in the trial. This
analysis may provide insight into the potential impact of such dietetic advice on
influencing perceptions of fish and LC n-3 PUFA consumption, which may then assist
in the development of behavioural strategies to increase consumption.
The aim of this study was to investigate perceptions of fish and LC n-3 PUFA
consumption expressed by participants of a dietary trial and to compare these
perceptions with those expressed by a sample of similar healthy adults not involved in
the trial.
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6.2 Methods

6.2.1 Participants

The study drew on individuals who had participated in the Smart trial, which has
been described in Chapter 2.
Semi-structured focus group interviews were conducted at the University of
Wollongong. Participants from all three trial arms who had completed the 12 month
clinical trial at the time of recruitment (n = 34) were invited to join the study by means
of email and follow-up telephone calls. University staff members who had not been
involved in the trial were recruited via an email sent to all general (non-academic) staff,
and all interested participants (n = 14) were invited to attend the groups via a follow-up
telephone call or email. The exclusion criteria for this group were participation in the
clinical trial or below 30 years of age, in order to match the mean age of the participants
of the Smart trial. All interested participants were sent an information sheet and consent
form which highlighted fish as a topic for discussion in the groups and were provided
with a parking voucher for the University of Wollongong. Ethical approval for this
study was granted by the University of Wollongong/South Eastern Sydney and Illawarra
Area Health Service Human Research Ethics Committee and signed informed consent
was obtained from all participants. A copy of the letters granting ethical approval and
relevant ethics amendments are provided in Appendix F.
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6.2.2 Focus group procedures

All focus groups were conducted in November 2009 and each ran for
approximately one hour. Clinical trial participants and University staff members were
assigned to different groups to ensure comparison of results. Prior to each session,
participants were oriented to the purpose of the focus groups and were informed of the
de-identification process. Participants were also informed that there were no right or
wrong answers and that they were free to leave the group at any time. All participants
provided information regarding age range, height, weight and highest level of education.
Clinical trial allocation as it pertained to specific or general fish advice was also noted
for the trial participants. Provided height and weight data was used to calculate BMI for
all participants.
Each focus group session was divided into two sections, one of which related to
fish consumption (reported here) and each section was conducted by a separate
moderator. The moderator who was not conducting the section acted as observer and
took notes on both the discussion and non-verbal cues such as body language and facial
expressions as recommended by Wong (216). The section relating to fish consumption
consisted of six pre-developed primary questions (Figure 6.1). Questions were
standardised to ensure comparability of data between groups (220). The questions were
developed based on the process proposed by Krueger and Casey (217). These questions
related to participants’ opinions on meeting recommendations for fish consumption,
based on the specific and general fish advice given in the trial for the trial participants
and the advice from health organisations for non-trial participants. Non-trial participants
were asked these questions in the context of their everyday lives, whilst trial
participants were asked about their experiences and attitudes to fish during and since
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completing the clinical trial. The questions also addressed factors that encouraged or
discouraged fish consumption; and opinions on the consumption of LC n-3 PUFA
supplements and LC n-3 PUFA enriched foods. Probing questions were used where
appropriate to allow participants to clarify or expand on comments.
1. What are your experiences in incorporating fish into your regular diet? [Probe:
What are your main reasons for including fish in your diet?]

2. What types of fish do you tend to include in your diet? [Probe: why do you choose
to include these types of fish?]

3. Are there any factors which you would consider to impair your ability to eat fish
regularly? [Probe: price, family preferences, availability]

4. What might encourage you to eat more fish? [Probe: change in price, greater
access]

5. Have you seen fish oil supplements? What do you think of them? [Probe: would
you consider these to be an alternative to fish? Why/why not?]

6. Have you seen LC n-3 PUFA enriched foods? What do you think of them? [Probe:
would you consider these to be an alternative to fish? Why/why not?]

Figure 6.1: Moderator questions for investigating focus group participant opinions on
fish and LC n-3 PUFA supplements and enriched foods
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6.2.3 Data analysis

Demographic data was analysed using SPSS (version 17.0, SPSS Chicago, IL,
2008). Between group differences in BMI were assessed using an independent t-test.
Between group differences in categorical variables were not conducted due to a
violation of the minimum cell frequency assumption.
All focus groups were digitally recorded, transcribed verbatim and deidentified.
Focus group transcripts were uploaded into a computer software package, NVivo 7.0
(QSR International Pty Ltd, Melbourne, Australia, 2007), to allow for data analysis and
coding. Data analysis was carried out according to the ‘framework’ analysis technique
(221), described in detail in Chapter 2. Initially, the moderator (EN) familiarised
themselves with the data by studying transcripts and notes taken by the observer (DNC).
A thematic framework was then identified and transcribed data was coded into a
number of sub-themes of factors which influenced fish and LC n-3 PUFA consumption.
The moderator (EN) carried out the analysis of transcribed data to identify sub-themes
within the focus group discussion. Coding processes were discussed with other
members of the research team (DNC and LT) to ensure reliability. These sub-themes
were then grouped and mapped into a number of larger themes, representing a broader
conceptual framework. Final thematic analysis, categorisation and conclusions were
reached by consensus by the moderator (EN) with the co-moderator of the groups
(DNC) and another member of the research team (LT).
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6.3 Results and Discussion

Eighteen participants involved in the clinical trial expressed an interest in the
focus groups and were scheduled into one of three groups. Three participants cancelled
due to time constraints, leaving a total of 15 participants in the clinical trial focus
groups. Fourteen University staff members contacted by email expressed an interest and
all took part in one of three focus groups, resulting in a total of 29 participants in six
focus groups. Clinical trial participants had a significantly higher BMI (p=0.023) and
tended to be older and less likely to have a university degree than those in the
University staff groups (Table 6.1), despite recruitment for general staff only.
The main themes relating to perceptions of fish consumption were health
impact, the cost of consuming fish products (both in terms of time and money), the
physical and sensory characteristics of fish, outlet choice and availability, food
preferences of family members, the culinary position of fish and social and ethical
concerns. The main themes relating to perceptions of LC n-3 PUFA supplement and
enriched food consumption were perceived influence on health, convenience relative to
fish consumption and preference for “natural” products. Sub-themes and exemplar
quotes are displayed in tables below. An overview of the themes as they related to fish
and LC n-3 PUFA supplements and enriched foods is also shown in Appendix G. As the
themes expressed were largely similar for both the clinical trial and University staff
members, they have been discussed together, with any differences between the groups
highlighted. Saturation of themes was reached throughout the course of both the clinical
trial and non-trial groups.
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Table 6.1: Characteristics of focus group participants
Clinical trial

University Staff

Total number of groups

3

3

Total number of participant

15

14

- females

80%

78.6%

- males

20%

21.4%

50 – 59

40 – 49

29.0

24.9

- year 10

13.3%

14.3%

- year 12

13.3%

0%

- TAFE

40%

28.6%

33.3%

57.1%

Gender, mean percentage

Mean age range
Mean BMI (kg/m2)
Education level, mean percentage:

- University degree

6.3.1 Perceptions of fish consumption

6.3.1.1 Perceptions of the health impact of fish consumption

Overall, fish was primarily viewed as a healthy product by both trial and nontrial participants, with a number of associated health benefits (Table 6.2). Participants
referred to fish as being a source of LC n-3 PUFA, with fatty fish referred to as the
healthiest fish option. Health benefits associated with consuming fish discussed
included improved brain health, prevention of Alzheimer’s disease, neural development
in children, joint functioning, management of arthritis, improving ‘good cholesterol’
152

levels, management of blood pressure and maintaining heart health. This finding was
consistent with the literature (98, 99, 101, 261), where it is also noted that females rate
the health value of food as more important than males (262). Our focus groups
contained mainly females, which may account for the prominence of health as a value
attributed to fish consumption.
Some participants from both groups expressed concern regarding potential
contaminants in fish, for example mercury. In addition, whilst generally being perceived
as a healthy product, several participants viewed fish as being a poor source of some
essential nutrients. Several participants referred to fish as providing less iron than red
meat, and thus, being unable to meet their nutritional requirements. Furthermore, whilst
fish itself was acknowledged as a healthy food, traditionally associated foods such as
hot chips and common cooking methods were perceived as having a detrimental effect
on the health value of the total meal. Fish was also viewed as being at a greater risk of
microbial contamination than red meat, also impacting upon participant’s perception of
it as a ‘healthy food’.
Dietary advice and exposure to information on the benefits of regularly
consuming fish appeared to influence participants’ decisions on consuming fish,
particularly for clinical trial participants. Conversely, non-trial participants rarely
mentioned the influence of dietary advice sources, but they did refer to advice provided
by health professionals such as doctors. This difference may reflect the use of dietary
advice materials provided to trial participants, where emphasis was placed on evidence
based recommendations for increased fish consumption and may represent a vehicle for
increasing awareness during dietary advice and education.
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Table 6.2: Perceptions of the health impact of fish consumption identified during focus
groups, including sub-themes and exemplar quotes
Theme
Perceived health
benefits

Potential
contaminants

Impaired ability
to meet nutritional
requirements
Association with
foods of poor
nutritional quality
Food safety

Knowledge and
education

Exemplar Quote
“I probably eat it solely for the health reason, and I know I
should eat it so I will try and put it in my diet more, um if it
wasn’t a healthy option I probably wouldn’t eat it that much”
(F, FG 5, non-trial participant)
“well I’m trying to eat the fish, um which has got lower
mercury content in the fish, so you’re sort of trying to choose
between um maybe nice taste but then you think, oh this might
be dangerous, so…” (F, FG 5, non-trial participant)
“Because my iron levels are never great so it’s important that I
eat my red meat” (F, FG 1, clinical trial participant)
“…cos that’s the other thing, fish might be healthy but it
usually comes with chips” [Male (M), FG 1, clinical trial
participant]
“I think sort of, I think, I mean you’ve got to handle all food
carefully obviously, but I think it’s a bit like the, the chicken
and the fish thing, you know, there’s the higher risk of, I don’t
know, souring” (F, FG 5, non-trial participant)
“So, so the research on it has been really helpful with
education, um so yeah for me, personally it rates very highly”
(F, FG 3, clinical trial participant)
“And personal health recommendations from doctors and
things and um, yeah [encourage fish consumption]” (F, FG 4,
non-trial participant)

6.3.1.2 Perceptions of financial and time cost associated with fish consumption

Many participants from both the trial and non-trial groups referred to both the
financial and time cost associated with fish consumption as influencing their ability and
inclination to consume fish (Table 6.3). Several participants from both groups viewed
fish as being more expensive than other protein sources such as meat, and as a result of
this, it was seen by some participants as a ‘treat’. Preparing fish was also viewed as
being associated with a greater amount of wastage than other protein sources, further
decreasing its perceived value for money. The perception of fish being expensive is
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reported in other studies (98, 105, 261), but not in all, with one study from the United
Kingdom reporting that consumers tended to view fish as being reasonably priced (108).
The perceived convenience of fish was dependant on the type of product
consumed. Participants viewed canned fish as being a highly convenient product,
particularly as a lunch meal, where it was viewed as being fast and easy to prepare, or
for an ‘emergency meal’. Frozen fish and specific types of fresh fish such as flathead
tails were also described as being convenient varieties of fish. Conversely, other types
of fish and seafood such as whole fish and crustaceans were seen as requiring a large
amount of time to prepare and eat. Fish based meals were also described as requiring
greater organisation to prepare than other protein sources. Participants identified that to
ensure they regularly consumed fish they had to schedule it into their weekly or
fortnightly meal plan. This was described as a potential way to increase fish
consumption to meet recommendations.
The convenience of specific fish products, such as canned and frozen fish was
discussed more often by non-trial participants. Previous research has also reported an
effect of age on perception of the difficulty associated with eating fish, with older
participants finding fish less inconvenient than younger participants (103, 107). In the
present study, there was a higher proportion of participants aged 50 years or older in the
trial group than the non-trial group (Table 6.1). Therefore it is possible that the older
trial participants placed less value on convenient fish products than the younger nontrial participants as they did not perceive fish to be an inconvenient product to begin
with.
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Table 6.3: Perceptions of the cost (financial and time) of fish consumption identified
during focus groups, including sub-themes and exemplar quotes
Theme

Exemplar Quote
“…it’s a bit hard to go past if you’re shopping and you’ve only got
like $10 or something, it’s a bit hard to go past a couple of kilos of
chicken thighs or something [laughs], and, or buy one piece of fish,
so yeah, I suppose price can sometimes prohibit…” (F, FG 4, nontrial participant)

Price

“…when they brought in those little tins of tuna in the different
flavours and stuff that you could stick in your lunchbox and, easy
fish meal” (F, FG 1, clinical trial participant)
“But the other is the time, like you’re saying about fresh fish, the
Time
time that you take to sort of prepare that and cook it apart from like a
barbeque, which you wouldn’t do at night, you know a weekend,
maybe but um yeah, so there’s that” (F, FG 6, non-trial participant)
Organisation “…but I think the way to do it is like [another participant] said, you
have to have a menu plan to be right on, I can remember growing up
we always had fish on Fridays, because I have a Catholic step-father
who always had, so we had fish every Friday. Um I think that’s the
way to do it is to keep one day and say that’s fish day, because
otherwise…” (F, FG 5, non-trial participant)
“…because, per kilo, by the time you do clean a fish, you’re wasting,
Wastage
you’re throwing out a lot, so yeah…” (F, FG 4, non-trial participant)
Convenience

6.3.1.3 Perceptions of physical and sensory characteristics of fish

As has been found in previous research (100), participant’s individual taste
preferences appeared to substantially affect their willingness to consume fish (Table
6.4). Taste preferences were the most commonly discussed factor influencing fish
consumption in the clinical trial participants, and also ranked highly for non-trial
participants. Many participants referred to freshness as being an important issue for fish,
with several participants expressing a dislike of fresh fish which had been frozen prior
to sale. A number of participants also stated that they felt that they were not adept at
determining the freshness of fish, in comparison to another protein source such as meat.
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Physical characteristics such as appearance, presence of bones and smell also
influenced participants’ fish consumption. The appearance of a whole fish was
something that participants or members of their families found disturbing. Similarly,
several non-trial participants indicated that they had an aversion to the bones found in
fish, and as a result of this, chose boneless fillets where possible, as has also been
outlined in previous research in the Australian population, in research focussing on the
perceptions of parents of young children (105). The smell associated with cooking fresh
fish was also a factor which resulted in some participants avoiding these types of fish.
In addition to also discussing the influence of taste preferences on fish
consumption, clinical trial participants tended to refer to the taste of fish as
flavoursome, whilst a number of non-trial participants discussed their desire to avoid
certain flavours when they chose fish. Consumers with a greater experience of fish have
been found to be more likely to view fish as having a pleasant taste than those who had
less experience and were less concerned by the presence of bones in fish (106). In the
present study, non-trial participants also referred to the presence of bones in fish as
being a barrier to regular consumption, whilst this was rarely mentioned by clinical trial
participants. While participants’ experience with fish was not measured in the present
study, these findings could suggest that clinical trial participants were more experienced
consumers of fish, and thus had different perceptions of taste than non-trial participants.
Clinical trial participants were asked about fish consumption patterns and preferences in
entering the trial but non-trial participants were not asked this on entering the focus
groups, so there may have been a bias in the focus group sample in this regard.

157

Table 6.4: Perceptions of physical and sensory characteristics of fish consumption
identified during focus groups, including sub-themes and exemplar quotes
Theme
Taste
preferences
Freshness

Sensory appeal

Appearance

Presence of
bones
Smell

Quality

Exemplar Quote
“I, I just, it’s my taste buds [laughs] I just like it [fish] much better
[than red meat]” (F, FG 2, clinical trial participant)
“We prefer the fish fresh, and if you don’t have it for a couple of
weeks and you’re having stuff out of the freezer, um then you have
fresh and you go oohhh, man can’t you tell? Yeah, it is much
nicer” (F, FG 4, non-trial participant)
“Mostly it’s the flavour as well, we just like the texture, we like
the flavour, it’s something different…” (M, FG 5, non-trial
participant)
“mmm, I relate to that as well, um, I always buy fillets, I find the
head and tail thing really urgh [laughs]” (F, FG 4, non-trial
participant)
“yes, the bones were a big issue for me, I still don’t like any fish
with bones in it, I’ve got to kind of get fillets or whatever” (M, FG
4, non-trial participant)
“Because of the smell factor, I rarely did it [cooked fish], because I
hated the house stinking of fish all, you know, for the next couple of
days, so we tended not to have as much…” (F, FG 2, clinical trial
participant)
“It’s vastly different like some of the tunas are really really you
know like in my opinion they’re only one step removed from
Snappy Tom [brand of cat food] [laughter], but some other tunas
really good quality tuna so I’ve found some of them are, there’s a
Sirena brand I think which is really nice” (M, FG 1, clinical trial
participant)

6.3.1.4 Perceptions of outlet choice and availability of fish

Participant’s opinions regarding the outlets which sold fish were also reported to
influence their purchasing and consumption of fish (Table 6.5). Many participants in
both the clinical trial and non-trial groups described fish as being difficult to access,
particularly when compared with protein sources such as meat. This was viewed to be
an issue mainly for accessing fresh fish, which participants perceived as only being
available at limited outlets. Some participants also referred to having to make special
shopping trips to purchase fish. An Australian study which examined the perceptions of
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parents of young children reported similar findings (105), however research involving a
representative sample of United Kingdom consumers found that fish was perceived as
being readily available (108) which may indicate cultural differences in the availability
of fish.
Many participants in the present study also expressed a preference for one type
of fish outlet over others. Participants viewed supermarkets as mainly selling fish that
was of lower quality and not fresh, whereas fish markets were seen as the preferable
choice for purchasing fish. Several participants also referred to specific fish markets as
being better than others, for a number of reasons including perceived standards of
hygiene and trustworthy labelling. Several participants also viewed the freshness of fish
as being specific to the outlet, with certain outlets seen to sell fresher fish than other
outlets.

Table 6.5: Perceptions of outlet choice and availability identified during focus groups,
including sub-themes and exemplar quotes
Theme
Access and
availability

Preference
for specific
vendor

Freshness
(specific to
outlet)

Exemplar Quote
“…you can find meat easily in the supermarket, like if you go to
Aldi [supermarket], you can find this, you know, shelves and
shelves of meat but you hardly can find, you know this you know
prepared, like a, like fish for you. Like if you want to go shopping
you have to go to different place, if you go to such, you know, Aldi,
and then, you know, to get your, the seafood, that’s definitely one
factor” (F, FG 6, non-trial participant)
“Oh, I’m actually a bit fussy about choosing the shop where I buy
the seafood from, well canned food is of course from a market, but
I wouldn’t buy seafood from a supermarket, because they don’t
look that fresh to me. I always go to Shellharbour, fish market” (F,
FG 5, non-trial participant)
“I think freshness, I think you worry about freshness when it comes
to fish, more than you do with, I think meat, because it’s more
available you sort of can tell easier, with fish you sort of have to be
careful, and yeah I wouldn’t buy it in Woolies [supermarket] or
anything like that, I’ll only go into Shellharbour [fish market] or
somewhere like that to get it” (F, FG 1, clinical trial participant)
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6.3.1.5 Perceptions of family preferences and past experiences of fish consumption

Family member’s food preferences appeared to influence participants’ decisions
to consume fish, and were discussed more often by non-trial participants than
participants who had been enrolled in the trial (Table 5.6). Many participants stated that
their children did not like fish, making it harder for participants to consume it regularly,
or limiting them to specific types of fish, such as fried or frozen varieties, that they
would not have otherwise chosen. Other participants stated that the negative reactions
of children to fish made consuming it an unpleasant experience, which resulted in
participants avoiding serving it at meals.
This finding is in accordance with much of the previous research, which has
highlighted the preferences of children as playing a large role in influencing an
individual’s decisions on the frequency of fish consumption, as well as the type of fish
consumed (99, 105, 107). In the present study, however, one trial participant stated that
as a result of her perceptions of the health benefits of fish, she no longer allowed her
children’s attitudes to be a barrier to regular fish consumption. It is possible that the
dietetic advice and education given during the trial allowed participants to place a
higher value on fish consumption, thus displacing the preferences of family members as
the main barrier. Other research has found that the presence of teenagers under the age
of 18 may detrimentally impact upon the frequency of fish consumption (100, 107).
Although we did not investigate the age of participant’s children, a larger number of
non-trial participants were under 50 years of age, and may have children still living at
home, while trial participants tended to be older.
Participants also referred to family traditions and cultural norms as influencing
their frequency of fish consumption. Participants referred to religious traditions such as
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having fish on Fridays, cultural traditions, and the attitudes of their parents as
influencing their own perceptions of fish, and affecting the types of fish they chose to
consume. Similarly, experiences with fish consumption as children were also reported
as influencing participant’s current consumption habits, as has been highlighted in past
research in the area (99).

Table 6.6: Perceptions of family preferences and past experiences identified during
focus groups, including sub-themes and exemplar quotes
Theme

Exemplar Quote

Family
preferences

“Yeah my, um daughter doesn’t particularly like fish, unless you
crumb it and tell her it’s chicken, then she’ll eat it [laughs], even
though she then, once she has a bite she goes this isn’t chicken, it’s
fish, she’ll then eat it, so it’s one of those things that you just kind
of start steering away from cos it’s just easier than putting up with
the complaints” (F, FG 2, clinical trial participant)
“…it’s a like a long traditional saying, that fish is always good. You
know, probably wouldn’t be as tasty as you know beef or somehow,
but you know in the conscious Chinese people’s mind, fish is always
good” (F, FG 6, non-trial participant)
“yeah, but I used to love it when I was a kid, that’s probably why I
love seafood” (F, FG 3, clinical trial participant)

Tradition

Childhood
experiences

6.3.1.6 Perceptions of cooking skill and role of fish in cuisine

Many participants from both groups perceived fish as a food which was difficult
to cook, in comparison with meat, as was also reported by McManus et al. (105) (Table
6.7). Several participants stated they lacked the confidence and knowledge to cook fish
well and as a result, tended not to cook it at home. As a result of this, however, many
participants stated that they enjoyed ordering fish when eating out at a restaurant, which
allowed them to have it cooked in more diverse ways than they might attempt. This, as
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well as the cost of fish, made it a food that many participants considered to be
associated with a ‘special occasion’, rather than everyday eating.
There was a commonly discussed opinion that fish had a high level of variety as
a food choice, which was seen as a favourable quality. Participants from both the
clinical trial and non-trial groups referred to the variety fish added to a meal, the
different flavours that could be incorporated with it, and the diversity of some fish
products, for example canned fish. One participant felt that including fish in her
family’s diet increased her children’s awareness of the variety available and the role of
fish in the diet. Some of the ways fish could be cooked were also discussed by trial
participants, which included cooking methods such as poaching, grilling and baking
with herbs.
Several participants from both groups expressed the viewpoint that specific
types of fish tended to be associated with certain meals. Many participants stated that
canned fish was mostly used for lunch food, whereas fresh fish tended to be limited to
the evening meal. Similarly, some participants stated that they viewed canned fish to be
a very different product to fresh fish, as a result of its different composition and uses.
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Table 6.7: Perceptions of cooking skill and role of fish in cuisine identified during
focus groups, including sub-themes and exemplar quotes
Theme

Exemplar Quote

Confidence in
cooking ability

“and, I don’t know, fresh fish, its difficult to cook, [to
other pt] I heard you saying you didn’t like cooking fish,
it’s not, it’s not as easy to cook as meat” (F, FG 1,
clinical trial participant)
“and I think that you’ve got such a variety, I think with meat, it’s
kind of just all the same [laughs] mostly, you know [laughs] and I
think that um with seafood you’ve got a better variety, you can use
different things and there’s different tastes, like so many different
tastes, it’s, it’s really good” (F, FG 2, clinical trial participant)
“Yeah, absolutely, I, I didn’t have a lot of fish in my diet before
doing this study, um, and I started to buy more, you know, salmon,
and other types of fish, and you know different ways of cooking it
so, you know, I certainly, you know grilled more fish, and
poached, I poached the salmon sometimes and…” (F, FG 3,
clinical trial participant)
“Mainly that I’m not much of a dinner eater anyway, and fish is
more or less of a dinner food, when I do have fish it’s usually for
lunch” (M, FG 6, non-trial participant)
“I, I really like canned tuna and canned salmon and um, but it’s
really different from um, from fresh fish. But it is very convenient,
stir it through a salad or whatever, it’s great” (M, FG 1, clinical trial
participant)
“if I go to a restaurant, go to a seafood restaurant, there’s nothing
nicer than just really just, ordering, while it’s prepared for you,
eating it, and cooked probably a little bit more flamboyantly and
differently than I would do at home, I’m not very adventurous when
I’m cooking fish at home” (F, FG 5, non-trial participant)
“…it’s more of going and buying it fresh and then preparing it, but
because it’s not as convenient it becomes almost like a special
occasion to do that” (M, FG 5, non-trial participant)
“but then I think it’s important for them to see that fish doesn’t only
come in fillets actually it, that’s how it looks before it’s filleted and
this is how you can actually eat it at the table, um so I try and make
sure we have whole fish and fillets and crustaceans as well, just to
show the variety” (F, FG 2, clinical trial participant)

Variety

Cooking
methods

Meal time
specificity
Difference
between fresh
and canned
Eating out

Special
occasions
Food
awareness

6.3.1.7 Social and ethical concerns relating to fish

Concern was expressed by participants regarding the sustainability of the fish
industry (Table 6.8), and some participants reported purposefully not choosing
particular species of fish which they perceived as being unsustainable. Participants also
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expressed a preference for local products where possible, but acknowledged that this
preference sometimes limited their choices when purchasing fish. Some participants
also stated that ethical considerations also influenced their decisions of which fish types
to purchase, such as the living conditions animals were kept in. These findings
somewhat contradict those reported in a previous study by Verbeke et al. (261), who
found that whilst sustainability and ethical issues were described as being important,
they were not associated with a change in attitude or purchasing behaviour. However, as
purchasing patterns were not measured in the current study, it cannot be concluded that
such perceptions influenced participant’s fish choices, and were not solely due to social
desirability bias.

Table 6.8: Perceptions of social and ethical concerns identified during focus groups,
including sub-themes and exemplar quotes
Theme

Exemplar Quote

Sustainability

“I do worry about the type, the types of fish that I some, that are
available for purchase and whether we should be buying them
because we’re actually fishing those species out” (F, FG 2, clinical
trial participant)
“and not only Australian, but local I think if you knew you were
supporting local fishermen I think that would be a great incentive” (F,
FG 4, non-trial participant)
“…the conditions of farmed fish I don’t think are that ethical, those
kind of considerations – Australian fish, ocean fish, mean that in a
fish shop there might only be a few choices” (F, FG 4, non-trial
participant)

Local
products
Ethical issues

6.3.1.8 Influence of clinical trial on perceptions of fish

Participants of the clinical trial also expressed the view that the trial influenced
their fish consumption patterns (Table 6.9). Whilst several participants stated that they
felt that involvement in the clinical trial encouraged them to increase their fish intake,
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one participant felt that she was not able to regularly consume fish as a result of the
small amount of protein she was instructed to have.

Table 6.9: Perceptions of the influence of the clinical trial on fish consumption
identified during focus groups, including sub-themes and exemplar quotes
Theme
Trial
instructions

Sample Quote
“I just found with the one I was on with your 90g of protein that
was all you could eat all day, if I ate one of those little cans that
was my protein for the day, so I found that I would hardly eat, I
mean I’d eat half a tin occasionally but I…” (F, FG 1, clinical trial
participant)
“Yeah, absolutely, I, I didn’t have a lot of fish in my diet before
doing this study, um, and I started to buy more, you know,
salmon, and other types of fish, and you know different ways of
cooking it so, you know, I certainly, you know grilled more fish,
and poached, I poached the salmon sometimes and…” (F, FG 3,
clinical trial participant)

6.3.2 Perceptions relating to consumption of LC n-3 PUFA supplements and
enriched products.

6.3.2.1 Perceived influence on health, convenience relative to fish consumption and
preference for “natural” products

Participant’s opinions on the health impacts of LC n-3 PUFA supplements and
enriched foods tended to vary from those on fish (Table 6.10). Whilst participants
acknowledged that LC n-3 PUFA supplements would provide a health benefit, all
participants agreed that fish provided additional benefits to those provided by the
supplement. The benefits discussed included the presence of additional nutrients and
protein in fish, as well as sensory benefits such as taste and enjoyment. When consumed
as part of a diet which contained fish, LC n-3 PUFA supplements were perceived as
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potentially augmenting the health benefits of fish, but never displacing the importance
of fish in the diet. These findings appear to differ from those reported by Patch et al.
(109), who found that consumers from the same geographical region as the present
study perceived functional foods as a suitable alternative to fish for the provision of LC
n-3 PUFA. However, it should be noted that Patch et al. (109) focused primarily on
sources of LC n-3 PUFA, which included fish and enriched foods, whereas the
additional benefits of fish reported in this study were factors other than LC n-3 PUFA,
such as other nutrients and the sensory qualities of fish.
The health benefits associated with consumption of LC n-3 PUFA supplements
were viewed as being particularly beneficial to specific groups or at specific life-stages.
Participants perceived LC n-3 PUFA supplements to be of greatest benefit to those who
did not consume fish, and also associated their benefit with specific life-stages, such as
pregnancy or old age. One participant expressed concern however, that consumption of
LC n-3 PUFA supplements might result in overconsumption of LC n-3 PUFA.
Some participants also expressed suspicion regarding the advertised health
benefits of LC n-3 PUFA supplements and enriched foods. Some participants felt that
they themselves did not have a substantial knowledge of the health impacts of LC n-3
PUFA in supplement form, and thus could not made an educated judgement on the
usefulness of these products. Participants expressed similar reservations about LC n-3
PUFA enriched foods, and queried if they contained the amount of LC n-3 PUFA they
claimed to, which has also been reported in previous research (109, 263). Whilst some
participants viewed the practice of enriching foods with LC n-3 PUFA as a marketing
ploy to increase sales, other participants conversely found the advertising and marketing
of LC n-3 PUFA foods useful when purchasing products.
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Whilst fish as a whole food was seen as providing additional benefits to
supplements and enriched foods, the convenience of these products was discussed by
participants from both the clinical trial and non-trial groups. LC n-3 PUFA supplements
and enriched foods were perceived as being a quick and easy way of increasing LC n-3
PUFA intake relative to consuming fish. Consuming supplements or enriched foods was
thus viewed by several participants as the preferable method increasing LC n-3 PUFA
intake in the case that requirements were increased, as a result of the convenience of
these products relative to fish.
Whilst LC n-3 PUFA supplements were generally well accepted by the
participants, there was a perception that adding LC n-3 PUFA to pre-existing foods such
as milk or eggs was interfering with natural processes. Some participants reported
perceiving these foods as ‘unnatural’, and as a result of this would not buy them. A
preference for natural sources of nutrients has also been seen in a sample of adults from
the United States (264). Similarly, several participants in both the clinical trial and nontrial groups reported a preference for plant-based sources of short chain n-3 PUFA such
as flaxseed, as an alternative to LC n-3 PUFA supplements or enriched foods. Such
plant-based products were perceived as being more natural than animal sources of these
fatty acids, and were commonly referred to as being interchangeable with LC n-3
PUFA. This may reflect some confusion between the roles of short and long chain n-3
PUFA present in both the clinical trial and non-trial participants.
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Table 6.10: Perceived influence of supplements and enriched foods on health,
convenience relative to fish consumption and preference for “natural” products
identified during focus groups, including sub-themes and exemplar quotes
Theme

Exemplar Quote

“and it’s [fish] still got the proteins and everything, you’re still
getting the proteins and everything else with it, it’s, it’s more a
complete, getting more into your complete package than just
fish oil” (F, FG 3, clinical trial participant)
Health requirements “My husband was actually starting taking, was taking the fish
oil before I got involved in this thing and then um since it ended
specific to life stage
I try to remember to take a fish oil um capsule, um again
because I’m getting older and the arthritis and all of those things
so as I said we’re taking it anyway” (F, FG 2, clinical trial
participant)
“but we also make sure the girls eat seafood because we know
Health benefits of
supplements/enriched it’s good for their brains, so they also take the fish oil tablets,
and both [participant’s husband] and I take fish oil tablets as
foods
well, um so supplementing that with the fresh food” (F, FG 5,
non-trial participant)
“But I, I must admit, I’m a little bit ignorant about it, when they
Trust
promote um fish oil capsules and the different sorts of capsules
and the potency of them and then, you know and they give you
a comparison of how much fish you’d need to eat as opposed to
taking this little capsule and you kind of go, I don’t know if
they’re pulling my leg or not, I’m a bit ignorant there” (F, FG
5, non-trial participant)
“based into options of you know, of a particular brand that
Marketing
aren’t selling well and they’re trying to up that, so to get away
from the negativity of white bread, and your children eating it
you know, and I see that as a marketing, I’d say you’d have to
eat an awful large loaf of bread [laughter] to get the daily dose
of omega-3 that you need, yeah” (F, FG 4, non-trial participant)
“I sometimes worry about over, like supplements kicking things
Toxicity of
off onto the wrong course, like we’ve got too much of this and
supplements
too much of that, I don’t know, I think it can be dangerous” (F,
FG 2, clinical trial participant)
“so having those tablets or the supplements may just help them
Convenience as
get that top-up, it’s a quick easy way of chucking down a couple
source of LC n-3
PUFA relative to fish of tablets and following it down with a bit of water” (M, FG 4,
non-trial participant)
“All these milks and different products that being added to the
“Natural way”
manufacturing process it’s not, it doesn’t taste, or in, look
natural to me, like I wouldn’t buy it because it’s been added
during the manufacturing process, it doesn’t appear that it’s
organic or anything” (F, FG 5, non-trial participant)
“See I take flaxseed oil, purely because it’s not a by-product of
Confusion between
animal, and I figure the, the, I read a fair bit before I started
long chain and short
taking it about the flaxseed plant oils versus the, the um animal
chain PUFA
oils and it was, just sounded like such a safer um more pleasant
thought to be taking” (F, FG 4, non-trial participant)
Importance of whole
foods rather than
nutrients
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This study is presented as a case study and as such results cannot be extrapolated
to the wider population, but the principles exposed could be tested in similar settings.
While attempts were made to match the non-trial to the clinical trial participants, the age
difference in particular may have been a limitation. In addition, whilst efforts were
made to recruit non-academic University staff, this group did have a higher proportion
of university educated participants than the trial participants. This difference in
education levels could have acted as a confounding factor, as higher levels of education
have previously been associated with a greater intention to consume fish (100).
However, similar responses between groups in areas such as health knowledge suggest
this did not cause undue bias. Factors such as the presence and age of a participant’s
children and experience with fish may have an indirect impact on perceptions of these
foods. Future research in this area might benefit from collecting more dietary data and
more detailed information on family circumstances and past experience with fish as
background information.
Furthermore, it must be noted that this study investigated participant’s
perceptions of fish consumption, including those factors which participants perceived to
be barriers to consumption, such as price and accessibility issues. As this research
focused on consumer’s perceptions of fish consumption, data was not collected on the
actual existence of these barriers (for example whether fish was actually more expensive
than other comparable protein sources), however it can be argued that perceived
barriers, regardless of whether they exist in reality, are highly relevant when considering
consumption behaviours.
An additional limitation of this study is that during the clinical trial, some
participants were given a specific fish consumption prescription, whilst others were
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given advice for general healthy eating inclusive of fish as a protein option. However,
analysis of themes suggested that the attitudes expressed by clinical trial participants
were similar, regardless of their study allocation.

6.4 Conclusion

This study highlighted some of the factors that can influence an individual’s
abilities and decisions to consume fish and LC n-3 PUFA supplements and enriched
foods. Fish was generally perceived as being a healthy food, with convenient varieties
available. Individual taste preferences also influenced the types of fish participants
chose to consume. However, perceptions of the price of fish, food preferences of
children and access to fresh fish appeared to have a negative impact upon consumption.
Conversely, LC n-3 PUFA supplements and enriched foods were perceived as
having some, but not all of the health benefits provided by fish. They were however
perceived as being useful at particular life stages, and were seen as a more convenient
way of increasing LC n-3 PUFA intake than fish. However, some participants expressed
suspicion of the marketing of these products and viewed some products as being
‘unnatural’.
This is the first known study to investigate the influence of dietetic advice in the
context of a clinical trial on perceptions of fish consumption. The themes which were
highlighted by this study were largely similar between clinical trial and non-trial
participants. Despite non-trial participants being more highly educated overall,
participants in both clinical trial and non-trial groups were similarly well versed in the
health benefits of fish and LC n-3 PUFA, supporting the premise that such benefits are
well known and accepted (102-104), regardless of exposure to dietary advice. In
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contrast, clinical trial participants appeared to place a higher value on education and
knowledge relating to these health benefits than non-trial participants, and referred to
the importance of scientific research, suggesting a potential influence of the dietary
intervention. However, factors such as price and availability of fish and family
preferences were substantial barriers for both groups, suggesting that dietetic advice and
education alone was not able to overcome these issues. These barriers, which were not
discussed in relation to LC n-3 PUFA supplements, may be a reason for the issues with
compliance to fish intake recommendations seen in the clinical trial (Chapter 5), which
were not seen for LC n-3 PUFA supplement consumption. This supports the central
hypothesis that behavioural factors impede the effectiveness of habitual fish
consumption advice. The apparent lack of an effect of dietary advice on these barriers
suggests that practical strategies combating perceptions of price and availability are
required in addition to dietetic advice and education in order to increase the
effectiveness of habitual fish consumption to that seen with supplements.
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CHAPTER 7 – EFFICACY OF FISH AND LC N-3 PUFA SUPPLEMENT
CONSUMPTION ON ADIPONECTIN LEVELS IN OVERWEIGHT ADULTS
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This chapter incorporates the results of the preceding studies to assess the
comparative efficacy of fish and LC n-3 PUFA consumption on total and HMW
adiponectin levels in humans. Firstly, the measurement methods developed in this thesis
are utilised in this chapter to ensure accurate measurement of fish intake advice. The
study design implemented in this chapter also builds on the factors found to impede the
effectiveness of fish and LC n-3 PUFA intake in Chapters 5 and 6 in order to ensure
optimal compliance to study intake recommendations, including providing study
participants with fish. The preceding studies in this thesis thus culminate in this chapter,
which is the first known study to assess the efficacy of fish and LC n-3 PUFA
supplement consumption on adiponectin levels, a biomarker of health.

7.1 Introduction

This thesis has provided evidence that the effectiveness of dietary advice to
consume fish and LC n-3 PUFA supplements may not be the same; however, the
comparative efficacy of the food and nutrient also need to be considered. Whilst few
studies have compared the health outcomes of fish and LC n-3 PUFA consumption, the
results of these studies suggest that consuming fish may be advantageous (58, 59, 61,
62), likely due to the role of food synergy.
Given the known prevalence and associated risk factors of the metabolic
syndrome, it is prudent to examine the impact of fish and LC n-3 PUFA consumption
on an outcome relevant to this disorder. The adipocyte hormone adiponectin is known
to have anti-obesity and insulin sensitising effects (120, 121), and can be considered to
be a biomarker of metabolic health. As mentioned in chapter 1, the HMW form of
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adiponectin has been shown to be a better predictor of the metabolic syndrome than
total adiponectin (151), and thus is also of relevance.
There is evidence to suggest that consumption of either fish or LC n-3 PUFA
supplements can increase total adiponectin levels in both animal (137, 138, 140, 141)
and human (76, 79, 83, 144-146) models. However, no studies have compared the
effects of fish and supplements providing the same amount of LC n-3 PUFA on both
total and HMW adiponectin levels. Research is thus required to test the proof-ofconcept of the differential effect of fish and LC n-3 PUFA supplement consumption on
this biomarker of health.
Furthermore, as was highlighted in Chapter 2, variations in the gene encoding
adiponectin, ADIPOQ, can influence circulating levels of adiponectin (174), whilst
SNPs in the FTO gene may influence adiponectin levels as well as health outcomes
(175, 177). Such variations could pre-dispose individuals to altered levels of
adiponectin and could thus confound the results of dietary interventions. However, no
known study assessing the effect of fish or LC n-3 PUFA consumption on adiponectin
levels has measured SNPs in ADIPOQ or FTO.
The aim of this study was to compare the effects of consumption of fish and LC
n-3 PUFA supplements, providing the same amount of LC n-3 PUFA, on total and
HMW adiponectin in overweight humans.
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7. 2 Methods

7.2.1 Study design

The Building Healthy Eating Practices (BHEeP) study was a six week dietary
study with overweight adults randomised to one of two parallel arms: fish diet group
(‘fish’) and LC n-3 PUFA supplement group (‘supplement’), both providing
approximately 1.8g of LC n-3 PUFA per day. Both groups underwent a two week run-in
period (t = -2 – 0 weeks), designed to orient them to the study protocol and to observe
any reductions in weight following commencement of the study, which could
potentially influence adiponectin concentrations. Following this two week run-in period,
both groups commenced the four week dietary intervention (t = 0 – 4 weeks). The study
design is shown in Figure 7.1. Primary outcomes were change in total and HMW
plasma adiponectin concentrations. Secondary outcomes were change in plasma LC n-3
PUFA, fasting insulin and glucose, body weight, percent body fat, waist circumference,
and fish and LC n-3 PUFA consumption.
Participants were recruited via advertisements sent to University of Wollongong
general and academic staff and flyers distributed at University of Wollongong events.
Researchers not involved in the participant interaction randomised participants into
study groups, with participants randomised by gender and BMI category (above and
below 30kg/m2). Inclusion criteria were aged 18 – 65 years, willing to consume fish,
BMI >25 and <37 kg/m2, waist circumference >94cm for men, >80cm for women,
generally well. Exclusion criteria were diabetes mellitus, impaired renal function,
smoking, not weight stable for the past six months, food allergies or habits inhibiting
compliance with the study design, illiteracy and inadequate conversational English,
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currently taking medications which may influence adiponectin levels including
thiazolidinediones, valproic acid, angiotensin converting enzyme inhibitors, and
glucocorticoids (122), pregnancy/lactation, high self-reported consumption of fish
(three to four serves per week).
Ethical approval was granted by the University of Wollongong Human Research
Ethics Committee and informed consent was obtained for all participants. Further
information on the study is shown in Appendix H. A copy of the letters granting ethical
approval and relevant ethics amendments are provided in Appendix I.

7.2.2 Dietary intervention

For six weeks both groups were advised to consume an isocaloric diet for weight
maintenance (meeting estimated energy requirements (265) with 1.25 physical activity
factor), of 25% protein, 45% carbohydrate, and 30% fat. Diets referred to low fat staple
foods (fruit, vegetables, cereals, lean meat, low fat milk and yoghurt) and small amounts
of nuts, seeds, spreads and oils. Examples of the diets prescribed to participants are
shown in Appendix J. Due to the effects of changes in alcohol consumption on
adiponectin levels (266, 267), participants were advised to maintain their normal level
of alcohol consumption over the course of the study. Following the two week run-in
period (t= -2 – 0 weeks), participants in the ‘fish’ group were provided with three serves
of 135g salmon (Birds Eye Atlantic Salmon Fillets, Simplot Australia), two serves of
66g sardines (adjusted for percentage fish in total canned product based on methods
outlined in Chapter 3; John West Sardines in Tomato Sauce, Simplot Australia) and one
serve of 55.1g tuna (adjusted for percentage fish based on methods outlined in Chapter
3; John West Tuna Temptors Lemon and Cracked Pepper, Simplot Australia) per week
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for four weeks (t = 0 – 4 weeks). Participants in the ‘fish’ group were provided with
recipes incorporating the provided study fish to increase compliance (Appendix K). Due
to an inability to consume sardines, one participant was provided with four serves of
135g salmon and one serve of 55.1g tuna per week. Fish provided was designed to
provide 1.86g of LC n-3 PUFA per day (approximately 812mg EPA + 1044mg DHA
per day). During the dietary intervention period (t = 0 – 4 weeks), participants in the
‘supplement’ group were given three LC n-3 PUFA supplements per day, to provide a
similar amount (1.8g per day) of total LC n-3 PUFA (1055.1mg EPA + 744.9mg DHA
per day; Blackmores Omega Daily). Participants in the ‘supplement’ group were not
given any specific advice regarding fish consumption.
The dosage of LC n-3 PUFA prescribed via fish or supplements was selected to
correspond with the LC n-3 PUFA dose provided in previous studies which found a
significant change in adiponectin following fish or LC n-3 PUFA consumption (76, 79),
following adjustment for study duration. The achievability of the prescribed fish intake
was also taken into account when developing the dosage of LC n-3 PUFA for the study.
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Week: -2 – 0
(run in period)

Week: 0 - 4
(dietary
intervention)

All participants: isocaloric diet
(25% protein, 45% carbohydrate, 30% fat)

‘Supplement’ group:
isocaloric diet plus
three LC n-3 PUFA
supplements per day
(~1.8g LC n-3
PUFA/day)

‘Fish’ group:
isocaloric diet plus five
serves of fish (salmon,
sardines, tuna) per
week (~1.8g LC n-3
PUFA/day)

Figure 7.1: Study design for comparison of short term effects of fish and LC n-3 PUFA
supplements on adiponectin levels in overweight adults

DH interviews (179) were taken by an Accredited Practising Dietitian (EN) prior
to the run-in period and at the end of the study to identify changes from habitual diets.
Fish and LC n-3 PUFA consumption was also assessed using 3-day FR, which covered
two week days and one weekend day. As AUSNUT2007 was available at the time of
analysis, dietary intake was calculated using the Foodworks software system (Xyris
Software, Highgate Hill, QLD, Australia, Version 6, 2009), using the ‘AUSNUT2007
Brands’ and ‘AUSNUT2007 Foods’ nutrient databases (40). Fish intake was calculated
as grams of fish consumed per week. Reported fish intake in addition to that provided
was calculated using the percentage fish in each dish or product, based on a validated
approximation of values from canned fish labels (Chapter 3) (253) and standardised
recipe data (Chapter 5).
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All remaining fish and supplements were collected at the end of the trial to
estimate compliance. Returned supplements were used to calculate LC n-3 PUFA intake
in the ‘supplement’ group, in addition to dietary LC n-3 PUFA which was calculated
from DH interview data for both groups.
All participants were advised to maintain their normal level of physical activity
over the duration of the study. Habitual physical activity was assessed prior to the run-in
period and at the end of the study via the Baecke questionnaire (268) (Appendix L). The
Baecke questionnaire is a self-administrated questionnaire which quantifies habitual
physical activity via measurement of occupation, sport and leisure time activities and
has been validated for the measurement of physical activity levels using doubly labelled
water (269).

7.2.3 Anthropometry

Body weight and percentage body fat were measured in an upright position prior
to the run-in period (t=-2 weeks), at the commencement of the intervention period (t=0
weeks) and at the end of the intervention period (t=4 weeks), in minimal clothing and
without shoes using scales with a bioelectrical impedance component (Tanita TBF-662).
Waist circumference was measured at t = -2, 0, and 4 weeks with a flexible tape
measure at umbilicus level.

7.2.4 Blood and genetic measurements

Insulin, glucose, plasma fatty acids and adiponectin were measured after fasting
at t = -2, 0, and 4 weeks. Insulin and glucose levels were measured by a quality assured
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pathology laboratory (Southern IML Pathology), whilst plasma phospholipids fatty
acids were analysed in the laboratories of the Functional Food Group, School of
Agriculture, Food and Wine at the University of Adelaide according to the methods
described by Tu et al. (270). Briefly, thin layer chromatography was used to separate
phospholipids from total lipid extracts. The samples were separated and quantified by
gas chromatography (Hewlett-Packard 6890; Palo Alto, CA). Fatty acids were identified
using commercial lipid standards (Nuchek Prep Inc, Elysian, USA). For this analysis,
combined EPA plus DHA as a percentage of the total fatty acids in the plasma
phospholipid was calculated.
Plasma total and HMW adiponectin concentrations were measured using a
multimeric enzyme-linked immunosorbent assay (Alpco Diagnostics Inc, Salem, NH)
run at the University of Wollongong (conducted by EN). This assay has been shown to
be sensitive and reproducible (171). All adiponectin concentrations were measured in
duplicate and any questionable results were re-tested. Care was taken to ensure all
samples from the same participant were measured in the same assay run.
Using the calibrator provided in the assay kit, eight standard samples were
created according to the Alpco protocol (171). Absorbance of the standards was
measured using a PowerWave x340 microplate reader (BioTek Instruments Inc.,
Vermont, USA) set to 492nm and a calibration curve was developed. This calibration
curve was then used to calculate the concentration of the samples after measuring their
absorbance on the microplate reader. The HMW and total adiponectin concentration of
samples was calculated as ug/mL.
For the measurement of SNPs in ADIPOQ and FTO, saliva samples were
collected (Oragene, DNA Genotek, USA) at t = 4 weeks. Due to the known ethnic
variations in the prevalence and effects of SNPs in ADIPOQ (271) and FTO (272),
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saliva samples were collected only from participants of Caucasian ethnicity. Analysis of
SNPs in ADIPOQ and FTO were carried out in the laboratories of the Illawarra Health
and Medical Research Initiative, University of Wollongong. The DNA was extracted
using a simple and non-evasive ethanol-precipitation procedure. For each individual, the
DNA extracted from saliva was quantified using a spectrophotometer and diluted at the
same working concentration (20μg/μl). SNP genotyping for ADIPOQ (rs266729) and
FTO (rs9939609, rs8050136) genes was performed in duplicate using MALDI-TOF
mass spectrometry (Sequenom MassARRAY iPLEX Platform).

7.2.5 Statistical analysis

Data was analysed using SPSS (version 17.0, SPSS Chicago, IL, 2008).
Normality of the data was determined using the Shapiro-Wilks test. Mean and SD of all
parametric variables were calculated, whilst median and IQR were calculated for nonparametric variables.
As the run-in period (t = -2 – 0 weeks) was designed to stabilise measures,
reduce the within- participant variation and minimise the possibility of regression to the
mean, the anthropometric and biochemical data from this period was not included in the
analysis. As the literature suggests that research should focus on the change in
adiponectin levels over time rather than single measures at an individual time point
(133), changes in total and HMW adiponectin from t = 0 to t = 4 weeks were calculated
and compared between groups via an independent samples t-test and Mann-Whitney test
for parametric and non-parametric data respectively. This approach has been previously
used in the adiponectin literature (144, 273). Changes in total and HMW adiponectin
from t = 0 to t = 4 weeks within groups were calculated and compared via a paired
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samples t-test and a Wilcoxan signed ranks test for parametric and non-parametric data
respectively, whilst changes in total and HMW adiponectin between genders was also
compared within each group via a Mann-Whitney test.
Differences in other biochemical and anthropometric variables over time and
between groups were measured via mixed between-within subjects ANOVA for
parametric variables, as described by Tabachnick and Fidell (274). For non-parametric
dietary data, differences between groups were measured via a Mann-Whitney test,
whilst differences in biochemical and anthropometric variables within groups over the
duration of the intervention period (t = 0 – 4 weeks) were measured via Wilcoxon
signed ranks test. Due to a violation of the minimum cell frequency assumption of the
Pearson chi-square analysis, Fisher’s exact test was used to determine if there was a
significant difference between the allelic frequencies of SNPs in ADIPOQ and FTO in
the ‘fish’ and ‘supplement’ groups.
Differences in intake of macronutrients, LC n-3 PUFA and fish consumption
over time and between groups as assessed by DH was measured via mixed betweenwithin subjects ANOVA for parametric variables. For non-parametric dietary data,
differences between groups were measured via a Mann-Whitney test, whilst differences
in consumption of macronutrients, LC n-3 PUFA and fish within groups over the
duration of the study were measured via Wilcoxon signed ranks test. Difference in
Baecke questionnaire scores over time and between groups was measured by mixed
between-within subjects ANOVA. Fish and LC n-3 PUFA intake as measured by FR
was compared to DH interview data at t = -2 and 4 weeks via Wilcoxon signed ranks
tests. The relationships between DH and FR measurements of LC n-3 PUFA intake and
plasma phospholipid EPA plus DHA were then assessed via Pearson’s correlation
coefficient for parametric data and Spearman’s correlation for non-parametric data.
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Compliance to recommended fish and supplement intake was measured as the
number of fish or supplements consumed (calculated from returned products) as a
percentage of the number of fish or supplements recommended, based on the number of
days each participant was in the trial (obtained from trial consultation records). As in
Chapter 5, consumption of greater than 100% of the recommendations was equated to
100% compliance. Mean and SD compliance of the study sample was then determined.

7.3 Results

Of the n= 93 individuals who expressed an interest in the study, n= 30 were
enrolled in the study (Figure 7.2). One participant withdrew after enrolling in the study
and another withdrew at the start of the intervention period (t = 0 weeks). At the end of
the intervention study, n= 28 participants remained in the study (‘fish’ group: n = 14,
‘supplement’ group: n= 14), although blood analyses were not able to be performed for
one participant at the start of the dietary intervention due a failed blood collection. Total
and HMW adiponectin results were excluded for one participant at all time points as a
result of implausible findings. Percentage body fat data was excluded for one participant
at the start of the dietary intervention (t = 0 weeks) due to machinery malfunction, and
Baecke questionnaire data was not available for one participant at the end of the
intervention (t = 4 weeks). As saliva samples for genetic analysis were collected only
from participants of Caucasian ethnicity, n = 25 saliva samples were available at t = 4
weeks.
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Expressed interest in study
(n=93)

Enrolled and randomised
(n=30)

‘Fish’
(n=15)

Total (n=30)

‘Supplement’
(n=1)

Withdrew prior
to start (n=1)

t = -2 weeks
(n=29)

‘Fish’
(n=15)

Withdrew
(n=1)

‘Fish’
(n=1)

t = 0 weeks
(n=28)

t = 4 weeks
(n=28)
Genetic
analysis (n=25)

‘Supplement’
(n=15)

‘Fish’ (n=14)
-percent body fat not
available (n=1)
-blood analyses not
available (n=1)
-excluded due to
implausible adiponectin
results (n=1)

‘Fish’ (n=14)
- physical activity not
available (n=1)
- excluded due to implausible
adiponectin results (n=1)

‘Supplement’
(n=14)

‘Supplement’
(n=14)

‘Supplement’
(n=14)
Genetic analysis
(n=12)

Genetic analysis (n=13)

Figure 7.2: Enrolment, randomisation and available data for study participants over the
duration of the clinical trial
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There were no significant differences in total and HMW adiponectin levels
between study groups at t = 0 (Table 7.1, Figure 7.3). Change in HMW adiponectin over
the intervention period was significantly different (p=0.009) between the ‘fish’ and
‘supplement’ groups, with HMW adiponectin increasing in the fish group and
decreasing in the supplement group. There were no significant differences in changes in
total adiponectin between groups.
The percentage of EPA + DHA in plasma phospholipids increased significantly
over the intervention period in both the ‘fish’ (p=0.001) and ‘supplement’ groups
(p=0.001), but there was no significant difference between the groups at t=4 weeks
(p=0.114) (Table 7.2). There were no significant differences in the change in
adiponectin levels between genders within the fish group (total adiponectin: p=0.126,
HMW adiponectin: p=0.234) or the supplement group (total adiponectin: p=0.641,
HMW adiponectin: p=0.317). There were no significant differences within or between
groups in any other anthropometric or biochemical variable. There was also no
significant difference between groups in the allelic frequencies of SNPs in ADIPOQ and
FTO (Table 7.3).
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Table 7.1: Mean + SD [median (IQR)] change in total and HMW adiponectin levels from t = 0 to t = 4 weeks
‘Fish’ (n=12)

‘Supplement’ (n=14)

p-value (between
groups)

t=0

t=4

Change (t = 0

p-value

to t = 4

(within group

weeks)

change)
p = 0.180 †

Total

6.93 + 2.82

7.74 + 3.36

0.81 + 1.95

adiponectin

[6.69 (4.43

[7.57 (4.97 –

(ug/mL)

– 8.38)]

HMW

t=0

t=4

Change (t = 0

p-value

to t = 4 weeks)

(within group

6.46 + 2.51

-0.14 + 2.05

[0.34 (-0.37 –

[6.25 (4.31

[5.96 (4.34

[0.51 (-1.19 –

10.10)]

1.01)]

– 8.47)]

– 8.91)]

1.44)]

3.63 + 2.45

3.92 + 2.96

0.29 + 0.97

3.39 + 2.07

2.81 + 1.80

-0.58 + 1.18

adiponectin

[3.62 (1.25

[3.62 (1.07 –

[0.01 (-0.25 –

[2.63 (1.61

[2.12 (1.30

[- 0.63 (-0.99 –

(ug/mL)

– 5.00)]

5.32)]

0.40)]

– 4.96)]

– 4.25)]

-0.22)]

¶ Wilcoxon signed ranks test

† Paired samples t-test

§Independent samples t-test

‡Mann-Whitney test

Change

p = 0.778¶

0.746§

0.860‡

p = 0.026¶

0.789§

0.009‡

change)
6.60 + 2.34

p = 0.321 †

t=0
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Mean change in adiponectin (ug/mL)

1.5
1
*

0.5

Fish

0

Supplement
-0.5
-1
-1.5
Total adiponectin

HMW adiponectin

Figure 7.3: Mean change in total and HMW adiponectin levels from t = 0 to t = 4
weeks (*P-value change between groups: p = 0.009)
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Table 7.2: Anthropometric and biochemical variables at t= -2, 0 and 4 weeks
‘Fish’

Variable

Mean (med.)

Males|Females
(n)
T= -2 wks
T=0 wks
T=4 wks
Weight (kg)
T=-2 wks

83.11 (80.25)

T=0 wks

82.82 (79.60)

T=4 wks

82.78 (78.45)

‘Supplement’

SD
(IQR)

p-value
fish
(within
group)

Mean (med.)

5|10
4|10
4|10

BMI (kg/m2)
T=-2 wks
T=0 wks
T=4 wks
Waist (cm)
T=-2 wks
T=0 wks
T=4 wks
Body fat (%)
T=-2 wks
T=0 wks^
T=4 wks
Glucose
(mmol/L)
T=-2 wks
T=0 wks*
T=4 wks
Insulin (mU/L)
T=-2 wks

SD
(IQR)

p-value fish
vs supps
(between
groups)
p-value
supps
(within
group)

5|9
5|9
5|9

13.74 (71.1589.88)
13.72 (70.9090.35)
13.91 (71.9590.85)

83.72 (80.50)
82.80 (79.05)
0.861¶

82.55 (78.45)

13.96 (71.60–
100.55)
13.55 (70.78–
98.68)
13.86 (70.4398.33)

28.93
28.83
28.81

2.98
2.98
3.01

29.26
28.95
28.84

3.00
2.93
2.93

95.76
94.96
94.86

9.57
10.00
9.90

98.57
97.61
97.11

10.70
10.80
10.84

37.28
36.89
36.57

7.16
7.13
6.5

35.97
35.09
34.74

7.27
7.86
8.10

5.34 (5.30)
5.32 (5.30)
5.26 (5.10)

0.38 (5.10-5.60)
0.52 (5.05-5.65)
0.38 (4.95–5.70)

5.21 (5.25)
5.28 (5.25)
5.14 (5.20)

0.38(4.95-5.23)
0.48(4.88-5.80)
0.43(4.78-5.55)

9.28 (8.10)

4.75 (6.05-13.05)

11.86 (9.80)

T=0 wks*

9.28 (7.10)

5.12 (5.80-12.00)

12.23 (10.65)

T=4 wks

9.20 (8.10)

3.38 (6.85-11.45)

7.24(6.9015.98)
9.00(7.1812.70)
9.15(5.68–
14.03)

EPA +
DHA(%)
T=-2 wks
T=0 wks*
T=4 wks

4.14 (4.03)
4.94 (4.81)
8.12 (8.90)

0.64 (3.71-4.59)
1.37 (4.04–5.41)
2.08 (5.90–9.74)

0.408¶

0.937¶

10.63 (9.15)

0.001¶

4.97 (4.75)
5.33 (5.07)
9.30 (9.54)

0.88 (4.39-5.76)
1.54 (4.27-5.89)
1.53(8.3710.31)

1.000‡
0.509¶

0.966§
Time:0.480
Group:0.947
Interaction:
0.647†
Time:0.083
Group:0.538
Interaction:
0.253†
Time:0.265
Group:0.536
Interaction:
0.955†

0.178¶

0.819§
0.427‡

0.302‡
0.198¶

1.000‡

0.001¶

0.550‡
0.114‡

* Data available for n = 27 participants (n=13 fish, n=14 supplements)
^ Data excluded for n = 1 participant due to machinery malfunction (data available for: n=13 ‘fish’, n=14
‘supplements’)
‡Mann-Whitney test

§Independent t-test

¶ Wilcoxon signed ranks test

† Mixed between-within subjects ANOVA
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Table 7.3: Allelic frequencies of SNPs in ADIPOQ (rs266729), and FTO (rs9939609, rs8050136) between ‘fish’ and ‘supplement’ groups

SNPs

‘Fish’

‘Supplement’

Genotypes

Genotypes

P-value^

rs266729

CC

GC/GG†

CC

GC/GG†

(ADIPOQ)

7

6

5

7

rs9939609

TT

AT/AA‡

TT

AT/AA‡

(FTO)

3

10

4

8

0.695

0.673
rs8050136

CC

CA/AA‡

CC

CA/AA‡

(FTO)

3

10

4

8
0.673

^ Fisher’s Exact Test
† G allele associated with decreased levels of adiponectin (174)
‡ A allele associated with increased risk of obesity (272)
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When calculated from DH interview data, the ‘fish’ group reported significantly
increasing fish intake (p=0.001), and were consuming significantly higher amounts of
fish than the ‘supplement’ group at the end of the intervention (p=0.000) (Table 7.4).
Similarly, significantly higher intakes of LC n-3 PUFA from the diet were reported by
the ‘fish’ group (p=0.000), however there was no significant difference between all LC
n-3 PUFA consumed from dietary and supplement sources (p=0.285). During the
intervention both the ‘fish’ and ‘supplement’ groups reported a reduced percentage
energy intake from total and saturated fat from dietary sources (time effect: p=0.005,
p=0.001 respectively), with no significant differences between groups (group effect:
p=0.186, p=0.526 respectively) (table 7.4). A significant interaction effect was also seen
for percentage energy from polyunsaturated fat from dietary sources (p=0.001).
There was no significant difference in fish consumption measured by FR and
DH at t = -2 weeks (p=0.280) and 4 weeks (p=0.970) (Table 7.5). Whilst there was a
significant difference in dietary LC n-3 PUFA intake measured by the two methods at t
= - 2 weeks (p=0.038), there was no significant difference at the end of the intervention
(p=0.889). Positive associations were found between plasma phospholipid EPA + DHA
and DH measures of LC n-3 PUFA at t = -2 weeks (r=0.334, p=0.077) and 4 weeks
(rs=0.459, p=0.014); and FR measures of LC n-3 PUFA at 4 weeks (rs=0.465, p=0.017).
No association was found between plasma phospholipid EPA + DHA and FR measures
of LC n-3 PUFA at t = -2 weeks (r=-0.256, p=0.189).
Mean and standard deviation compliance for the ‘fish’ and ‘supplement’ groups
was 87.51 + 16.54% and 90.23 + 11.20%, respectively.
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Table 7.4:Reported daily dietary intake and physical activity levels at t= -2 and 4 weeks
‘Fish’

Variables

Fish (g)
T=-2 wks
T= 4 wks
LC n-3 PUFA
(mg)
T=-2 wks
T=4 wks (diet
only)
T = 4 wks (diet
+ supp)
Energy (kJ)
T= -2 wks
T= 4 wks

Mean
(med.)

SD
(IQR)

‘Supplement’

p-value fish
(within group)

24.75
(20.41)
90.98
(87.24)

18.80 (10.1538.42)
21.90 (84.58 –
99.18)

359.06
(211.78)
1901.16
(1925.14)
N/A

341.07 (150.20 –
499.26)
328.11 (1898.20 –
1957.03)
N/A

8173.06
(8029.36)
7536.06
(7017.61)

1740.14 (6581.859435.74)
2287.46 (6414.04
– 7888.74)

0.001¶

0.001¶

0.074¶

Mean
(med.)

SD
(IQR)

38.53
(36.09)
30.31
(20.84)

22.39 13.9931.01)
29.54 (13.99 –
31.01)

502.81
(493.44)
339.65
(264.83)
1990.73
(1982.53)

295.04 (230.02 –
662.50)
213.67 (203.78450.61)
206.32 (1800.63–
2194.98)

8584.13
(9148.50)
7680.67
(6960.58)

2190.11 (6905.5010136.46)
2514.00 (5840.40
– 8892.84)

Protein (%E)
T= -2 wks
T= 4 wks

19.58
20.20

4.10
2.53

21.03
21.33

3.53
5.06

Total fat (%E)
T = -2 wks
T= 4 wks

31.50
29.35

4.18
5.35

30.61
25.14

6.75
7.14

SFA (%E)
T= -2 wks
T= 4 wks

12.02
8.99

3.17
2.09

10.57
9.20

3.62
2.90

PUFA (%E)
T= -2 wks
T= 4 wks

5.29
6.84

1.48
1.27

5.42
4.37

1.94
1.56

MUFA (%E)
T = -2 wks
T= 4 wks

11.88
11.73

2.56
3.17

12.26
9.39

4.08
3.30

CHO (%E)
T = -2 wks
T= 4 wks

43.63
44.81

7.15
5.18

44.04
47.96

5.62
6.53

Etoh (%E)
T= - 2 wks

3.40 (2.53)

2.64 (1.73 – 5.33)

2.11 (1.36)

T= 4 wks

3.20 (2.48)

2.79 (1.70 – 3.65)

2.24 (0.004 3.95)
3.19 (0.19 –
4.52)

Baecke
questionnaire scores
T = -2 wks
T= 4 wks*

7.80
7.65

1.44
1.33

0.875¶

2.87 (2.26)

7.09
7.37

1.18
1.11

p value fish vs
supps (between
groups)
p-value
supps
(within
group)
0.064§
0.140¶

0.000‡

0.051‡
0.000‡
0.030¶

0.285^

0.962§
0.056¶

0.769‡
Time: 0.553
Group: 0.321
Interaction:
0.838†
Time: 0.005
Group: 0.186
Interaction:
0.197†
Time: 0.001
Group: 0.526
Interaction:
0.177†
Time: 0.505
Group: 0.021
Interaction:
0.001†
Time: 0.060
Group: 0.331
Interaction:
0.088†
Time: 0.036
Group: 0.389
Interaction:
0.244†
0.186‡
0.603‡

0.279¶

Time: 0.578
Group: 0.302
Interaction:
0.072†

‡Mann-Whitney test

^ Mann-Whitney test (compared to dietary LC n-3 PUFA at t = -2 weeks)

¶ Wilcoxon signed ranks test

† Mixed between-within subjects ANOVA

§ Independent t-test
*Data available for n = 27 participants (n=13 ‘fish’, n=14 ‘supplements’)
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Table 7.5: Mean + SD and [median (IQR)] fish (grams/day) and LC n-3 PUFA (mg/day) measured by DH interview and FR at t = -2 and 4
weeks

Intake

Timepoint

Diet history

Food record

Wilcoxon signed
ranks p-value

Fish (g/day)

t = -2 weeks

25.14 + 35.20 [0.00 (0.00 – 47.19)]

0.280

57.46 + 39.82 [60.84 (19.13

55.48 + 50.29 [50.33 (0.00 –

0.970

– 86.81)]

93.59)]

445.27 + 327.97 [366.68

272.40 + 358.83 [175.10 (65.46 –

(191.82 – 646.72)]

306.36)]

1941 + 281.75 [1943.99

1943.46 + 661.36 [2000.97

(1859.05 – 2024.78)]

(1676.88 – 2252.97)]

32.86 + 21.78 [29.14 (12.75
– 53.37)]

t = 4 weeks

LC n-3 PUFA

t = -2 weeks

(mg/day)
t = 4 weeks (diet + supp)

0.038

0.889
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7.4 Discussion

The results of this study suggest that short-term consumption of fish and
LC n-3 PUFA supplements do not have the same effect on HMW adiponectin
levels. Over the course of a dietary intervention which incorporated the same
amount of LC n-3 PUFA provided by either fish or LC n-3 PUFA supplements, a
significantly different change in HMW adiponectin was found between groups.
This was due to a small increase in HMW adiponectin in the ‘fish’ group, whilst
the ‘supplement’ group experienced a significant decrease. A similar pattern was
seen for total adiponectin; however this did not reach statistical significance.
These changes occurred whilst factors known to be associated with adiponectin
levels, such as weight and insulin levels (275), remained relatively constant.
Due to the known positive role of adiponectin in mediating inflammation
(124, 125) and improving insulin sensitivity (129) and weight management (121),
and thus its position as a biomarker of health, it is important to identify modifiable
lifestyle factors such as dietary components which can increase the concentration
of this hormone in the body. Furthermore, as research has emphasized the
importance of HMW adiponectin in the mediation of these effects (151), it is
crucial that the effects of dietary components on this multimer are also assessed.
This research has provided early evidence for the superior impact of fish
consumption on HMW adiponectin over that of LC n-3 PUFA supplements, thus
further highlighting the value of fish consumption and identifying a potential
mechanism for the known effects of fish consumption on diseases with an
underlying inflammatory pathogenesis (16-18, 20-22, 24-29, 276, 277) .
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This data provides proof-of-concept that fish is more efficacious at
increasing HMW adiponectin levels than LC n-3 PUFA supplements, suggesting
that the health benefits of fish may not be limited to the LC n-3 PUFA content
alone. It is currently not known why differential effects on HMW adiponectin
were seen for fish and LC n-3 PUFA supplement consumption, and whilst this
study was not designed to test mechanisms for change, some possibilities can be
proposed. As a whole food, fish consists of a variety of additional nutrients and
bioactive ingredients which could impact upon health. As highlighted in Chapter
1, consumption of fish protein has been linked to improvements in insulin
sensitivity (71) and insulin response (70) in humans. Furthermore, other
components present in fish such as selenium and vitamin D have also been
associated with a range of health benefits in humans (278, 279). Specifically,
selenium levels have been shown to be associated with increased HDL
concentrations (280), which may be related to adiponectin metabolism (281). As
the intervention diets in the present study were matched for total LC n-3 PUFA
content, it is reasonable to suggest that compounds such as those listed above, in
addition to the LC n-3 PUFA, may have played a role in the changes in HMW
adiponectin levels. The differential effects of fish and LC n-3 PUFA found in the
present study are supported by research by Cobiac et al. (58), who found
improvements in haemostatic factors in hyperlipidemic men following fish, but
not LC n-3 PUFA supplement, consumption.
No previous research has compared the effects of fish and LC n-3 PUFA
supplements on HMW adiponectin and only one study has done so using total
adiponectin as an outcome. As outlined in Chapter 1, Ramel et al. (149) found
similar reductions in total adiponectin in participants consuming diets containing
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varying levels of LC n-3 PUFA from fish and supplement sources. However,
Ramel et al. (149) did not investigate changes in HMW adiponectin levels, which
have been found to increase independently of changes to total adiponectin (152).
Furthermore, unlike the present study, the amount of LC n-3 PUFA from fish and
supplement sources was not matched in the study conducted by Ramel et al.
(149), making it difficult to unravel the influence of higher LC n-3 PUFA
consumption from that of food synergy.
Whilst there is a paucity of literature comparing the effects of fish and LC
n-3 PUFA supplement consumption on HMW adiponectin, several studies have
examined the impact of either fish or LC n-3 PUFA supplement consumption on
total adiponectin with varying results. Guebre-Egziabher et al. (79); Kondo et al.
(83); and Lara et al. (76) found increases in total adiponectin levels following fish
consumption, whilst Krebs et al. (145), Sneddon et al. (144) and Gammelmark et
al. (146) found similar results after supplementation with LC n-3 PUFA. A
limitation of these studies however, is that none examined the effect of fish or
supplement consumption on HMW adiponectin. Only one previous study has
examined the influence of either fish or LC n-3 PUFA supplements on HMW
adiponectin, and did not see a significant effect of supplements (147). Given the
known biological importance of HMW adiponectin, it is crucial to investigate this
component in addition to total adiponectin, as non-significant changes in total
adiponectin could mask a significant change in the HMW multimer, as was found
in the present study.
In the present study, consumption of LC n-3 PUFA supplements resulted
in a decrease in total and HMW adiponectin levels. This contrasts with the results
of previous studies which have found significant increases in total adiponectin
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levels following supplementation with LC n-3 PUFA (144-146); however
differences in study designs may explain this. Krebs et al. (145) found significant
increases in adiponectin levels following supplementation with LC n-3 PUFA as
part of a weight loss programme, inclusive of a low energy meal replacement
diet, in overweight women. Whilst no change in adiponectin was seen in a control
group also undergoing weight loss, these findings occurred in the context of
energy restriction and weight loss, which have been shown to increase adiponectin
levels (282). The current study implemented an isocaloric diet, with no
significant weight changes seen during the intervention period. Sneddon et al.
(144) provided participants with both LC n-3 PUFA and conjugated linoleic acid
supplements as part of an ad libitum diet, where participants were advised to
maintain their regular food intake with no specific dietary advice given. As no
dietary assessments were performed in the study conducted by Sneddon et al
(144), changes in dietary LC n-3 PUFA over the course of the study cannot be
determined. Similarly, a recent study by Gammelmark et al. (146), during which
participants were provided with LC n-3 PUFA supplements over a six week
period, only took dietary assessments at baseline without investigating changes in
dietary LC n-3 PUFA intake over the course of the study.
Genetic analysis performed in the present study confirmed that there was
no difference between the allelic frequency of SNPs in an adiponectin encoding
gene and a gene associated with risk of obesity in the ‘fish’ and ‘supplement’
groups. These SNPs, which have been associated with alterations in circulating
levels of adiponectin and risk factors for the metabolic syndrome and its
associated diseases (174, 177, 272) could potentially confound the results of this
study if variations existed between study groups. However, similar frequency of
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these SNPs in both study groups suggests the findings of the present study were
due to dietary changes rather than genetic variation between groups. This is a
strength of the current study, as no previous studies have investigated genetic
variation between groups.
An additional strength of the current study was that other dietary variables
were controlled for through a prescribed study diet which was confirmed through
dietary assessment. This excludes the potential confounding influence of changes
in consumption of dietary components such as total and saturated fat, which,
whilst decreasing over time in both groups, did not differ significantly between
groups at any time. Dietary and biochemical data suggest our participants were
able to meet dietary targets. The DH interview data indicated the ‘fish’ group
consumed significantly higher amounts of LC n-3 PUFA from dietary sources
than the ‘supplement’ group at four weeks (Table 7.4). The inclusion of total LC
n-3 PUFA consumed (calculated from returned supplements) suggested that both
groups consumed similar amounts of LC n-3 PUFA from dietary and supplement
sources as planned. This was supported by the plasma phospholipid fatty acid
analysis, which found no difference in levels of EPA plus DHA between groups at
the end of the intervention, and the results of the compliance analysis, which
found similar levels of compliance in the ‘fish’ and ‘supplement’ groups.
Comparison of LC n-3 PUFA consumption collected from DH interviews
with a biomarker of intake found positive associations at t= -2 weeks (r=0.334,
p=0.077) and 4 weeks (rs=0.459, p=0.014), suggesting this methodology gave an
accurate indication of consumption. Consumption of fish and LC n-3 PUFA as
measured by DH and FR were found to be largely similar, with no significant
difference between intake at t = -2 weeks for fish (p=0.280) and at t=4 weeks for
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fish and LC n-3 PUFA intake (p=0.970, p=0.889 respectively). Levels of LC n-3
PUFA intake were significantly lower for the FR at t = -2 weeks (p=0.038), and
no association was found between this methodology and plasma phospholipid
EPA plus DHA levels at this time point. This suggests the FR recorded LC n-3
PUFA less accurately than DH interviews at t = -2 weeks, likely as a result of
infrequent fish consumption prior to the study being poorly measured by the 3-day
FR, as outlined in Chapter 2. Increases in the frequency of fish consumption for
the ‘fish’ group and the contribution of supplements to total LC n-3 PUFA for the
‘supplement’ group during the dietary intervention meant FR were more accurate
at t = 4 weeks than at t = -2 weeks, as demonstrated by the significant association
with plasma fatty acid levels (p=0.017).
This study was limited by its small sample size and the short time period
of the dietary intervention, which may not have been sufficient to see all changes
in study outcomes. However, as no previous research has compared the effects of
fish and LC n-3 PUFA supplement consumption on HMW adiponectin, or indeed,
many other health outcomes, this study has helped to establish proof-of-concept.
The lack of a separate study group which did not receive either fish or
supplements is also a limitation of this study; however the run-in period addressed
some of this problem by eliminating the risk of weight loss following
commencement of dietary advice influencing adiponectin levels. Furthermore, a
number of other recent studies seeking to explore the effect of dietary components
on adiponectin have also had no comparison group (79, 283).
Furthermore, while efforts were made to match total LC n-3 PUFA
provided by the fish and supplements, dietary modelling was based upon nutrient
information panels of the fish products. This nutrient information was based upon
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routine laboratory analysis of the LC n-3 PUFA content performed by the food
company, however, small variations in the LC n-3 PUFA content of individual
products cannot be ruled out. In addition, as was found in a previous study also
comparing the health effects of fish and LC n-3 PUFA supplements (58), the EPA
and DHA content of the two diets was not matched, with the ‘fish’ group
receiving more DHA and less EPA than the ‘supplement’ group. Research
suggests that the effects of these fatty acids are not interchangeable (284) and thus
may have played a role in the differing outcomes seen for the ‘fish’ and
‘supplement’ groups. However, it should be noted that fish tends to be higher in
DHA (78) whilst most commercially available LC n-3 PUFA supplements are
higher in EPA (285-289). This further highlights the importance of consuming
whole foods, as the ratio of constituent nutrients may not be the same in a purified
supplement. Furthermore, when comparing the efficacy of fish and LC n-3 PUFA
supplements, it is important to consider the options available to consumers. If
consumers were advised to increase their consumption of LC n-3 PUFA
supplements, the vast majority of supplements available to them would be rich in
EPA; therefore it is prudent that an EPA rich supplement be chosen for
comparison, as in the present study.

7.5 Conclusion

This study, which was the first to compare the effects of fish and LC n-3
PUFA supplements on total and HMW adiponectin, has shown that short-term
consumption of fish and supplements do not have the same effect on this
hormone. Whilst the changes in HMW adiponectin found in this study were
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relatively small, the differing patterns seen with fish and LC n-3 PUFA
supplement consumption imply dissimilar biological effects which necessitate
further investigation.
This novel study has thus provided proof-of-concept that fish is more
efficacious in increasing HMW adiponectin levels in humans than LC n-3 PUFA
supplements, and has given early evidence that fish may be more beneficial to
health than LC n-3 PUFA alone, supporting the central hypothesis of this thesis.
This finding was made in the absence of confounding factors such as dietary and
genetic variations between groups.
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CHAPTER 8 – CONCLUSION
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8.1 Introduction

The practice of dietetics is dependent on evidence-based dietary advice
which reflects present research findings. However, it is currently unclear whether
dietary advice should focus on whole foods or nutrients, with much research
targeting a single nutrient and overlooking the intrinsic value of the food it is
found in, as in the case of fish and LC n-3 PUFA. Furthermore, there is a need for
nutrition research which tests the effectiveness of dietary advice and
interventions, thus aiding in the development of viable and evidence-based
dietetic practice.
This thesis has provided the first proof-of-concept that consuming fish is
more beneficial in increasing a biomarker of metabolic health than LC n-3 PUFA
supplements. However, the results of a 12 month clinical trial and social research
suggested that behavioural factors can impede the effectiveness of advice to
increase habitual fish intake, and that habitual consumption of LC n-3 PUFA
supplements may be more viable in the ‘free-living’ environment.
The results of this thesis contribute to the growing body of evidence which
suggests that whole foods have value above and beyond that of their constituent
nutrients. However, the problems associated with meeting recommendations for
habitual fish consumption identified in this thesis highlight the need to consider
the effectiveness, as well as the efficacy, of any dietary advice or intervention.
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8.2 Core thesis findings

The results of this thesis suggest that the impact of whole foods and
nutrients on health outcomes is multi-faceted. A comparison of the health impact
of fish versus LC n-3 PUFA consumption thus required the use of cross-cutting
study designs which examined all aspects of this issue, including methods
development, assessments of effectiveness of dietary advice (incorporating social
research) and testing of dietary efficacy.
In order to expose the impact of a dietary intervention on health, accurate
measures of dietary intake which are relevant to the geographic region in question
are required. As a result of the limitations to the current methods of measuring
fish and LC n-3 PUFA consumption used in the literature (Chapter 1), alternate
methods of measuring intake needed to be developed before the analyses
assessing the effectiveness of dietary advice and the efficacy of fish and LC n-3
PUFA consumption could be conducted. The measurement strategies developed in
this thesis improved upon the previous methods available by taking into account
additional ingredients in canned fish products and were specialised for the
Australian context. This is particularly relevant given the known geographic
variations in the LC n-3 PUFA content of the food supply (84, 85).
These measurement methods were then utilised in Chapter 3 to assess the
effectiveness of dietary advice to consume fish and LC n-3 PUFA, from both
dietary and supplement sources, over the duration of a 12 month clinical trial. The
long duration of this trial and the fact that the dietary recommendations received
mimicked clinical dietetic practice was novel in the literature and provided a
better model to investigate effectiveness of dietary recommendations than was
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available in the current body of research (58, 59, 61, 76, 79, 83). The results of
this study suggested meeting recommendations for moderate fish intake was
problematic over the 12 month period. Fish consumption and compliance to
recommendations was found to peak at the three month time point of the 12
month intervention and was found to be highly individualised, with a large degree
of variation seen between trial participants, irrespective of trial group.
Comparatively, compliance to supplement recommendations was higher, with less
inter-individual variation than was seen for fish consumption. The results of this
study suggest that in the long term, recommendations to consume supplements
were more effective than those to consume fish, and highlight the problematic
nature of maintaining habitual fish consumption, even at levels lower than those
recommended by health bodies around the world.
Given the low levels of fish consumption shown in the above study and
those known to exist in the wider Australian context (91), it was then prudent to
investigate perceptions of fish and LC n-3 PUFA which may influence
consumption levels. Exploration of perceptions of fish and LC n-3 PUFA
consumption in participants from the 12 month clinical trial and control
individuals from the same institution exposed a number of barriers to fish
consumption, including price, preferences of family members and access to fresh
fish. These barriers were similar to those reported in the international literature
(98, 100), and by parents of young children in the Australian context (105). In
comparison, whilst negative perceptions of the marketing of LC n-3 PUFA
supplements and enriched foods and a preference for natural alternatives were
expressed by some participants, these products were perceived as a more
convenient way of increase LC n-3 PUFA intake than fish. Perceptions of both
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fish and LC n-3 PUFA were similar for individuals who had participated in the 12
month clinical trial and controls from the host institution. Substantial barriers to
fish consumption remained following participation in the dietary trial, suggesting
dietary advice effective was not entirely effective in overcoming these issues and
improving perceptions of fish consumption.
The final study of this thesis utilised the findings of the previous studies to
compare the efficacy of fish and LC n-3 PUFA consumption on increasing
adiponectin levels, a biomarker of metabolic health with a known role in
mediating inflammation (124, 125) and improving insulin sensitivity (129) and
weight management (121). Measurement strategies developed in this thesis were
utilised to ensure correct measurement of fish and LC n-3 PUFA intake. In order
to examine the influence of LC n-3 PUFA consumption independent of fish,
supplements were used as a vehicle to increase LC n-3 PUFA intake, and thus to
compare the effect of consuming the whole food and the single nutrient. Building
on the findings outlined in Chapters 5 and 6, participants were provided with the
fish and LC n-3 PUFA supplements to overcome barriers to consumption and
ensure adequate intake. This study provided the first proof-of-concept that fish
and LC n-3 PUFA supplements did not have the same effect on HMW
adiponectin levels. Small, but significantly different, changes were found between
groups, with fish consumption found to result in small increases in HMW
adiponectin levels in overweight humans, whereas supplements providing the
same amount of LC n-3 PUFA did not.
Furthermore, provision of fish in the six week intervention ensured the
majority of participants were able to comply to fish consumption
recommendations, with similar levels of compliance found for participants
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advised to consume fish and supplements. Compliance to fish consumption
recommendations was substantially lower during the 12 month intervention than
was seen during the six week clinical trial, despite participants of the six week
trial being advised to consume three times more fish per week. Whilst the shorter
duration of this trial may have played a role, it would appear that provision of fish
is a defining factor in participant’s willingness to follow fish consumption
recommendations. This concept is also supported by the results outlined in
Chapter 5, as provision of fish overcomes issues relating to price and access to
fresh fish, which were two of the main barriers identified in this study.
The findings of this thesis support the central hypothesis that consumption
of fish, a whole food, is more advantageous to that of the single nutrient LC n-3
PUFA in improving a biomarker of metabolic health. This may be due to the
effect of food synergy, as fish contains many other components with other
biological roles, in addition to LC n-3 PUFA. This does, however, contradict the
perception that the health benefits associated with fish consumption are solely the
result of its LC n-3 PUFA content, which is evident in much of the literature (17,
19, 20, 23, 24, 28, 29).
However, while this thesis has shown fish to be more efficacious than LC
n-3 PUFA supplements in relation to the impact on HMW adiponectin levels, it is
clear that this is not the case for the effectiveness of dietary advice to consume
more fish. Poor long term compliance and behavioural barriers to fish
consumption advice identified in this thesis suggest increasing habitual fish intake
to the levels shown to increase HMW adiponectin would be problematic, whilst
regular consumption of LC n-3 PUFA in the form of supplements appears to be
more achievable. While this thesis has shown fish consumption to be more
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efficacious in managing a biomarker of metabolic health, achieving habitual
consumption at the level used in this thesis with dietary advice alone is unlikely in
the Australian context. The issue of how to increase habitual fish intake and thus
improve the effectiveness of dietary advice to increase fish consumption thus
remains an open question.

8.3 Limitations

As the previous chapters in this thesis have identified the limitations of
each individual study, the wider limitations of this thesis as a whole will now be
discussed. The concepts of the efficacy of dietary intervention and the
effectiveness of dietary advice underpin the theoretical framework utilised in this
thesis. A traditional trial design exists for ‘effectiveness studies’, which consists
of a heterogeneous study sample representative of the target population which is
recruited with limited exclusion criteria, with interventions closely replicating
conduct found in the ‘free-living’ environment (290, 291). Whilst some aspects of
the 12 month clinical trial utilised in this thesis mirror this model in part, the trial
used in this thesis cannot be labelled an ‘effectiveness trial’ per se. However, the
data provided by the clinical trial allowed for exploration of the factors
underpinning the concept of effectiveness, including adherence and perceptions of
fish and LC n-3 PUFA consumption. Future research which more closely
followed the design of a traditional effectiveness study could further elucidate
factors influencing the practicality of fish and LC n-3 PUFA consumption in the
‘free-living’ environment.
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This thesis involved secondary analysis of a 12 month randomised
controlled trial which was not powered to test changes in fish and LC n-3 PUFA
consumption. Participants from this clinical trial also formed a convenience
sample for the social research outlined in Chapter 6. Furthermore, it should be
noted that participants in the 12 month clinical trial, social research and proof-ofconcept study were volunteers for dietary interventions, meaning they may have
been more health conscious than the wider population, which may restrict the
degree to which the results of thesis can be extrapolated to the greater Australian
population. Whilst this may limit the generalisability of the findings of this thesis,
when considered in the context of a clinical trial this thesis provides useful
insights into the effectiveness of fish and LC n-3 PUFA consumption advice.

8.4 Future directions and recommendations

Whilst this thesis has exposed a number of novel concepts relating to fish
and LC n-3 PUFA consumption, it has also highlighted several areas which need
to be further investigated. This thesis has shed light on the problematic nature of
maintaining habitual fish consumption and has identified a number of factors
which may influence this. Future research should examine these factors further as
potential strategies for increasing fish intake. For example, in this thesis
secondary analysis of a 12 month clinical trial found fish consumption to be
highly variable at all time points. The potential lack of knowledge regarding the
percentage fish in canned products may have inhibited participant’s abilities to
meet fish consumption recommendations, and therefore, dietary advice based on
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individual consumption levels which educates participants on the fish content of
canned products should be investigated as a potential strategy of increasing intake.
It must be acknowledged that the Australian-wide data on fish
consumption reported in this thesis is from the NNS, which was conducted in
1995 (256). Whilst this is the most recent nationally representative data on fish
consumption in Australian adults, it may no longer be indicative of current fish
intake levels. Whilst data on fish consumption reported in Chapter 5 was collected
from a small sample and cannot be compared to the results of the NNS due to the
novel measurement methods developed in this thesis (Chapter 3), it suggested that
participants were not meeting current fish consumption recommendations (36).
There is thus a great need for updated nationally representative data on fish
consumption in Australia. The Australian Health Survey, which is currently
underway, will incorporate two 24 hour recalls and a food frequency
questionnaire to obtain information on consumption patterns of Australians (292).
Future research should use this data to measure updated fish consumption data,
and compare it to fish intake levels from 1995.
This thesis found that the health benefits of fish consumption appeared to
be well known regardless of exposure to dietetic advice and education. Such
advice did not appear to modify perceived barriers to consuming fish which
included, amongst others, perceptions of price, access to fresh fish and limited
confidence in cooking fish. It is recommended that future research focus on
overcoming these barriers in preference to providing further education on the
health benefits of fish consumption, as this appears to have reached a saturation
point, as acknowledged in the literature (102-104). Further research should
examine these barriers via more representative social research strategies such as
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surveys in order to confirm the findings of this thesis in a wider population and
identify strategies of overcoming these barriers. Such research should examine
whether these barriers are ‘real’ or perceived barriers to determine the best
strategies to overcome them. These strategies could further involve the food
industry in potentially modifying the cost of some products and increasing
awareness of simple methods of preparing fish. Another strategy would be to
focus on improving consumer perceptions of frozen and canned fish, which are
often more affordable and may be easier to access and cook than fresh fish,
effectively overcoming several barriers to consumption.
Whilst this thesis gave proof-of-concept that fish consumption resulted in
increases in HMW adiponectin levels whereas LC n-3 PUFA supplement
consumption did not, it should be noted that this was achieved through high fish
and LC n-3 PUFA intake which is unlikely to be achievable in the ‘free-living’
environment. Future research should thus replicate this study at consumption
levels similar to those recommended by health organisation around the world, for
example two to three serves of fish per week. If similar results are found, it would
suggest that increasing habitual fish intake could be a realistic strategy to increase
HMW adiponectin levels in humans.
Finally, it must be noted that dwindling fish stocks and the overfishing of
some species are substantial obstacles to increasing the consumption of fish and
LC n-3 PUFA supplements alike (293). This thesis has focused on the
effectiveness of dietary advice and the efficacy of fish and LC n-3 PUFA
consumption from a health perspective, and thus has not addressed sustainability
issues, which are outside of the scope of this research. However, it must be
acknowledged that these are important considerations with implications for both
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fish and LC n-3 PUFA supplement consumption, and require further research in
order to ensure intake requirements can continue to be met.

8.5 Conclusion

In conclusion, this thesis has provided evidence that consuming fish is
more beneficial to health (in terms of HMW adiponectin levels) than consuming
LC n-3 PUFA supplements alone. This research highlights the value of whole
foods beyond their constituent nutrients and the role of food synergy in
maintaining health. This research is valuable as it supports a growing body of
evidence emphasizing the importance of whole foods whilst providing new
evidence in the case of fish and LC n-3 PUFA, a topical food and nutrient of large
importance to public health, on a novel biomarker of health. The results of this
thesis reinforce the need to re-focus nutrition research and patient advice and
education on whole foods rather than single nutrients. These findings also reveal a
responsibility for nutrition professionals to ensure the intrinsic value of whole
foods is recognised, in addition to that of the individual nutrients they supply.
Furthermore, the concept of effectiveness, the likely impact of an
intervention in the ‘free-living’ environment, is crucial for understanding the
practicality of dietary advice and interventions but is rarely considered in nutrition
research. This research is the first to consider both the comparative efficacy of a
dietary intervention and the effectiveness of dietary advice focusing on a whole
food and a nutrient, thus providing evidence not only on the actual health
outcome, but also on the feasibility of dietary advice to increase fish and LC n-3
PUFA consumption as a public health strategy, with a focus on the Australian
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context. The novel analysis of the comparative effectiveness of dietary advice
targeting fish and LC n-3 PUFA supplement consumption indicated that meeting
habitual fish consumption recommendations is problematic, and intake at the
levels utilised in this thesis is improbable with dietary advice alone. This reveals
the need for nutrition researchers to consider both the efficacy and effectiveness
of dietary advice and interventions and to reflect on strategies to increase the
practicality of consuming whole foods to that of single nutrients in supplement
form. In the specific case of fish and LC n-3 PUFA examined in this thesis,
research is now needed to investigate further strategies of increasing fish
consumption in both the Australian and international context.
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Appendix A: Smart study (Chapters 4 and 5) participant information sheet

PARTICIPANT INFORMATION SHEET
THE SMART DIET
Who are we?
This study is funded by the National Health and Medical Research Council and is being
conducted by a group of researchers from the Smart Foods Centre at the University of
Wollongong. Professor Linda Tapsell, the study leader, is Director of the National
Centre of Excellence in Functional Foods. Dr Marijka Batterham, Dr Karen Charlton and
Dr Yasmine Probst are academic staff members of the Smart Foods Centre in the
School of Health Sciences, Ms Jane O’Shea is study co-ordinator, Ms Rebecca Thorne is
a research dietitian while Ms Anne McMahon is a PhD student and academic within the
Smart Foods Centre.
Study investigators

Professor Linda Tapsell

Dr Marijka Batterham

Dr Karen Charlton

Dr Yasmine Probst

Ms Jane O’Shea (ph 02 4221 5124)

Ms Rebecca Thorne (ph 02 4221 5992)

Ms Anne McMahon (ph 02 4221 4829)
Study Mobile: 0458 203 701

Why are we doing this?
The project aims to assess the benefits and achievability of different dietary
approaches in the management of overweight. The results of this research will
contribute to better understanding of the role of food components in diets
for weight loss and healthy weight maintenance and thereby more effective
treatment.
What will we ask you to do?
This research is a 12-month dietary intervention study in which you will receive dietary
advice from a qualified dietitian. Your diet will be assessed and then you will be
prescribed a weight loss dietary plan to follow for 12 months, with monthly follow up
with a dietitian for the first three months, followed by three-monthly visits thereafter.
You will also be required to take one capsule every day for the 12 month period, which
may contain either fish oil or an inactive ingredient.
The study also involves the use of a facility known as the Wollongong Room
Calorimeter, before, during and after the dietary intervention, to assess your energy
balance and ability to burn fat. The facility is a closed room which measures oxygen
consumed and carbon dioxide produced by the person staying inside. From these
measurements we are able to calculate energy expenditure, which is important in
understanding how body weight is controlled.
If you decide to participate in the study, we will require you to attend for a total of 15-
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17 separate visits for various measurements and procedures. At the start of the study
and at months three and 12, you will be required to attend the research facility three
times: (1) once for dietary assessment, anthropometry (weight, height, body fat) and to
be fitted with a 24-hour blood pressure (BP) monitor; (2) once for the 24-hr
calorimeter visit and blood sampling; and (3) once for a dual energy x-ray
absorptiometry (DEXA) scan (to be performed at Wollongong Nuclear Medicine) A
DEXA scan tells us how much fatty tissue is in your whole body. Dietary assessments
and anthropometrical measurements will also be performed at months 1, 2, 6, 9 (i.e.
four visits). You will also be invited to participate in two interviews. The first will take
approximately ½ - one hour in the first three months and the second similarly take ½ one hour in the last three months of the trial. Anne McMahon will try to co-ordinate
this interview with one of your required visits. If time constraints are an issue for you
Anne McMahon will contact you to arrange another suitable time and meeting place.
Blood pressure (BP) will be measured for a continuous 24-hr period at baseline and at
three and 12 months of follow-up using a Spacelabs monitor. The monitor will be
programmed to take readings every 20 minutes during awake time (06h00-22h00) and
every 30 minutes during asleep time (22h00-06h00). The information will be
downloaded to a computer software programme for analysis.
Fasting blood samples taken at the beginning of the study and at three and 12 months
will be analysed for fatty acids, cholesterol and other blood lipids, insulin, glucose and
leptin (a hormone) concentrations. Additional blood samples for fatty acid analyses will
be taken at six and nine months. DNA material will be extracted from baseline blood
samples in order to assess the prevalence genetic markers associated with energy
expenditure and different response to the weight loss diets.
The study also involves questionnaires to be completed at home and to be returned to
the university in a timely manner. Participants are asked to fill in a food diary, complete a
physical activity questionnaire and to wear an activity monitor at home over three days
at the start and the end of the study.
A flow chart of your commitments is outlined on the following page.
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Interested in the study

Call us
Screening questionnaire completed and eligibility
assessed

Pre study assessment (<2 hours)
 Visit to calorimeter facility
 Weight and height
 Body composition
 Diet history interview
 Activity and health questionnaires
 3 day food records to be taken and filled out at
home and returned prior to calorimeter visit
 Activity monitors to be worn for 3 days and
returned with food records.
DEXA scan
(Wollongong Nuclear Medicine, Piccadilly
Centre)
t=0

Calorimeter visit
(overnight stay; Room
41. 302)
+ blood collection
+ BP monitor to be worn
for 24 hours

Start of diet
month
Diet
counselling
(1 hour).
Capsules
provided.
Weight,
body fat.

t = 1 month*

t = 2 months*

Diet
support
(½ hour)
Weight,
body fat, 3day food
records.

Diet
support
(½ hour)
Weight,
body fat,
3-day food
records.

t = 12 months

t = 12 months**

t = 9 months**

Post-study assessment (1
hour)
 Weight
 Body composition
 Diet history interview
 Activity, health
questionnaires,
 3 day food records to be
filled in and returned within
1-2 weeks

Calorimeter visit
(overnight stay
Room 41.302)
+ blood collection
+ BP monitor to be
worn for 24 hours

Diet support
(½ hour)
+ Blood
collection
(fatty acids)
+ 3-day food
records

DEXA scan
(WNM, Piccadilly
Centre)

t = 6 months
Diet support
(½ hour)
+ Blood
collection
(fatty acids)
+ 3-day
food
records

t = 3 months*
Calorimeter visit
(overnight stay;
Room 41. 302)
+ blood collection
+ BP monitor to
be worn for 24
hours
DEXA scan
(Wollongong
Nuclear Medicine,
Piccadilly Centre)
t=0
Diet support
(½ hour)
Weight, body
fat, 3-day
food records.

* First interview to be arranged for preferably for one of
these times
** Second interview to be arranged preferably at one of
these times
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Pre study assessment (Visit 1)
This involves providing us with background information and will take around two hours.
You will also be shown the Wollongong room calorimeter during this visit and be
orientated to protocols used in the calorimeter. You will be given a number of
questionnaires on activity levels and food intake. You will be asked to wear an activity
monitor (the size of a pager) on your waist for a three day period (two weekdays and
one weekend day). It is taken off when you shower and go to bed. You will also be
asked to complete a three-day food diary on these same three days.
At this visit we will measure:
a)
Weight, height and waist circumference measures.
b)
Body composition using bioelectrical impedance analysis using Tanita scales.
c)
An Accredited Practising Dietitian will conduct a diet history interview to assess
usual dietary intake.
We will also show you examples of menus for your stay in the calorimeter to ensure
that you are willing to consume those foods in the amounts provided.
Calorimeter Stays (Baseline, three months, 12 months)
At baseline and at three and 12 months of follow-up, you will be required to stay in the
calorimeter for a 24-hour period. The calorimeters are enclosed spaces (3.0 x 2.1 x
2.4m) which may cause discomfort to some people. A computer with internet access is
provided in the room, as well as a TV with a number of DVDs for your viewing
enjoyment. The room contains a desk and chair, fold-away bed, toilet, sink and is airconditioned. There is also a window providing an ocean view. You will be shown the
calorimeter when you attend for your pre-study assessment (see Figure on previous
page) and will have the opportunity to ask questions about the facility at that visit.
The procedure for the calorimeter stay is as follows:
You should arrive at 8:00am after following an organised meal plan for the 24 hours
beforehand and having fasted for at least ten hours.
At these visits we will measure:
a)
Your resting energy expenditure where you will need to lie down in a supine
position rest for 30 minutes without falling asleep.
b)
Your weight and body composition.
c)
Your urine output which helps us determine your energy expenditure. We will
need to collect all urine during your 24 hour calorimeter stays.
Bloods: Blood pressure and a blood sample will be taken the morning you leave the
calorimeter for analyses of glucose, insulin, lipids levels, fatty acids and DNA markers
associated with energy expenditure and different response to the weight loss diets.
Meals: You will be asked to eat all of the food provided by us and only the foods
provided by us during your stays in the calorimeter. All meals will be prepared using
normal foods, and will be designed to contain recommended amounts of vitamins and
other essential nutrients. Meal times will be set to replicate your usual meal pattern.
Physical activity: During your stays in the calorimeter your physical movements will be
monitored using a digital Doppler motion sensor. These units operate in the same way
as common burglar alarms. You will also wear the activity monitor while you are awake.
You will be asked to do certain activities (e.g. walking around the chamber, stepping on
wooden block) at set intervals to replicate the activities you perform outside the
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chamber.
DietAdvice website: During your stay in the calorimeter we request that you use an
automated dietary assessment website developed by the University of Wollongong to
help to pass the time. The website has been developed to ensure your privacy is upheld
and information will not be accessible by anyone other than the researchers on the
study. The website will ask you about your usual food intake similar to your pre-study
visit and your dietary counselling sessions. The information will be used to validate the
accuracy of the information reported on the website. The website is managed by Dr
Yasmine Probst who will be available by telephone and on email if you have any
difficulties with using the website. You will be able to withdraw at any time from using
the website without any penalty or prevention from participating in the trial.
Dietary Counselling
4th Visit: At this visit you will receive dietary counselling and a dietary plan for the
twelve month intervention period and be supplied with a six-month supply of capsules.
1, 2, 3, 6, 9 and 12 month visits: At these visits, the dietitian will go through your
dietary plan and determine if you have any questions or problems with your program. At
the six and nine month visits, blood samples will be drawn in addition to dietary
counselling.
Interviews
First Interview At one of your visits in the first three months you will be asked to
participate in a ½-one hour interview on general health and wellbeing issues and about
what might have attracted you to participate in the trial.
Second interview The last interview will be scheduled to occur within the last three
months of the trial and will be similarly on your thoughts and understanding of general
health and wellbeing and your views on the trial itself. It is expected that the interview
will again be approximately ½-one hour.
Anne McMahon will contact you to confirm a time for both interviews. There is no
preparation necessary for these interviews as Anne McMahon is looking to hear your
views. The interviews will be recorded so your thoughts are transcribed exactly. Anne
McMahon is a PhD student and will be utilising this information for her doctoral study.
Any individual comments will not be identifiable in any reports or publications developed
from these interviews. The recordings and transcribed documents of the interviews will
be kept in a locked secure cabinet. You will be able to withdraw at any time from the
interview/s without any penalty or prevention from participating in the trial.
Three and twelve month visits
This is a repeat of your initial assessment. At this visit we will again measure:
a)
Weight and waist circumference measures
b)
Body composition
c)
Conduct a diet history interview
d)
Questionnaires and activity monitors will be provided for return within one-two
weeks
e)
DEXA scan
f)
24-hr calorimeter stay, including blood analyses
g)
24-hr blood pressure monitoring
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Who can participate?
We are looking for healthy male and female participants aged 18 - 60 years who are
overweight. It is important that you are willing to consume only the types and
amounts of foods provided to you during your stays in the calorimeter.
You should not participate in this study if you:



Know or suspect that you are pregnant
Your energy requirements will be increased during pregnancy and this
will compromise some of the calculations



Are breast feeding
Your energy requirements will be increased during breastfeeding and
this will compromise some of the calculations



Suffer from diseases that may alter the energy expenditure pattern e.g. cancer,
endocrine disorders, diabetes, AIDS
Wear a pacemaker
Smoke cigarettes regularly
Are taking regular medication (except the oral contraceptive pill)
Suffer from any food allergies
Be unwilling to consume fish
Have lost or gained more than approximately 3kg over the past six months, or are
on a weight-reducing diet
Regularly take fish oil supplements and are unwilling to stop taking them during the
study
Cannot understand English










What are the possible disadvantages and risks of taking part?
The taking of blood samples may produce some temporary discomfort and may result in
mild bruising at the site of sampling. Any bruising would be expected to resolve in a few
days. The DEXA scan which will be conducted at Wollongong Nuclear Medicine is
associated with an extremely small radiation dose which is 700 times less than a chest xray and 100 times less than a coast to coast plane flight. We do not foresee any other
risks or any disadvantages (except for the time commitment required of you) in taking
part in this study.
If you feel too uncomfortable, for example whilst in the calorimeter, you may stop the
study at any time. You may if you wish also withdraw your consent for the use of your
data in the study.

What will we do with the information and samples we obtain?
All information will be kept secure and identified by a code rather than by your actual
name. Nothing which identifies individual participants will be published. Standards of
medical confidentiality will apply. As a result of the study you will be able to gain some
information about your body fat percentage, how many calories you are using in a day
and your dietary intake. Blood samples will be stored for no less than five years on site
at the University of Wollongong.
If at any time you have any questions, please do not hesitate to ask. Your
involvement in the research is entirely voluntary. You are free to withdraw
from the research at anytime without penalty. If you have any enquiries
regarding the conduct of the research please contact the Secretary of the
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University of Wollongong Human Research Ethics Committee on (02)
42214457.
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Appendix B: Ethical approval letters for the Smart study and its relevant
amendments (Chapters 4 and 5)
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Appendix C:
Table 1: database of percentage fish in canned products (Chapter 3)

Type of canned product
Tuna in water
John West light tuna in springwater
Home Brand tuna chunks in springwater
Safcol tuna in springwater
Sole Mare tuna in springwater, chunk
style
John West tuna slices in springwater
Seakist tuna in springwater
Sirena tuna in natural springwater
Woolworths Select tuna in springwater
Weight Watchers Tuna in Springwater
Safcol premium springwater
You'll love Coles chunks in springwater
Portview sandwich tuna in springwater
Ocean rise tuna slices in springwater
Ocean rise tuna chunks in springwater
No frills chunk style in springwater
Tuna in oil
John West tuna in olive oil blend
Greenseas tuna in oil (olive oil)
Homebrand tuna chunks in oil
Sole Mare Tuna in ollve oil (chunk style)
John West tuna slices in olive oil
John West tuna slices smoked in olive oil
Sirena tuna in oil Italian Style
Sirena Tuna La Vita Lite in oil
Sirena tuna slices in oil italian style
Woolworths Select sandwich tuna in
olive oil
Woolworths Select tuna in pure olive oil
Safcol premium extra virgin olive oil
Smart Buy tuna chunks in veg oil
You'll love Coles tuna chunks in veg oil
You'll love Coles tuna chunks in olive oil
You'll love Coles tuna s'wich style olive
oil
You'll love Coles s'wich style veg oil
Portview sandwich tuna in oil
Ocean rise tuna slices in olive oil
No Frills sandwich tuna in oil
Tuna in brine
Greenseas tuna chunks in brine
Homebrand tuna in brine
John West tuna in brine
Seakist tuna in brine
Woolworths Select tuna chunks in brine

Weight of
total
product (g)

Weight of fish
(g)

Percentage
fish

95
95
95

66.5
69.35
66.5

70%
73%
70%

95
125
510
95
95
95
95
425
185
125
95
95

72.2
75
306
70.3
70.3
61.75
61.75
310.25
140.6
87.5
70.3
69.35

76%
60%
60%
74%
74%
65%
65%
73%
76%
70%
74%
73%

95
95
95
95
125
125
95
95
125

66.5
64.6
69.35
72.01
75
75
70.3
70.3
75

70%
68%
73%
75.80%
60%
60%
74%
74%
60%

95
95
95
185
185
185

70.30
70.3
70.3
120.25
129.5
135.05

76%
74%
74%
65%
70%
73%

95
185
185
125
95

69.35
129.5
140.6
86.25
69.35

73%
70%
76%
69%
73%

95
185
425
510
95

80
135.05
297.5
306
70.3

84.21%
73%
70%
60%
74%
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Smart Buy tuna chunky in brine

185

120.25

65%

You'll Love Coles sandwich style in brine

95

66.5

70%

95
185
125
425
95

69.35
140.6
87.5
263.5
69.35

73%
76%
70%
62%
73%

95

54.15

57%

100
95
95
95
95
95
95

42
52.25
53.2
52.25
47.5
72.01
52.25

42%
55%
56%
55%
50%
76%
55%

100

47

47%

100
95
95

46
57.95
59.85

46%
61%
63%

95

33.25

35%

95
95
95
95
95

33.25
38
38
53.2
54.15

35%
40%
40%
56%
57%

95
95
95
95
95
100
100
100

45.6
46.55
52.25
51.3
64.6
45
49
44

48%
49%
55%
54%
68%
45%
49%
44%

185
100
100
100
100

92.5
63
49
42
59

50%
63%
49%
42%
59%

100
100
100

58
44
45

58%
44%
45%

100

46

46%

100

53

53%

95

47.5

50%

You'll Love Coles chunks in brine
Portview sandwich tuna in brine
Ocean rise tuna slices in brine
Black and gold tuna in brine
No frills chunks in brine
Flavoured Tuna
John West Tuna Temptors (zesty
vinaigrette)
John West Tuna Temptors (tomato
salsa)
Greenseas Tomato and Onion
Greenseas Sweet Chilli
Home Brand Tomato and Onion
Safcol Tuna with Spicy Chilli
Sole Mare Tuna in Oil with Chilli
Sirena Tuna Tomato and Onion
Greenseas chunky tuna Mustard and
mayonnaise
Greenseas chunky tuna Sweetcorn and
mayo
Greenseas lemon pepper
Greenseas natural smoke flavour
Greenseas tuna snackpot lemon
pepper/mayo
Greenseas tuna snackpot savoury
tomato
Greenseas tuna snackpot sweet chili
Greenseas tuna snackpot creamy tomato
Greenseas spicy chili
Greenseas mustard mayo
Greenseas tuna sundried tomato and
onion
Greenseas tomato and basil
Greenseas tomato and capsicum
Homebrand chilli
Homebrand lemon pepper
John west light tuna onion and tomato
John west light sweet chili
John west spicy tomato
John west slices sundried tomato and
basil
John west tuna smoked
John west tuna sweet seeded mustard
John west tuna temptor tomato salsa
John west tuna tempter chili
John west tuna tempter lemon and
cracked pepper
John west tuna tempter mango
John west tuna tempter mild Indian curry
John west tuna tempter onion and
tomato savory
John west tuna temptor oven dried
tomato basil
John west tuna tempter sweetcorn and
mayo
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Safcol Gourmet tomato and onion
Safcol gourmet lemon pepper
Safcol gourmet penang curry
Safcol gourmet sweet chilli
Safcol premium lemon cracked pepper
Safcol premium tuna thai sweet chili
Safcol premium tuna mild chilli and olive
oil
Safcol gourmet thai green curry
Sirena in oil chilli
Sirena in oil lemon pepper
Sirena in puttanesca
Sirena tuna la vita lite chili
Sirena tuna la vita spicy tomato
Sirena tuna in sweet chili sauce
Sirena tuna slices chili and oil
Sole mare tuna with beans
Sole mare tuna with chili
Select tuna in chilli
Select tuna in onion savoury sauce
Select tuna in sweet mustard
Select tuna in tomato with basil
Select tuna lightly smoked
Select tuna sweet chili sauce
Select lemon and cracked pepper
Select tuna with tomato salsa
Safcol gourmet pouch lemon and
pepper
Safcol gourmet pouch sweet chili sauce
Safcol gourmet pouch oven dried tomato
and herb
Seakist lunch kit mayo corn cracker
Seakist lunch kit 1000 Island
Greenseas seasalt and cracked pepper
Greenseas salsa
Greenseas herb and garlic
Greenseas lime and cracked black
pepper
Greenseas tomato and carmelised onion
Greenseas red curry
Coles smart buy tomato and onion
Coles smart buy tomato and basil
Coles smart buy lemon and pepper
You'll love Coles sweet chili
You'll love Coles Mexican style
You'll love Coles Spanish style
You'll love Coles thai red curry
You'll love Coles tomato and chili
You'll love Coles japanese style
You'll love Coles Morrocan style
Sirena soy and ginger
Sirena lite spicy tomato
Sirena springwater and lemon0
Portview tomato and onion
Portview lime and cracked pepper
Portview lime and chili

95
95
95
95
95
95

47.5
57
47.5
47.5
57
47.5

50%
60%
50%
50%
60%
50%

95
95
95
95
95
95
95
95
125
185
185
95
95
95
95
95
95
95
95

64.6
42.75
52.25
74.1
61.75
51.965
51.965
69.825
75
83.25
75.85
61.75
48.45
53.2
53.2
61.75
53.2
66.5
56.05

68%
45%
55%
78%
65%
54.70%
54.70%
73.50%
60%
45%
41%
65%
51%
56%
56%
65%
56%
70%
59%

100
100

80
75

80%
75%

100
95
95
95
95
95

65
38
38
59.85
52.25
59.85

65%
40%
40%
63%
55%
63%

95
95
95
95
95
95
95
95
95
95
95
95
95
95
95
95
95
95
95

56.05
51.3
48.45
38.95
49.4
70.3
58.9
37.05
46.55
49.4
51.3
57.95
52.25
70.3
51.3
76
52.25
66.5
67.45

59%
54%
51%
41%
52%
74%
62%
39%
49%
52%
54%
61%
55%
74%
54%
80%
55%
70%
71%
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Portview smoked
Portview sweet chili and onion
Portview sundired tomato and basil
Portview tomato and capers
Ocean rise tuna slices in olive oil with
chili
Portview lemon and pepper tuna
No frills lemon and cracked pepper
No frills tomato and carmelised onion
No frills sweet thai chili

95
95
95
95

68.4
51.3
55.1
53.2

72%
54%
58%
56%

125
95
95
95
95

85
64.6
62.7
42.75
52.25

68%
68%
66%
45%
55%

Salmon in springwater
John West Salmon Tempters in
Springwater
John West Salmon Slices in Springwater
Safcol atlantic salmon in springwater
Safcol premium salmon in springwater

95
125
170
200

57
75
115.6
140

60%
60%
68%
70%

Salmon in springwater
John West Salmon Tempters in
Springwater
John West Salmon Slices in Springwater
Safcol atlantic salmon in springwater
Safcol premium salmon in springwater

95
125
170
200

57
75
115.6
140

60%
60%
68%
70%

Salmon in brine
John West Red Salmon
Ally Pink Salmon
Paramount red salmon
Select red salmon
Homebrand Pink salmon
John west pink salmon
Paramount pink salmon
Select pink salmon
You'll love Coles red salmon
You'll love Coles pink salmon
Smart buy pink salmon
Ocean rise premium red salmon
No frills pink salmon

105
105
100
415
210
105
100
210
210
105
415
105
105

79
82
99
332
168
79
99
84
168
84
336.15
103.95
103.95

75.24%
78.10%
99%
80%
80%
75.24%
99%
40%
80%
80%
81%
99%
99%

95

43.7

46%

95

57.95

61%

95
95
125

56.05
57
75

59%
60%
60%

95
95

64.6
57

68%
60%

95
95
95
100

68.4
59.85
57.95
80

72%
63%
61%
80%

Flavoured Salmon
John West Salmon Tempters (onion and
tomato)
John West Salmon Tempters (sweet
chilli and lime)
Greenseas salmon sundried tomato and
basil
Greenseas sea salt and cracked pepper
John west slices smoked
John west salmon tempters lemon and
cracked pepper
John west salmon tempters mayo
John west salmon tempters smoked
flavour
Safcol atlantic salmon lemon and capers
Safcol atlantic salmon mild red chili
Safcol salmon pouch lemon and dill
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Safcol salmon pouch lime cracked
pepper
Safcol salmon pouch mild red chili
Greenseas smoked

100
100
95

80
73
58.9

80%
73%
62%

Sardines in springwater
Brunswick sardines in springwater
Homebrand sardines in springwater
John west sardines springwater

106
125
110

94.34
90
74.8

89%
72%
68%

Sardines in oil
John West Scottish Sardines (in
vegetable oil)
Brunswick sardines in oil
Brunswick sardines soya oil
Homebrand sardines in oil
King oscar sardines olive oil
King oscar sardines olive oil double layer
Santamaria sardines in oil
Black and gold sardines in veg oil
No frills sardines in veg oil

110
106
106
125
105
105
120
125
125

74.8
94.34
94.34
90
81.9
81.9
84
75
90

68%
89%
89%
72%
78%
78%
70%
60%
72%

106
125
110

74.2
90
64.9

70%
72%
59%

100
105
105
120
120
125
125
125

53
73.5
67.2
84
78
90
75
87.5

53%
70%
64%
70%
65%
72%
60%
70%

85
100
85
85

63.75
70
63.75
60

75%
70%
75%
70%

85

63.75

75%

Anchovies (all types)
Always fresh flat anchovies

45

26.1

58%

Kippers (all types)
John west kipper fillets in brine

200

150

75%

Mussels (all types)
Always fresh smoked mussels
Homebrand mussels smoked

85
100

63.75
70

75%
70%

Mackeral (all types)
Homebrand mackeral in oil

425

191.25

65%

Flavoured sardines
Brunswick sardines tomato sauce
Home brand sardines in tomato sauce
John west sardines tomato sauce
John west sardines tempters onion and
tomato
King Oscar sardines hot chilli
King oscar sardines tomato sauce
Santamaria sardines in hot sauce
Santamaria sardines in tomato sauce
Smart buy Sardines in tomato sauce
Black and gold sardines in tomato sauce
No frills sardines in tomato sauce
Oysters (all types)
John West Smoked Oysters (in veg oil)
Home Brand Smoked oysters
Always fresh smoked oysters
John West Smoked Oysters (in chili)
John West Smoked Oysters (in BBQ
sauce)
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Homebrand mackeral in tomato sauce
John west mackeral fillets in brine

425
125

276.25
93.75

65%
72%

Herring (all types)
Always fresh herring mango
John west herrings tomato

190
200

114
130

60%
65%

Crab
Always fresh crab

170

120.7

71%

Prawns
Always fresh prawns

200

120

60%
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Appendix D:
Table 1: Summary of recipe sources utilised to estimate percentage fish in mixed dishes (Chapter 5)
Mixed

Mean + SD

dish

percentage fish (%)

Fish burger

28.70 + 12.06

Fish soup

24.02 + 14.12

Recipe sources (n = 5)

1. The Australian Women’s Weekly. Thai Fish Burger. [cited 2010: 22/10/10]; Available from:
http://aww.ninemsn.com.au/article.aspx?id=786400
2. Tassal. Salmon Fish Finger Burgers. [cited 2012. 20/01/12]; Available from:
http://www.tassal.com.au/search.html?searchword=burger
3. Taste. Thai Fish Burger. [cited 2010. 22/10/10]; Available from:
http://www.taste.com.au/recipes/13655/thai+fish+burger
4. All Recipes. Yummy Lemon Salmon Burgers. [cited 2010. 22/10/10]; Available from:
http://allrecipes.com/Recipe/Yummy-Lemon-Salmon-Burgers/Detail.aspx
5. Australian Food. Fish Burger. [cited 2010. 22/10/10]; Available from:
http://australianfood.about.com/od/fishseafood/r/FishBurger.htm
1. The Australian Women’s Weekly. Mediterranean Fish Soup with Rouille. [cited 2010: 22/10/10];
Available from: http://aww.ninemsn.com.au/article.aspx?id=786626
2. Coles. Mediterranean Seafood Soup with Garlic Toasts. [cited 2010: 22/10/10]; Available from:
http://recipes.coles.com.au/recipes/275/mediterranean-seafood-soup-with-garlic-toasts/
3. Woolworths. Miso Soup with Ocean Trout. [cited 2010: 22/10/10]; Available from:
http://www.woolworths.com.au/wps/wcm/connect/website/recipes/recipes/recipes-content/miso-soupwith-ocean-trout
4. Taste. Curried Fish Soup with Pappadums. [cited 2010: 22/10/10]; Available from:
http://www.taste.com.au/recipes/22735/curried+fish+soup+with+pappadums
5. All Recipes. Creole Fish Soup. [cited 2010: 22/10/10]; Available from:
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http://allrecipes.com/Recipe/Creole-Fish-Soup/Detail.aspx
Fish pasta

24.32 + 2.27

with
tomato
sauce

Fish cake

50.52 + 14.69

Seafood

45.26 + 17.37

stir-fry

1. Taste. Fish, Fennel and Tomato Spaghetti. [cited 2010: 22/10/10]; Available from:
http://www.taste.com.au/recipes/8728/fish+fennel+and+tomato+spaghetti
2. All Recipes. Diavolo Sauce with Pasta. [cited 2010: 22/10/10]; Available from:
http://allrecipes.com.au/recipe/1484/diavolo-sauce-with-pasta.aspx
3. Woolworths. Pasta with Tomato Based Sauce and Fish. [cited 2010: 22/10/10]; Available from:
http://www.woolworths.com.au/FoodIdeas/RecipeFinder/?RecipeId=800&PageNumber=8&selMealTy
pe=&selCookingStyle=&selMainIngredient=7&QuickFindRecipe
4. Coles. Tuna and Olive Pasta. [cited 2010: 22/10/10]; Available from: http://www.coles.com.au/RecipesMeal-Ideas/Meal-Base/Shellfish.aspx
5. Simply Great Meals. Fettuccine with Calamari Ragu. [cited 2010: 22/10/10]; Available from:
http://www.simplygreatmeals.com.au/recipe/1194/fettuccine-with-calamari-ragu
1. Birds Eye. Fish Patty. [cited 2010: 22/10/10]; Available from: http://birdseye.com.au
2. Best Recipes. Fish Cake. [cited 2010: 22/10/10]; Available from: www.bestrecipes.com.au
3. Sam Stern. Sam Stern’s Student Cookbook. London: Walker Books Ltd; 2008 (pg 167)
4. The Australian Women’s Weekly. Cooking Class Basic. Sydney: ACP Publishing Pty Ltd; 2004 (pg 25)
5. Taste. Fish Cake. [cited 22/10/10]; Available from: www.taste.com.au
1. Greenseas. Tuna Noodle Stir-fry. [cited 2010: 22/10/10]; Available from:
http://greenseas.com.au/recipe.asp?name=TunaNoodleStirfry
2. Western Australia Department of Fisheries. Seafood Stirfy. [cited 2010: 22/10/10]; Available from:
http://www.fish.wa.gov.au/wf/recipes/LoavesFishes.php?0000#a03
3. The Australian Women’s Weekly. Seafood and Edamame Stirfry. [cited 2010: 22/10/10]; Available
from: http://aww.ninemsn.com.au/article.aspx?id=790280
4. Birds Eye. Black Bean Fish Stir Fry. [cited 2010: 22/10/10]; Available from:
http://www.birdseye.com.au/Pasta-Rice-and-Stir-Fries/Black-Bean-Fish-Stir-Fry-Recipe.asp
5. All Recipes: Seafood and Vegetable Stir Fry. [cited 2010: 22/10/10]; Available from:
http://allrecipes.com.au/recipe/7703/seafood-and-vegetable-stir-fry.aspx
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Sushi

23.80 + 7.87

Seafood

37.75 + 14.76

quiche

Seafood
marinara

48.44 + 5.31

1. Simply Great Recipes. Sushi. [cited 2010: 22/10/10]; Available from:
http://www.simplygreatmeals.com.au/Recipes.aspx?page=&diabetic=0&type=&keywords=sushi&id=1
55
2. Birds Eye. Honey Sesame Fish Sushi. [cited 2010: 22/10/10]; Available from:
http://www.birdseye.com.au/Fish-and-Seafood/Honey-Sesame-Fish-Sushi-Recipe.asp
3. Best Recipes. Cucumber Sushi. [cited 2010: 22/10/10]; Available from:
http://www.bestrecipes.com.au/recipe/Cucumber-Sushi-L4503.html
4. The Australian Women’s Weekly. Salmon and Cucumber Sushi. [cited 2010: 22/10/10]; Available
from: http://aww.ninemsn.com.au/article.aspx?id=786277
5. Woolworths. Sushi. [cited 2010: 22/10/10]; Available from:
http://www.woolworths.com.au/FoodIdeas/RecipeFinder/Index.asp?RecipeId=532&hidebuttons=true
1. Taste. Seafood Quiche with Dill Mesclun Salad. [cited 2010: 22/10/10]; Available from:
http://www.taste.com.au/recipes/12914/seafood+quiche+with+dill+mesclun+salad
2. Greenseas. Tuna Leek Tart. [cited 2010: 22/10/10]; Available from:
http://greenseas.com.au/recipe.asp?name=TunaLeekTart
3. Woolworths. Seafood Quiche. [cited 2010: 22/10/10]; Available from:
http://www.woolworths.com.au/foodideas/RecipeFinder/?RecipeId=315&PageNumber=1&selMealTyp
e=&selCookingStyle=&selMainIngredient=7&QuickFindRecipe=
4. Coles. Seafood Quiche. [cited 2010: 22/10/10]; Available from:
http://www.coles.com.au/asp/recipes/recipe.asp?rid=164
5. Best Recipes. Tuna and Lemon Pepper Quiche. [cited 2010: 22/10/10]; Available from:
http://www.bestrecipes.com.au/recipe/Tuna-and-Lemon-Pepper-Quiche-L1278.html
1. The Australian Women’s Weekly. Speedy Seafood Marinara. [cited 2010: 22/10/10]; Available from:
http://aww.ninemsn.com.au/article.aspx?id=781007
2. Find-A-Seafood-Recipe. Seafood Marinara. [cited 2010: 22/10/10]; Available from: http://www.find-aseafood-recipe.com/seafood-marinara-recipe.html
3. Vineyard Shop. Seafood Marinara. [cited 2010: 22/10/10]; Available from:
http://www.vineyardshop.com.au/PageRender.aspx?PageID=115
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Seafood

36.65 + 9.72

pizza

Seafood

25.26 + 5.64

mornay

Tuna bake

27.21 +4.13

4. Kitchen Cook. Seafood Marinara. [cited 2010: 22/10/10]; Available from:
http://www.kitchencookingrecipes.com/recipes/seafood-marinara.html
5. Gourmet Saint. Seafood Marinara. [cited 2010: 22/10/10]; Available from:
http://www.gourmetsaint.com.au/TGSPC/Seafood_Marinara.htm
1. Greenseas. Mediterranean Tuna Pizzas. [cited 2010: 22/10/10]; Available from:
http://greenseas.com.au/recipe.asp?name=MediterraneanTunaPizzas
2. John West. Salmon Pizza. [cited 2010: 22/10/10]; Available from: http://www.johnwest.com.au/healthyrecipes/Salmon/Salmon-Pizza-recipe.aspx
3. The Australian Women’s Weekly. Chilli Seafood Pizza. [cited 2010: 22/10/10]; Available from:
http://aww.ninemsn.com.au/article.aspx?id=787604
4. Coles. Seafood Pizza. [cited 2010: 22/10/10]; Available from: http://www.coles.com.au/Recipes-MealIdeas/Meal-Base/Fish.aspx
5. Taste. Pizza Marinara. [cited 2010: 22/10/10]; Available from:
http://www.taste.com.au/recipes/16848/pizza+marinara
1. The Australian Women’s Weekly. Cooking Class Basic. Sydney: ACP Publishing Pty Ltd; 2004 (pg 27)
2. Western Australia Department of Fisheries. Seafood Mornay. [cited 2010: 22/10/10]; Available from:
http://www/fish.wa.gov.au
3. Best Recipes. Seafood Mornay. [cited 2010: 22/10/10]; Available from:
http://www.bestrecipes.com.au/recipe/Seafood-Mornay-L2512.html
4. Taste. Seafood Mornay. [cited 2010: 22/10/10]; Available from: www.taste.com.au
5. Simply Great Meals. Seafood Mornay. [cited 2010: 22/10/10]; Available from:
www.simplygreatmeals.com.au
1. Taste. Tuna Bake. [cited 2010: 22/10/10]; Available from: www.taste.com.au
2. The Australian Women’s Weekly. Crunchy Cheddar Tuna Bake. [cited 2010: 22/10/10]; Available from:
http://aww.ninemsn.com.au/article.aspx?id=785208
3. Best Recipes. Tuna Bake. [cited 2010: 22/10/10]; Available from: www.bestrecipes.com.au
4. Greenseas. Tuna Bake. [cited 2010: 22/10/10]; Available from: http://greenseas.com.au
5. Simply Great Recipes. Tuna Bake. [cited 2010; 22/10/10]; Available from:
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www.simplygreatrecipes.com.au
Tuna curry

32.21 + 7.15

Tuna

30.06 + 6.78

casserole

Garlic
prawns

77.70 + 12.94

1. Greenseas. Thai Green Tuna Vegetable Curry. [cited 2010: 22/10/10]; Available from:
http://greenseas.com.au/recipe.asp?name=ThaiGreenTunaVegetableCurry
2. Best Recipes. Easy Tuna Curry. [cited 2010: 22/10/10]; Available from:
http://www.bestrecipes.com.au/recipe/Easy-Tuna-Curry-L3942.html
3. John West. Thai Green Tuna Curry. [cited 2010: 22/10/10]; Available from:
http://www.johnwest.com.au/healthy-recipes/Tuna/Thai-Green-Tuna-Curry-recipe.aspx
4. All Recipes. Tuna Curry in a Hurry. [cited 2010: 22/10/10]; Available from:
http://allrecipes.com/Recipe/Tuna-Curry-in-a-Hurry/Detail.aspx
5. Recipezaar. Tuna Curry. [cited 2010: 22/10/10]; Available from: http://www.recipezaar.com/TunaCurry-137387
1. The Australian Women’s Weekly. Tuna Fish Casserole. [cited 2010: 22/10/10]; Available from:
http://aww.ninemsn.com.au/article.aspx?id=785933
2. Best Recipes. Tasty Tuna Casserole. [cited 2010: 22/10/10]; Available from:
http://www.bestrecipes.com.au/recipe/Tasty-Tuna-Casserole-L2259.html
3. All Recipes. Tuna Casserole. [cited 2010: 22/10/10]; Available from:
http://allrecipes.com.au/recipe/8368/tuna-casserole.aspx
4. Grandpa Pencil. Tuna Casserole. [cited 2010: 22/10/10]; Available from:
http://www.grandpapencil.net/activity/arecipe/tuncase.htm
5. Kitchen Cooking Recipes. Tuna Casserole. [cited 2010: 22/10/10]; Available from:
http://www.kitchencookingrecipes.com/recipes/tuna-casserole-recipe.html
1. Best Recipes. Creamy Garlic Prawns. [cited 2010: 22/10/10]; Available from:
http://www.bestrecipes.com.au/recipe/Creamy-Garlic-Prawns-L608.html
2. The Australian Women’s Weekly. Barbequed Lemon Garlic Prawns. [cited 2010: 22/10/10]; Available
from: http://www.houseandgarden.com.au/barbecued_lemon_garlic_prawns.htm
3. Woolworths. Garlic Prawns. [cited 2010: 22/10/10]; Available from:
http://www.woolworths.com.au/FoodIdeas/RecipeFinder/Index.asp?RecipeId=713&hidebuttons=true
4. Coles. Garlic Prawns. [cited 2010: 22/10/10]; Available from: http://www.coles.com.au/Recipes-Meal274

Battered

71.94 + 10.51

prawns

Crumbed

70.85 + 16.40

prawns

Prawn
chow mein

22.35 + 6.85

Ideas/Meal-Base/Shellfish.aspx
5. Taste. Garlic Prawns. [cited 2010: 22/10/10]; Available from:
http://www.taste.com.au/recipes/7307/garlic+prawns
1. The Australian Women’s Weekly. Deep-fried Battered Prawns with Sichuan Pepper and Salt and
Lemon. [cited 2010: 22/10/10]; Available from: http://aww.ninemsn.com.au/article.aspx?id=787106
2. Taste. Beer Battered Prawns with Tomato Chilli Relish. [cited 2010: 22/10/10]; Available from:
http://www.taste.com.au/recipes/20454/beer+battered+prawns+with+tomato+chilli+relish
3. Best Recipes. Coconut Curry Prawns. [cited 2010: 22/10/10]; Available from:
http://www.bestrecipes.com.au/recipe/Coconut-Curry-Prawns-L327.html
4. Lifestyle Food. Deep Fried Battered Prawns with Sweet Chilli and Carrot Dipping Sauce. [cited 2010:
22/10/10]; Available from: http://www.lifestylefood.com.au/recipes/356/deepfried-battered-prawnswith-sweet-chilli-and-carrot-dipping-sauce
5. That’s Life. Beer Battered Prawns. [cited 2010: 22/10/10]; Available from:
http://www.thatslife.com.au/article.asp?ArticleID=1361&ParentCategoryID=3&CategoryID=37&Pid=3
1. All Recipes. Crumbed Prawns. [cited 2010: 22/10/10]; Available from:
http://allrecipes.com.au/recipe/6534/crumbed-prawns.aspx
2. Taste. Crumbed Prawns with Spicy Soba Noodles. [cited 2010: 22/10/10]; Available from:
http://www.taste.com.au/recipes/4956/crumbed+prawns+with+spicy+soba+noodles
3. Free Recipes. Crumbed Prawns. [cited 2010: 22/10/10]; Available from:
http://www.freerecipes.co.nz/popup.php?sb_id=369
4. Kelloggs. Chilli Prawns. [cited 2010: 22/10/10]; Available from:
http://www.kelloggs.com.au/tabid/170/Default.aspx
5. Reader’s Digest. Crumbed Prawns. [cited 2010: 22/10/10]; Available from:
http://www.readersdigest.com.au/food-and-recipes/crumbed-prawns/article119460.html
1. Cook It Simply. Prawn Chow Mein. [cited 2010: 22/10/10]; Available from:
http://www.cookitsimply.com/recipe-0010-0446u3.html
2. Big Oven. Prawn Chow Mein. [cited 2010: 22/10/10]; Available from: http://www.bigoven.com/8885Prawns-Chow-Mein-recipe.html
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Spring roll

15.52 + 5.00

with
prawns

Prawn and

23.31 + 5.57

pasta salad

Crumbed

64.30 + 9.63

3. Cook Chinese. King Prawn Chow Mein. [cited 2010: 22/10/10]; Available from:
http://www.cookchinese.co.uk/cookchinese/King-Prawn-Chow-Mein.html
4. Chinese Food Recipes. King Prawn Chow Mein. [cited 2010: 22/10/10]; Available from:
http://www.chinese-foodrecipes.com/noodles.html
5. Healthy Recipes for Kids. Eggy Prawn Chow Mein [cited 2010: 22/10/10]; Available from:
http://www.healthy-eating-made-easy.com/healthy-recipes-for-kids.html
1. The Australian Women’s Weekly. Chinese Spring Rolls. [cited 2010: 22/10/10]; Available from:
http://aww.ninemsn.com.au/article.aspx?id=780782
2. Taste. Prawn Spring Rolls with Plum and Shiso. [cited 2010: 22/10/10]. Available from:
http://www.taste.com.au/recipes/15087/prawn+spring+rolls+with+plum+and+shiso
3. All Recipes. Pork and Prawn Spring Rolls. [cited 2010: 22/10/10]. Available from:
http://allrecipes.com.au/recipe/2276/pork-and-prawn-spring-rolls.aspx
4. Lifestyle Food. Prawn Spring Rolls. [cited 2010: 22/10/10]. Available from:
http://www.lifestylefood.com.au/recipes/9940/prawn-spring-rolls
5. Rasa Malaysia. Fried Spring Rolls. [cited 2010: 22/10/10]. Available from:
http://rasamalaysia.com/recipe-fried-spring-rolls/
1. Coles. Prawn Noodle Salad. [cited 2010: 22/10/10]. Available from:
http://recipes.coles.com.au/recipes/132/prawn-noodle-salad/.
2. All Recipes. Shrimp Linguine Salad. [cited 2010: 22/10/10]. Available from:
http://allrecipes.com/Recipe/Shrimp-Linguine-Salad/Detail.aspx
3. The Australian Women’s Weekly. Prawn and Avocado Pasta Salad. [cited 2010: 22/10/10]. Available
from: http://aww.ninemsn.com.au/article.aspx?id=790318
4. Taste. Prawn Avocado Baby Roma Truss Tomato Pasta Salad. [cited 2010: 22/10/10]. Available from:
http://www.taste.com.au/recipes/20885/prawn+avocado+baby+roma+truss+tomato+pasta+salad
5. Femail. Prawn Pasta Salad. [cited 2010: 22/10/10]. Available from: http://www.femail.com.au/prawnpasta-salad.htm
1. Taste. Crumbed Calamari. [cited 2010: 22/10/10]; Available from:
http://www.taste.com.au/recipes/7517/crumbed+calamari
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calamari

Battered

55.84 + 12.50

calamari

Salt and
pepper
squid

72.44 + 20.93

2. Kusina Down Under. Crumbed Calamari. [cited 2010: 22/10/10]; Available from:
http://kusinadownunder.blogspot.com/2008/05/crumbed-calamari.html
3. A Dash of Flavour. Crumbed Calamari. [cited 2010: 22/10/10]; Available from:
http://adashofflavour.blogspot.com/2009/04/crumbed-calamari.html
4. Coral Sea Wines. Crumbed Calamari. [cited 2010: 22/10/10]; Available from:
http://www.coralseawines.com.au/epages/coco15359.sf/en_AU/?ObjectPath=/Shops/coco15359/Produc
ts/R6
5. What’s for Dinner? Crumbed Calamari. [cited 2010: 22/10/10]; Available from:
http://www.whatsfordinner.co.za/index.php?option=com_resepte&task=show_recipe&id=242
1. All Recipes. Buttermilk Battered Calamari. [cited 2010: 22/10/10]; Available from:
http://allrecipes.com/Recipe/Buttermilk-Battered-Calamari/Detail.aspx
2. Recipe Link. Beer Batter Dipped Calamari. [cited 2010: 22/10/10]; Available from:
http://www.recipelink.com/cookbooks/2000/0385485387_3.html
3. Italian Recipes. Battered Calamari. [cited 2010: 22/10/10]; Available from:
http://recipesitalian.com/battered-calamari/
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Battered
oysters

37.86 + 4.14
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5. Food Down Under. Battered Oysters. [cited 2010: 22/10/10]; Available from:
http://fooddownunder.com/cgi-bin/recipe.cgi?r=24837

278

Appendix E: National Nutrition Survey Food Groupings (Chapter 5)

-

11. Non-alcoholic beverages
o 111. Tea
o 112. Coffee and coffee substitutes
o 113. Fruit and vegetable juices and drinks
o 114. Soft drinks, flavoured mineral waters and electrolyte drinks
o 115. Mineral waters and water
o 116. Water with other additions as a beverage

-

12. Cereals and cereal products
o 121. Flours and other cereal grains and starches
o 122. Regular breads and rolls
o 123. Breakfast cereals, plain, single source
o 124. Fancy breads, flat breads, English-style muffins and crumpets
o 125. Pasta and pasta products
o 126. Rice and rice products
o 127. Breakfast cereals, mixed source
o 128. Breakfast cereal, hot porridge type

-

13. Cereal-based products and dishes
o 131. Sweet biscuits
o 132. Savoury biscuits
o 133. Cakes, buns, muffins, scones, cake-type desserts
o 134. Pastries
o 135. Mixed dishes where cereal is the major ingredient
o 136. Batter-based products
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-

14. Fats and oils
o 141. Dairy fats
o 142. Margarine
o 143. Vegetable oil
o 144. Other fats
o 145. Unspecified fats

-

15. Fish and seafood products and dishes
o 151. Fin fish (excluding canned)
o Crustacea and molluscs (excluding canned)
o Other sea and freshwater foods
o Packed (canned and bottled) fish and seafood
o Fish and seafood products
o Mixed dishes with fish or seafood as the major component

-

16. Fruit products and dishes
o 161. Pome fruit
o 162. Berry fruit
o 163. Citrus fruit
o 164. Stone fruit
o 165. Tropical fruit
o 166. Other fruit
o 167. Mixtures of two or more groups of fruit
o 168. Dried fruit, preserved fruit
o 169. Mixed dishes where fruit is the major component

-

17. Egg products and dishes
o 171. Eggs
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o 172. Dishes where egg is the major ingredient
o 173. Egg substitutes and dishes
-

18. Meat, poultry and game products and dishes
o 181. Muscle meat
o 182. Game and other carcase meats
o 183. Poultry and feathered game
o 184. Organ meats and offal, products and dishes
o 185. Sausages, frankfurts and saveloys
o 186. Processed meat
o 187. Mixed dishes where beef or veal is the major component
o 188. Mixed dishes where lamb or pork, bacon, ham is the major
component
o 189. Mixed dishes where poultry or game is the major component

-

19. Milk products and dishes
o 191. Dairy milk
o 192. Yoghurt
o 193. Cream
o 194. Cheese
o 195. Frozen milk products
o 196. Other dishes where milk or a milk product is the major
component
o 197. Milk substitutes
o 198. Flavoured milks

-

20. Soup
o 201. Soup
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o 202. Dry soup mix
o 203. Canned condensed soup
-

21. Seed and nut products and dishes
o 211. Seeds and seed products
o 212. Nuts and nut products

-

22. Savoury sauces and condiments
o 221. Gravies and savoury sauces
o 222. Pickles, chutneys and relishes
o 223. Salad dressings
o 224. Stuffings

-

23. Vegetable products and dishes
o 231. Potatoes
o 232. Cabbage, cauliflower and similar brassica vegetables
o 233. Carrot and similar root vegetables
o 234. Leaf and stalk vegetables
o 235. Peas and beans
o 236. Tomato and tomato products
o 237. Other fruiting vegetables
o 238.Other vegetables and vegetable combinations
o 239. Dishes where vegetable is the major component

-

24. Legume and pulse products and dishes
o 241. Mature legumes and pulses
o 242. Mature legumes and pulse products and dishes

-

25. Snack foods
o 251. Potato snacks
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o 252. Corn snacks
o 253. Extruded snacks
o 254. Pretzels and other snacks
-

26. Sugar products and dishes
o 261. Sugar, honey and syrups
o 262. Jam and lemon spreads, chocolate spreads
o 263. Dishes and products other than confectionery where sugar is
the major component

-

27. Confectionery and health bars
o 271. Chocolate and chocolate-based confectionery
o 272. Cereal-, fruit-, nut- and seed-bars
o 273. Other confectionery

-

28. Alcoholic beverages
o 281. Beers
o 282. Wines
o 283. Spirits
o 284. Other alcoholic beverages

-

29. Special dietary foods
o 291. Formula dietary foods
o 292. Enteral formula

-

30. Miscellaneous
o 301. Beverage flavourings
o 302. Yeast: yeast, vegetable and meat extracts
o 303. Artificial sweetening agents
o 304. Herbs, spices, seasonings and stock cubes
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o 305. Essences
o 306. Chemical raising agents and cooking ingredients
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Appendix F: Ethical approval letters for the social research and its relevant
amendments (Chapters 6)
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Appendix G: Themes influencing perceptions of fish and LC n-3 PUFA
supplement and enriched foods identified during focus groups (Chapter 6)

Health impact of fish
consumption
 Perceived health benefits
 Potential contaminants
 Nutritional requirements
 Association with other
foods
 Food safety
 Knowledge and
education

Physical and sensory
characteristics
 Taste preferences
 Freshness
 Sensory appeal
 Appearance
 Presence of bones
 Smell
 Quality

Social and ethical concerns
 Sustainability
 Local products
 Ethical issues

Cost (financial and time)
 Price
 Convenience
 Time
 Organisation
 Wastage

Perceptions of fish
consumption

Outlet choice and
availability
 Access and availability
 Preference for specific
vendor
 Freshness (specific to
outlet)

Cooking skill and role of fish in
cuisine
 Confidence in cooking
ability
 Variety
 Cooking methods
 Meal time specificity
 Fresh versus canned
 Eating out
 Special occasions
 Food awareness

Influence of clinical trial
 Trial instructions
Family preferences and past
experiences
 Family preferences
 Tradition
 Childhood experiences

Figure 1: Perceptions of fish consumption identified in focus groups
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Convenience


Convenience as a source
of LC n-3 PUFA relative
to fish

Perceived influence on health








Importance of whole
foods
Health requirements
specific to life stage
Health benefits of LC n-3
PUFA
supplements/enriched
foods
Toxicity
Trust
Marketing

Perceptions of LC n-3
PUFA supplements
and enriched foods

Preference for ‘natural’ products



‘Natural way’
Confusion between short and
long chain n-3 PUFA

Figure 2: Perceptions of LC n-3 PUFA supplements and enriched foods identified
in focus groups
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Appendix H: BHEeP study (Chapter 7) participant information sheet

PARTICIPANT INFORMATION SHEET
Building Healthy Eating Practices (BHEeP)
Who are we?
This study is being conducted by a group of researchers from the Smart Foods Centre
at the University of Wollongong. Professor Linda Tapsell, the study leader, is Director
of the Smart Foods Centre. Dr Marijka Batterham is Director of the Statistical
Consulting Service in the School of Mathematics and Applied Statistics, and Dr Yasmine
Probst is an academic staff member of the Smart Foods Centre in the School of Health
Sciences. Dr Beverly Muhlhausler is an academic staff member of the University of
Adelaide. Ms Elizabeth Neale is a PhD candidate within the Smart Foods Centre.
Study investigators

Professor Linda Tapsell

Dr Marijka Batterham

Dr Yasmine Probst

Dr Beverly Muhlhausler

Ms Elizabeth Neale
o Ms Neale is the contact for the study. If you have any questions about
the study or would like further information please contact her on ph.
0458 203 701, or email epn579@uow.edu.au

Why are we doing this?
The project aims to assess the benefits of different dietary approaches on
hormone levels which assist in the management of weight. We also aim to
investigate the effects of different dietary approaches on fatty acid levels in the
blood and on measures of weight and fat mass in the body.
What will we ask you to do?
Participation in this study is voluntary. This research is a six week dietary intervention
study in which you will receive dietary advice from an Accredited Practising Dietitian.
Your diet will be assessed and then you will be prescribed a specific meal plan to follow
for six weeks, with regular follow up with a dietitian during this time. You will also be
required to take supplements as provided by the Smart Foods Centre, over the last four
weeks of the study.
If you decide to participate in the study, we will require you to attend a total of 3 – 4
separate visits for various measurements and procedures. At the start of the study and
at weeks two (2) and six (6), you will be required to attend the research facility for
dietary assessment, anthropometry (weight, height, body fat) and blood sampling. Fasting
blood samples taken at the beginning of the study and at two and six weeks will be
analysed for fatty acids, insulin, glucose, and adiponectin (a hormone) concentrations.
The study also involves questionnaires to be completed at home and to be returned to
the university in a timely manner. Participants are asked to fill in a food diary, and
complete a physical activity questionnaire.
A flow chart of your commitments is outlined on the following page.
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Interested in the study

Call us
Screening questionnaire completed and eligibility
assessed

t =0 weeks
Diet counselling
(2 hours).
Diet history undertaken
Weight, body fat measured.
Blood samples taken.
Activity questionnaire
3 day food records to be taken and
filled out at home and returned prior to
next visit

t = 2 weeks
Diet support
(1 hour)
Supplements provided.
Weight, body fat, 3-day food
records.
Blood samples taken

t = 4 weeks
If required, come to the
University to collect
additional supplements

t = 6 weeks
Final dietary session
(2 hours)
Diet history undertaken
Weight, body fat measured.
Blood samples taken.
3 day food records to be taken
and filled out at home and
returned in 1 -2 weeks
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First visit:
This visit will take approximately two hours. You will be given a number of
questionnaires on activity levels and food intake. You will be given a three-day food diary
which you will be asked to complete at home and return at your next appointment. This
diary will take approximately 45 minutes in total to complete over the course of three
days. During this visit:
d)
We will measure weight, height and waist circumference measures and body
composition using bioelectrical impedance analysis using Tanita scales.
e)
An Accredited Practising Dietitian will conduct a diet history interview to assess
usual dietary intake
f)
An Accredited Practising Dietitian will provide you with a specific meal plan for
the duration of the study, which will be explained to you. You will have the
opportunity to discuss alterations to the meal plan with the dietitian in accordance
with your food habits and cost preferences.
g)
We will take fasting blood samples for analyses of insulin, glucose, fatty acids and
adiponectin levels.
Second visit (t = 2wks):
This visit will take approximately one to two hours. At this visit you will be given
another three-day food diary which you will be asked to complete at home and return
at your next appointment. This diary will take approximately 45 minutes in total to
complete over the course of three days. During this visit:
a)
We will measure weight, height and waist circumference measures and body
composition using bioelectrical impedance analysis using Tanita scales.
b)
The dietitian will go through your dietary plan and determine if you have any
questions or problems with your program. Changes may be made to your
dietary plan to include consumption of supplements.
c)
We will take fasting blood samples for analyses of insulin, glucose, fatty acids and
adiponectin levels.
d)
You will be provided with a four week supply of supplements.
Third visit (t = 6wks):
This visit will take approximately two hours. At this visit you will be given another
three-day food diary which you will be asked to complete at home and return at your
next appointment. This diary will take approximately 45 minutes in total to complete
over the course of three days. You will also be asked to complete an activity
questionnaire regarding habitual physical activity. During this visit:
a) We will measure weight, height and waist circumference measures and body
composition using bioelectrical impedance analysis using Tanita scales.
b) An Accredited Practising Dietitian will conduct a diet history interview to assess
usual dietary intake
c) We will take fasting blood samples for analyses of insulin, glucose, fatty acids and
adiponectin levels.
d) You will also have the opportunity to discuss the trial with the dietitian, and
provide feedback including any recommended changes for future studies.
You will also have the opportunity to visit the University between two and six weeks of the
study, should you require re-fills of your supplements.
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Who can participate?
We are looking for healthy male and female participants aged 18 - 65 years who are
overweight.
You should not participate in this study if you:



Know or suspect that you are pregnant
Your energy requirements will be increased during pregnancy and this
will compromise some of the calculations



Are breast feeding
Your energy requirements will be increased during breastfeeding and
this will compromise some of the calculations



Suffer from diseases that may alter the energy expenditure pattern e.g. cancer,
endocrine disorders, diabetes, AIDS
Are taking regular medication (except the oral contraceptive pill)
Suffer from any food allergies
Are unwilling to consume fish
Have lost or gained more than approximately 3kg over the past six months, or are
on a weight-reducing diet
Regularly take fish oil supplements and are unwilling to stop taking them during the
study
Cannot understand English








What are the possible benefits of taking part?
As a result of your involvement in the study, you will have several dietary assessments
performed by an Accredited Practising Dietitian. You will be provided with an
individualised meal plan which will meet your energy requirements. You also have to
opportunity to gain information on your weight, height and fat mass, and blood levels of
glucose, insulin, fatty acids and adiponectin levels upon completion of the study.

What are the possible disadvantages and risks of taking part?
The taking of blood samples may produce some temporary discomfort and may result in
mild bruising at the site of sampling. Any bruising would be expected to resolve in a few
days. Consumption of high levels of the supplements given in this study may result in
increased bleeding time for participants taking anti-coagulant medication such as
Warfarin. If during your involvement in the study your Doctor advises you to begin anticoagulant medication you should advise the study investigators and discontinue this
study.

What will we do with the information and samples we obtain?
All data will be kept on site at the Smart Foods Centre, University of
Wollongong in a locked location. All information will be identified by a code rather than
by your actual name. No information which identifies individual participants will be
published. Standards of medical confidentiality will apply. As a result of the study you
will be able to gain some information about your body fat percentage, and your dietary
intake. Blood samples will be stored for no less than fifteen years on site at the
University of Wollongong.
You are free to withdraw from the research at any time, and if you wish, you
may also withdraw your consent for the use of your data in the study.
The data collected will be analysed and reported in a deidentified format
scientific journal and as part of conference presentations. It will also form a component

292

of Ms Neale’s PhD thesis.
If at any time you have any questions, please do not hesitate to ask. Your
involvement in the research is entirely voluntary. You are free to withdraw
from the research at anytime without penalty. If you have any enquiries
regarding the conduct of the research please contact the Secretary of the
University of Wollongong Human Research Ethics Committee on (02)
42214457.
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Appendix I: Ethical approval letters for the BHEeP study and its relevant
amendments (Chapters 7)
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Appendix J: Examples of BHEeP study diets prescribed during: i) the run-in
period, ii) the dietary intervention (‘fish’ group) and iii) the dietary intervention
(‘supplement’ group) (Chapter 7)
i) Daily Prescription for: BHEePXX

Food Group

Vegetables

Fruit

Wholegrain Bread,
cereals,
Pasta, rice

One serve

Per day

1 cup raw
(salad),
½ cup cooked

5

1 piece
1 cup

2

½ cup pasta,
1/3 cup rice,
1 slice bread

Mon

Energy Intake: 6.5MJ

Tue

Wed

Thur

Fri

Sat

Sun

Weekly
Tally

6

Protein-Rich Foods
Lean Meat
(Red and/or White)

30g

150g/
day

COOKED
Legumes

Eggs

½ cup
Cooked

2/week

1 med egg

2/week

Cheese
(reduced fat)

30g

2/week

Milk, yoghurt
(reduced fat)

1 cup,
1 tub

2

Nuts, Seeds,
Spreads and Oils
Monounsaturated
(Oils, margarines,
nuts, peanut butter,
avocado)
Polyunsaturated
(Oils, margarines)

1 tsp
spread/oil
/avocado

4

10g nuts

1 tsp
spread/oil

2
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ii) Daily Prescription for: BHEePXX Energy Intake: 6.5MJ
Food Group

Vegetables

Fruit

Wholegrain
Bread, cereals,
Pasta, rice

One serve

Per
day

1 cup raw
(salad),
½ cup
cooked

5

1 piece
1 cup

2

½ cup pasta,
1/3 cup rice,
1 slice bread

Protein-Rich
Foods
Lean Meat
(Red and/or
White)

30g
COOKED

Eggs
Cheese
(reduced fat)

1 med egg

1/week

30g

2/week

Milk, yoghurt
(reduced fat)

1 cup,
1 tub

2

Monounsaturated
(Oils, margarines,
nuts, peanut butter,
avocado)
Polyunsaturated
(Oils, margarines)
Provided food
- Frozen
-

Canned

1 tsp
spread/oil
/avocado

Wed

Thur

Fri

Sat

Sun

120g/
day

2/week

Nuts, Seeds,
Spreads and Oils

Tue

6

½ cup
Cooked

Legumes

Mon

0

10g nuts

1 tsp
spread/oil

3

1 piece

3/week

1 can

3/week
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Weekly
Tally

iii) Daily Prescription for: BHEePXX Energy Intake: 6.5 MJ

Food Group

Vegetables

Fruit

Wholegrain
Bread, cereals,
Pasta, rice

One serve

Per day

1 cup raw
(salad),
½ cup cooked

5

1 piece
1 cup

2

½ cup pasta,
1/3 cup rice,
1 slice bread

Protein-Rich
Foods
30g
Lean Meat
(Red and/or
White)

2/week

Cheese
(reduced fat)

30g

2/week

Milk, yoghurt
(reduced fat)

1 cup,
1 tub

2

Monounsaturated
(Oils, margarines,
nuts, peanut butter,
avocado)

Polyunsaturated
(Oils, margarines)

Capsule

Thur

Fri

Sat

Sun

COOKED

1 med egg

Nuts, Seeds,
Spreads and Oils

Wed

150g/
day

2/week

Eggs

Tue

6

½ cup
Cooked

Legumes

Mon

1 tsp
spread/oil
/avocado

4

10g nuts

1 tsp
spread/oil

2

1 capsule

3/day
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Weekly
Tally

Appendix K: Sample of recipes given to ‘fish’ group participants to increase
compliance to prescribed fish consumption during BHEeP study (Chapter 7)

Fantastic Fish!
Fish is not only a healthy food choice; it is also delicious and can be
cooked in many different ways. These simple and fast recipes will show you ways
you can easily include a variety of different fish meals in your eating plan.

Frozen fish

Salmon Kebabs
Serves: 1
Cooking time: 20 minutes

Ingredients
-

1 frozen fish fillet (provided)

-

¼ red capsicum, cut into large wedges

-

¼ red onion, cut into large wedges

-

1 yellow squash

-

4 small mushrooms, cut into wedges

-

1 tsp olive oil

-

1 tsp Cajun seasoning

-

8 x 6 inch bamboo skewers

-

½ cup low fat natural yoghurt

Contains:
- 1 x frozen fish serve
- 1 – 2 x vegetable
serve
- 1 x fat serve
- ½ x dairy serve

Method
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1. Defrost salmon in the refrigerator overnight or in microwave
2. Cover skewers with water and soak for 10 minutes
3. Dice salmon into 3cm cubes and combine all ingredients in a mixing bowl.
Toss to coat salmon evenly, then thread all ingredients onto skewers
4. Cook skewers on a preheated BBQ or griddle pan on medium – high for
approximately 1 -2 minutes each side. Serve with yoghurt

Eat with a simple side salad to increase your vegetable intake
Seal in an air-tight container for a tasty and convenient lunch the next day

Spicy Atlantic Salmon With Lime Mayonnaise
Serves: 1
Cooking time: 10 minutes

Ingredients:

Contains:
- 1 x frozen fish serve
- 3 x vegetable serve
- 1 x fat serve

-

1 frozen fish fillet (provided)

-

½ teaspoon each of turmeric and chili powder

-

1 tbsp reduced fat mayonnaise

-

Grated rind of 1 lime

-

2 tablespoons lime juice

-

1½ cups mixed vegetables

Method
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1. Coat the top of each fish fillet with combined turmeric, chilli powder and
cook in a lightly oiled non-stick frying pan for 4-5 minutes on each side or
until cooked
2. Combine mayonnaise with lime rind and juice and chill until required
3. Steam vegetables and serve with cooked salmon and drizzle with lime
mayonnaise

Canned fish

Salad Nicoise
Serves: 1
Preparation time: 20 minutes (plus cooling and refrigeration)

Ingredients:
-

1 can tuna (provided)

-

100g green beans, trimmed, halved

-

1 tsp olive oil

-

2 tsp white wine vinegar

-

1 tsp lemon juice

-

1 small red onion, sliced thinly

-

2 medium roma tomatoes, cut into

Contains:
- 1 x canned fish serve
- 2 vegetable serves
- 1 x fat serve

thin wedges
-

1 tbsp seeded black olives

-

2 tsp fresh basil, finely shredded

-

2 tsp parsley, chopped
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Method:
1. Boil, steam or microwave beans until tender, drain. Rinse under cold
water; drain.
2. Whisk oil, vinegar and juice together in large bowl; add beans and
remaining ingredients, mix gently.

Top Tip # 1
Need a fast, healthy breakfast? Try canned sardines on wholegrain toast

Sardine and ricotta bruschetta
Makes: 2

Ingredients:
Bruschetta base:
-

¼ loaf ciabatta or ¼ French stick

-

1 clove garlic, halved

Contains:
- 1 x canned fish serve
- ½ dairy serve
- 2 grain serves

Ricotta and sardines
-

1 can sardines (provided), bones removed

-

50g reduced fat ricotta cheese

-

Zest of 1 lemon

-

1 tbsp fresh thyme, chopped
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Method:
1. To make the bruschetta base: cut the bread into thick slices and toast both
sides until crisp and golden. Rub one side of each bread slice with the
garlic.
2. To make the ricotta and sardine topping: Put the ricotta, lemon zest and
thyme in a bowl and mix to combine. Spread the ricotta over the toasts and
top with sardines and lemon slices.

Top Tip # 2
Try canned tuna or sardines on a salad sandwich or wrap for a convenient and
healthy lunch
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Appendix L: Baecke questionnaire for measurement of habitual physical activity
in the BHEeP study (Chapter 7)
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